{
  "variants": [
    {
      "id": 1,
      "feature_type": "rearrangement",
      "gene1": "BCR",
      "gene2": "ABL1",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "BCR--ABL1 Fusion"
    },
    {
      "id": 9,
      "feature_type": "rearrangement",
      "gene1": "ALK",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "ALK Fusion"
    },
    {
      "id": 12,
      "feature_type": "rearrangement",
      "gene1": "ALK",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "ALK"
    },
    {
      "id": 15,
      "feature_type": "rearrangement",
      "gene1": "ALK",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Translocation",
      "feature": "ALK Translocation"
    },
    {
      "id": 18,
      "feature_type": "rearrangement",
      "gene1": "BRD4",
      "gene2": null,
      "locus": "t(15;19)",
      "rearrangement_type": "Translocation",
      "feature": "BRD4 Translocation"
    },
    {
      "id": 19,
      "feature_type": "rearrangement",
      "gene1": "CCND1",
      "gene2": null,
      "locus": "t(11;14)",
      "rearrangement_type": "Translocation",
      "feature": "CCND1 Translocation"
    },
    {
      "id": 21,
      "feature_type": "rearrangement",
      "gene1": "CCND3",
      "gene2": null,
      "locus": "t(6;14)",
      "rearrangement_type": "Translocation",
      "feature": "CCND3 Translocation"
    },
    {
      "id": 22,
      "feature_type": "rearrangement",
      "gene1": "COL1A1",
      "gene2": "PDGFB",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "COL1A1--PDGFB Fusion"
    },
    {
      "id": 23,
      "feature_type": "rearrangement",
      "gene1": "EML4",
      "gene2": "ALK",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "EML4--ALK Fusion"
    },
    {
      "id": 25,
      "feature_type": "rearrangement",
      "gene1": "ESRP1",
      "gene2": "RAF1",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "ESRP1--RAF1 Fusion"
    },
    {
      "id": 27,
      "feature_type": "rearrangement",
      "gene1": "EWSR1",
      "gene2": "FLI1",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "EWSR1--FLI1 Fusion"
    },
    {
      "id": 28,
      "feature_type": "rearrangement",
      "gene1": "FGFR2",
      "gene2": "TACC3",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "FGFR2--TACC3 Fusion"
    },
    {
      "id": 29,
      "feature_type": "rearrangement",
      "gene1": "FGFR2",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "FGFR2 Fusion"
    },
    {
      "id": 30,
      "feature_type": "rearrangement",
      "gene1": "FGFR2",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "FGFR2"
    },
    {
      "id": 32,
      "feature_type": "rearrangement",
      "gene1": "FGFR3",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "FGFR3 Fusion"
    },
    {
      "id": 33,
      "feature_type": "rearrangement",
      "gene1": "FGFR3",
      "gene2": "NSD2",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "FGFR3--NSD2 Fusion"
    },
    {
      "id": 34,
      "feature_type": "rearrangement",
      "gene1": "IGH",
      "gene2": null,
      "locus": "t(11;14)(q13;q32)",
      "rearrangement_type": "Translocation",
      "feature": "IGH Translocation"
    },
    {
      "id": 35,
      "feature_type": "rearrangement",
      "gene1": "IGH",
      "gene2": null,
      "locus": "t(4;14)(q16;q32)",
      "rearrangement_type": "Translocation",
      "feature": "IGH Translocation"
    },
    {
      "id": 36,
      "feature_type": "rearrangement",
      "gene1": "NTRK1",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "NTRK1 Fusion"
    },
    {
      "id": 39,
      "feature_type": "rearrangement",
      "gene1": "NTRK2",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "NTRK2 Fusion"
    },
    {
      "id": 42,
      "feature_type": "rearrangement",
      "gene1": "NTRK3",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "NTRK3 Fusion"
    },
    {
      "id": 45,
      "feature_type": "rearrangement",
      "gene1": "PDGFRA",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "PDGFRA"
    },
    {
      "id": 46,
      "feature_type": "rearrangement",
      "gene1": "FIP1L1",
      "gene2": "PDGFRA",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "FIP1L1--PDGFRA Fusion"
    },
    {
      "id": 47,
      "feature_type": "rearrangement",
      "gene1": "BCR",
      "gene2": "PDGFRA",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "BCR--PDGFRA Fusion"
    },
    {
      "id": 48,
      "feature_type": "rearrangement",
      "gene1": "PDGFRB",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "PDGFRB"
    },
    {
      "id": 49,
      "feature_type": "rearrangement",
      "gene1": "ETV6",
      "gene2": "PDGFRB",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "ETV6--PDGFRB Fusion"
    },
    {
      "id": 50,
      "feature_type": "rearrangement",
      "gene1": "RET",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "RET"
    },
    {
      "id": 52,
      "feature_type": "rearrangement",
      "gene1": "RET",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "RET Fusion"
    },
    {
      "id": 57,
      "feature_type": "rearrangement",
      "gene1": "ROS1",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "ROS1 Fusion"
    },
    {
      "id": 59,
      "feature_type": "rearrangement",
      "gene1": "RUNX1",
      "gene2": "RUNX1T1",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "RUNX1--RUNX1T1 Fusion"
    },
    {
      "id": 60,
      "feature_type": "rearrangement",
      "gene1": "SLC45A3",
      "gene2": "BRAF",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "SLC45A3--BRAF Fusion"
    },
    {
      "id": 62,
      "feature_type": "rearrangement",
      "gene1": "TMPRSS2",
      "gene2": "ERG",
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "TMPRSS2--ERG Fusion"
    },
    {
      "id": 66,
      "alternate_allele": "T",
      "cdna_change": "c.944C>T",
      "chromosome": "9",
      "end_position": "133748283",
      "exon": "5",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.T315I",
      "reference_allele": "C",
      "rsid": "rs121913459",
      "start_position": "133748283",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.T315I (Missense)"
    },
    {
      "id": 67,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "9",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "ABL1 (Missense)"
    },
    {
      "id": 68,
      "alternate_allele": "G",
      "cdna_change": "c.943A>G",
      "chromosome": "9",
      "end_position": "133747582",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.T315A",
      "reference_allele": "A",
      "rsid": "rs1057519772",
      "start_position": "133747582",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.T315A (Missense)"
    },
    {
      "id": 70,
      "alternate_allele": "G",
      "cdna_change": "c.951C>G",
      "chromosome": "9",
      "end_position": "133748290",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F317L",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "133748290",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F317L (Missense)"
    },
    {
      "id": 71,
      "alternate_allele": "G",
      "cdna_change": "c.949T>G",
      "chromosome": "9",
      "end_position": "133748288",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F317V",
      "reference_allele": "T",
      "rsid": "rs1057519773",
      "start_position": "133748288",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F317V (Missense)"
    },
    {
      "id": 72,
      "alternate_allele": "A",
      "cdna_change": "c.949T>A",
      "chromosome": "9",
      "end_position": "133748288",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F317I",
      "reference_allele": "T",
      "rsid": "rs1057519773",
      "start_position": "133748288",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F317I (Missense)"
    },
    {
      "id": 73,
      "alternate_allele": "G",
      "cdna_change": "c.950T>G",
      "chromosome": "9",
      "end_position": "133747586",
      "exon": "5",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F317C",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "133747586",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F317C (Missense)"
    },
    {
      "id": 74,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "9",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ABL1"
    },
    {
      "id": 75,
      "alternate_allele": "A",
      "cdna_change": "c.763G>A",
      "chromosome": "9",
      "end_position": "133738306",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.E255K",
      "reference_allele": "G",
      "rsid": "rs387906517",
      "start_position": "133738306",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.E255K (Missense)"
    },
    {
      "id": 76,
      "alternate_allele": "T",
      "cdna_change": "c.764A>T",
      "chromosome": "9",
      "end_position": "133738307",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.E255V",
      "reference_allele": "A",
      "rsid": "rs387906516",
      "start_position": "133738307",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.E255V (Missense)"
    },
    {
      "id": 77,
      "alternate_allele": "C",
      "cdna_change": "c.757T>C",
      "chromosome": "9",
      "end_position": "133738357",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.Y253H",
      "reference_allele": "T",
      "rsid": "rs121913461",
      "start_position": "133738357",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.Y253H (Missense)"
    },
    {
      "id": 78,
      "alternate_allele": "G",
      "cdna_change": "c.1075T>G",
      "chromosome": "9",
      "end_position": "133748414",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F359V",
      "reference_allele": "T",
      "rsid": "rs121913452",
      "start_position": "133748414",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F359V (Missense)"
    },
    {
      "id": 79,
      "alternate_allele": "G",
      "cdna_change": "c.1076T>G",
      "chromosome": "9",
      "end_position": "133748358",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F359C",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "133748358",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F359C (Missense)"
    },
    {
      "id": 80,
      "alternate_allele": "A",
      "cdna_change": "c.1075T>A",
      "chromosome": "9",
      "end_position": "133748414",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.F359I",
      "reference_allele": "T",
      "rsid": "rs121913452",
      "start_position": "133748414",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.F359I (Missense)"
    },
    {
      "id": 92,
      "alternate_allele": "T",
      "cdna_change": "c.895G>T",
      "chromosome": "9",
      "end_position": "133747531",
      "exon": "5",
      "feature_type": "somatic_variant",
      "gene": "ABL1",
      "protein_change": "p.V299L",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "133747531",
      "variant_annotation": "Missense",
      "feature": "ABL1 p.V299L (Missense)"
    },
    {
      "id": 106,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "14",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "AKT1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "AKT1 (Missense)"
    },
    {
      "id": 107,
      "alternate_allele": "T",
      "cdna_change": "c.49G>A",
      "chromosome": "14",
      "end_position": "105246551",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "AKT1",
      "protein_change": "p.E17K",
      "reference_allele": "C",
      "rsid": "rs34409589",
      "start_position": "105246551",
      "variant_annotation": "Missense",
      "feature": "AKT1 p.E17K (Missense)"
    },
    {
      "id": 108,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "AKT2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "AKT2 (Missense)"
    },
    {
      "id": 109,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "AKT3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "AKT3 (Missense)"
    },
    {
      "id": 110,
      "alternate_allele": "T",
      "cdna_change": "c.3604G>A",
      "chromosome": "2",
      "end_position": "29443613",
      "exon": "23",
      "feature_type": "somatic_variant",
      "gene": "ALK",
      "protein_change": "p.G1202R",
      "reference_allele": "C",
      "rsid": "rs1057519783",
      "start_position": "29443613",
      "variant_annotation": "Missense",
      "feature": "ALK p.G1202R (Missense)"
    },
    {
      "id": 111,
      "alternate_allele": "C",
      "cdna_change": "c.3521T>G",
      "chromosome": "2",
      "end_position": "29443696",
      "exon": "23",
      "feature_type": "somatic_variant",
      "gene": "ALK",
      "protein_change": "p.F1174C",
      "reference_allele": "A",
      "rsid": "rs1057519697",
      "start_position": "29443696",
      "variant_annotation": "Missense",
      "feature": "ALK p.F1174C (Missense)"
    },
    {
      "id": 112,
      "alternate_allele": "T",
      "cdna_change": "c.3586C>A",
      "chromosome": "2",
      "end_position": "29443631",
      "exon": "23",
      "feature_type": "somatic_variant",
      "gene": "ALK",
      "protein_change": "p.L1196M",
      "reference_allele": "G",
      "rsid": "rs1057519784",
      "start_position": "29443631",
      "variant_annotation": "Missense",
      "feature": "ALK p.L1196M (Missense)"
    },
    {
      "id": 113,
      "alternate_allele": "G",
      "cdna_change": "c.3806G>C",
      "chromosome": "2",
      "end_position": "29432682",
      "exon": "25",
      "feature_type": "somatic_variant",
      "gene": "ALK",
      "protein_change": "p.G1269A",
      "reference_allele": "C",
      "rsid": "rs1057519781",
      "start_position": "29432682",
      "variant_annotation": "Missense",
      "feature": "ALK p.G1269A (Missense)"
    },
    {
      "id": 114,
      "alternate_allele": "T",
      "cdna_change": "c.3617C>A",
      "chromosome": "2",
      "end_position": "29443600",
      "exon": "23",
      "feature_type": "somatic_variant",
      "gene": "ALK",
      "protein_change": "p.S1206Y",
      "reference_allele": "G",
      "rsid": "rs1057519782",
      "start_position": "29443600",
      "variant_annotation": "Missense",
      "feature": "ALK p.S1206Y (Missense)"
    },
    {
      "id": 115,
      "alternate_allele": "G",
      "cdna_change": "c.2632A>G",
      "chromosome": "X",
      "end_position": "66943552",
      "exon": "8",
      "feature_type": "somatic_variant",
      "gene": "AR",
      "protein_change": "p.T878A",
      "reference_allele": "A",
      "rsid": "rs137852578",
      "start_position": "66943552",
      "variant_annotation": "Missense",
      "feature": "AR p.T878A (Missense)"
    },
    {
      "id": 116,
      "alternate_allele": "A",
      "cdna_change": "c.2105T>A",
      "chromosome": "X",
      "end_position": "66931463",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "AR",
      "protein_change": "p.L702H",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "66931463",
      "variant_annotation": "Missense",
      "feature": "AR p.L702H (Missense)"
    },
    {
      "id": 117,
      "alternate_allele": "G",
      "cdna_change": "c.641C>G",
      "chromosome": "X",
      "end_position": "47426121",
      "exon": "7",
      "feature_type": "somatic_variant",
      "gene": "ARAF",
      "protein_change": "p.S214C",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "47426121",
      "variant_annotation": "Missense",
      "feature": "ARAF p.S214C (Missense)"
    },
    {
      "id": 118,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ARID1A",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "ARID1A (Nonsense)"
    },
    {
      "id": 119,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ARID1A",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "ARID1A (Frameshift)"
    },
    {
      "id": 120,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ARID1A",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ARID1A"
    },
    {
      "id": 121,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ASXL1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "ASXL1 (Nonsense)"
    },
    {
      "id": 122,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ASXL1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "ASXL1 (Frameshift)"
    },
    {
      "id": 123,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ATM",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "ATM (Frameshift)"
    },
    {
      "id": 124,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ATM",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "ATM (Splice Site)"
    },
    {
      "id": 125,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ATM",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "ATM (Nonsense)"
    },
    {
      "id": 129,
      "alternate_allele": "A",
      "cdna_change": "c.3380C>A",
      "chromosome": "11",
      "end_position": "108150313",
      "exon": "23",
      "feature_type": "somatic_variant",
      "gene": "ATM",
      "protein_change": "p.A1127D",
      "reference_allele": "C",
      "rsid": "rs1555090340",
      "start_position": "108150313",
      "variant_annotation": "Missense",
      "feature": "ATM p.A1127D (Missense)"
    },
    {
      "id": 130,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ATM",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ATM"
    },
    {
      "id": 131,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BARD1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BARD1"
    },
    {
      "id": 138,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BCOR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "BCOR (Nonsense)"
    },
    {
      "id": 139,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BCOR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "BCOR (Frameshift)"
    },
    {
      "id": 140,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BCOR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "BCOR (Splice Site)"
    },
    {
      "id": 141,
      "alternate_allele": "C",
      "cdna_change": "c.4376A>G",
      "chromosome": "X",
      "end_position": "39921444",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "BCOR",
      "protein_change": "p.N1425S",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "39921444",
      "variant_annotation": "Missense",
      "feature": "BCOR p.N1425S (Missense)"
    },
    {
      "id": 142,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BCR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BCR"
    },
    {
      "id": 143,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BLM",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BLM"
    },
    {
      "id": 144,
      "alternate_allele": "T",
      "cdna_change": "c.1799T>A",
      "chromosome": "7",
      "end_position": "140453136",
      "exon": "15",
      "feature_type": "somatic_variant",
      "gene": "BRAF",
      "protein_change": "p.V600E",
      "reference_allele": "A",
      "rsid": "rs113488022",
      "start_position": "140453136",
      "variant_annotation": "Missense",
      "feature": "BRAF p.V600E (Missense)"
    },
    {
      "id": 146,
      "alternate_allele": "TT",
      "cdna_change": "c.1798_1799GT>AA",
      "chromosome": "7",
      "end_position": "140453137",
      "exon": "15",
      "feature_type": "somatic_variant",
      "gene": "BRAF",
      "protein_change": "p.V600K",
      "reference_allele": "AC",
      "rsid": "rs121913227",
      "start_position": "140453136",
      "variant_annotation": "Missense",
      "feature": "BRAF p.V600K (Missense)"
    },
    {
      "id": 166,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRAF",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRAF"
    },
    {
      "id": 185,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRCA1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRCA1"
    },
    {
      "id": 201,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRCA2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRCA2"
    },
    {
      "id": 214,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRCA2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "BRCA2 (Nonsense)"
    },
    {
      "id": 219,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRIP1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRIP1"
    },
    {
      "id": 226,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "CDK12",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CDK12"
    },
    {
      "id": 227,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "CHEK1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CHEK1"
    },
    {
      "id": 234,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "CHEK2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CHEK2"
    },
    {
      "id": 241,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "CTNNB1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CTNNB1"
    },
    {
      "id": 242,
      "alternate_allele": "T",
      "cdna_change": "c.2369C>T",
      "chromosome": "7",
      "end_position": "55249071",
      "exon": "20",
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": "p.T790M",
      "reference_allele": "C",
      "rsid": "rs121434569",
      "start_position": "55249071",
      "variant_annotation": "Missense",
      "feature": "EGFR p.T790M (Missense)"
    },
    {
      "id": 243,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "EGFR"
    },
    {
      "id": 248,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": "20",
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Insertion",
      "feature": "EGFR (Insertion)"
    },
    {
      "id": 254,
      "alternate_allele": "G",
      "cdna_change": "c.2573T>G",
      "chromosome": "7",
      "end_position": "55259515",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": "p.L858R",
      "reference_allele": "T",
      "rsid": "rs121434568",
      "start_position": "55259515",
      "variant_annotation": "Missense",
      "feature": "EGFR p.L858R (Missense)"
    },
    {
      "id": 267,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "EGFR (Nonsense)"
    },
    {
      "id": 270,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": "19",
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "EGFR (Nonsense)"
    },
    {
      "id": 272,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": "19",
      "feature_type": "somatic_variant",
      "gene": "EGFR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Deletion",
      "feature": "EGFR (Deletion)"
    },
    {
      "id": 276,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ERBB2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "ERBB2 (Missense)"
    },
    {
      "id": 277,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ERBB2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ERBB2"
    },
    {
      "id": 278,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ERBB3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "ERBB3 (Missense)"
    },
    {
      "id": 279,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ERCC2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "ERCC2 (Missense)"
    },
    {
      "id": 281,
      "alternate_allele": "A",
      "cdna_change": "c.1150G>T",
      "chromosome": "1",
      "end_position": "8073509",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "ERRFI1",
      "protein_change": "p.E384*",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "8073509",
      "variant_annotation": "Nonsense",
      "feature": "ERRFI1 p.E384* (Nonsense)"
    },
    {
      "id": 282,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ESR1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ESR1"
    },
    {
      "id": 283,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ETV6",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "ETV6 (Nonsense)"
    },
    {
      "id": 284,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ETV6",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "ETV6 (Frameshift)"
    },
    {
      "id": 285,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "EZH2 (Nonsense)"
    },
    {
      "id": 286,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "EZH2 (Frameshift)"
    },
    {
      "id": 287,
      "alternate_allele": "T",
      "cdna_change": "c.1938C>A",
      "chromosome": "7",
      "end_position": "148508726",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": "p.Y646*",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "148508726",
      "variant_annotation": "Nonsense",
      "feature": "EZH2 p.Y646* (Nonsense)"
    },
    {
      "id": 288,
      "alternate_allele": "A",
      "cdna_change": "c.1937A>T",
      "chromosome": "7",
      "end_position": "148508727",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": "p.Y646F",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "148508727",
      "variant_annotation": "Missense",
      "feature": "EZH2 p.Y646F (Missense)"
    },
    {
      "id": 289,
      "alternate_allele": "T",
      "cdna_change": "c.1936T>A",
      "chromosome": "7",
      "end_position": "148508728",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": "p.Y646N",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "148508728",
      "variant_annotation": "Missense",
      "feature": "EZH2 p.Y646N (Missense)"
    },
    {
      "id": 290,
      "alternate_allele": "C",
      "cdna_change": "c.2045C>G",
      "chromosome": "7",
      "end_position": "148506467",
      "exon": "18",
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": "p.A682G",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "148506467",
      "variant_annotation": "Missense",
      "feature": "EZH2 p.A682G (Missense)"
    },
    {
      "id": 291,
      "alternate_allele": "A",
      "cdna_change": "c.2075C>T",
      "chromosome": "7",
      "end_position": "148506437",
      "exon": "18",
      "feature_type": "somatic_variant",
      "gene": "EZH2",
      "protein_change": "p.A692V",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "148506437",
      "variant_annotation": "Missense",
      "feature": "EZH2 p.A692V (Missense)"
    },
    {
      "id": 292,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FANCL",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "FANCL"
    },
    {
      "id": 293,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FBXW7",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "FBXW7 (Missense)"
    },
    {
      "id": 294,
      "alternate_allele": "T",
      "cdna_change": "c.742C>T",
      "chromosome": "4",
      "end_position": "1803564",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "FGFR3",
      "protein_change": "p.R248C",
      "reference_allele": "C",
      "rsid": "rs121913482",
      "start_position": "1803564",
      "variant_annotation": "Missense",
      "feature": "FGFR3 p.R248C (Missense)"
    },
    {
      "id": 295,
      "alternate_allele": "G",
      "cdna_change": "c.746C>G",
      "chromosome": "4",
      "end_position": "1803568",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "FGFR3",
      "protein_change": "p.S249C",
      "reference_allele": "C",
      "rsid": "rs121913483",
      "start_position": "1803568",
      "variant_annotation": "Missense",
      "feature": "FGFR3 p.S249C (Missense)"
    },
    {
      "id": 296,
      "alternate_allele": "T",
      "cdna_change": "c.1180G>T",
      "chromosome": "4",
      "end_position": "1806089",
      "exon": "8",
      "feature_type": "somatic_variant",
      "gene": "FGFR3",
      "protein_change": "p.G370C",
      "reference_allele": "G",
      "rsid": "rs121913479",
      "start_position": "1806089",
      "variant_annotation": "Missense",
      "feature": "FGFR3 p.G370C (Missense)"
    },
    {
      "id": 297,
      "alternate_allele": "G",
      "cdna_change": "c.1118A>G",
      "chromosome": "4",
      "end_position": "1806099",
      "exon": "8",
      "feature_type": "somatic_variant",
      "gene": "FGFR3",
      "protein_change": "p.Y373C",
      "reference_allele": "A",
      "rsid": "rs121913485",
      "start_position": "1806099",
      "variant_annotation": "Missense",
      "feature": "FGFR3 p.Y373C (Missense)"
    },
    {
      "id": 298,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FLCN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "FLCN (Nonsense)"
    },
    {
      "id": 301,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FLCN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "FLCN (Frameshift)"
    },
    {
      "id": 304,
      "alternate_allele": "G",
      "cdna_change": "c.2071T>C",
      "chromosome": "13",
      "end_position": "28601361",
      "exon": "17",
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": "p.F691L",
      "reference_allele": "A",
      "rsid": "rs759272576",
      "start_position": "28601361",
      "variant_annotation": "Missense",
      "feature": "FLT3 p.F691L (Missense)"
    },
    {
      "id": 305,
      "alternate_allele": "G",
      "cdna_change": "c.1987A>C",
      "chromosome": "13",
      "end_position": "28602381",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": "p.K663Q",
      "reference_allele": "T",
      "rsid": "rs1057520026",
      "start_position": "28602381",
      "variant_annotation": "Missense",
      "feature": "FLT3 p.K663Q (Missense)"
    },
    {
      "id": 306,
      "alternate_allele": "A",
      "cdna_change": "c.881T>A",
      "chromosome": "10",
      "end_position": "8106058",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "GATA3",
      "protein_change": "p.M294K",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "8106058",
      "variant_annotation": "Missense",
      "feature": "GATA3 p.M294K (Missense)"
    },
    {
      "id": 307,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "IDH1"
    },
    {
      "id": 310,
      "alternate_allele": "T",
      "cdna_change": "c.395G>A",
      "chromosome": "2",
      "end_position": "209113112",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": "p.R132H",
      "reference_allele": "C",
      "rsid": "rs121913500",
      "start_position": "209113112",
      "variant_annotation": "Missense",
      "feature": "IDH1 p.R132H (Missense)"
    },
    {
      "id": 311,
      "alternate_allele": "A",
      "cdna_change": "c.394C>T",
      "chromosome": "2",
      "end_position": "209113113",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": "p.R132C",
      "reference_allele": "G",
      "rsid": "rs121913499",
      "start_position": "209113113",
      "variant_annotation": "Missense",
      "feature": "IDH1 p.R132C (Missense)"
    },
    {
      "id": 316,
      "alternate_allele": "T",
      "cdna_change": "c.419G>A",
      "chromosome": "15",
      "end_position": "90631934",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH2",
      "protein_change": "p.R140Q",
      "reference_allele": "C",
      "rsid": "rs121913502",
      "start_position": "90631934",
      "variant_annotation": "Missense",
      "feature": "IDH2 p.R140Q (Missense)"
    },
    {
      "id": 317,
      "alternate_allele": "A",
      "cdna_change": "c.516G>T",
      "chromosome": "15",
      "end_position": "90631837",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH2",
      "protein_change": "p.R172S",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "90631837",
      "variant_annotation": "Missense",
      "feature": "IDH2 p.R172S (Missense)"
    },
    {
      "id": 318,
      "alternate_allele": "T",
      "cdna_change": "c.515G>A",
      "chromosome": "15",
      "end_position": "90631837",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH2",
      "protein_change": "p.R172K",
      "reference_allele": "C",
      "rsid": "rs121913503",
      "start_position": "90631837",
      "variant_annotation": "Missense",
      "feature": "IDH2 p.R172K (Missense)"
    },
    {
      "id": 319,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "15",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "IDH2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "IDH2"
    },
    {
      "id": 321,
      "alternate_allele": "T",
      "cdna_change": "c.419G>A",
      "chromosome": "15",
      "end_position": "90631934",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH2",
      "protein_change": "p.R140Q",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "90631934",
      "variant_annotation": "Missense",
      "feature": "IDH2 p.R140Q (Missense)"
    },
    {
      "id": 324,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "1",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "JAK1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "JAK1"
    },
    {
      "id": 325,
      "alternate_allele": "A",
      "cdna_change": "c.1966G>T",
      "chromosome": "1",
      "end_position": "65312353",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "JAK1",
      "protein_change": "p.V656F",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "65312353",
      "variant_annotation": "Missense",
      "feature": "JAK1 p.V656F (Missense)"
    },
    {
      "id": 326,
      "alternate_allele": "T",
      "cdna_change": "c.1901C>A",
      "chromosome": "1",
      "end_position": "65312418",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "JAK1",
      "protein_change": "p.A634D",
      "reference_allele": "G",
      "rsid": "rs869312953",
      "start_position": "65312418",
      "variant_annotation": "Missense",
      "feature": "JAK1 p.A634D (Missense)"
    },
    {
      "id": 327,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "JAK2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "JAK2"
    },
    {
      "id": 328,
      "alternate_allele": "T",
      "cdna_change": "c.1849G>T",
      "chromosome": "9",
      "end_position": "5073770",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "JAK2",
      "protein_change": "p.V617F",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "5073770",
      "variant_annotation": "Missense",
      "feature": "JAK2 p.V617F (Missense)"
    },
    {
      "id": 329,
      "alternate_allele": "T",
      "cdna_change": "c.1714G>A",
      "chromosome": "19",
      "end_position": "17948010",
      "exon": "13",
      "feature_type": "somatic_variant",
      "gene": "JAK3",
      "protein_change": "p.A572T",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "17948010",
      "variant_annotation": "Missense",
      "feature": "JAK3 p.A572T (Missense)"
    },
    {
      "id": 330,
      "alternate_allele": "T",
      "cdna_change": "c.1533G>A",
      "chromosome": "19",
      "end_position": "17949108",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "JAK3",
      "protein_change": "p.M511I",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "17949108",
      "variant_annotation": "Missense",
      "feature": "JAK3 p.M511I (Missense)"
    },
    {
      "id": 331,
      "alternate_allele": "T",
      "cdna_change": "c.2570T>A",
      "chromosome": "19",
      "end_position": "17943438",
      "exon": "19",
      "feature_type": "somatic_variant",
      "gene": "JAK3",
      "protein_change": "p.L857Q",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "17943438",
      "variant_annotation": "Missense",
      "feature": "JAK3 p.L857Q (Missense)"
    },
    {
      "id": 335,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KIT"
    },
    {
      "id": 339,
      "alternate_allele": "T",
      "cdna_change": "c.2009C>T",
      "chromosome": "4",
      "end_position": "55595519",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.T670I",
      "reference_allele": "C",
      "rsid": "rs121913516",
      "start_position": "55595519",
      "variant_annotation": "Missense",
      "feature": "KIT p.T670I (Missense)"
    },
    {
      "id": 340,
      "alternate_allele": "C",
      "cdna_change": "c.1961T>C",
      "chromosome": "4",
      "end_position": "55594258",
      "exon": "13",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.V654A",
      "reference_allele": "T",
      "rsid": "rs121913523",
      "start_position": "55594258",
      "variant_annotation": "Missense",
      "feature": "KIT p.V654A (Missense)"
    },
    {
      "id": 345,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KIT"
    },
    {
      "id": 346,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": "13",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KIT"
    },
    {
      "id": 347,
      "alternate_allele": "T",
      "cdna_change": "c.1671G>T",
      "chromosome": "4",
      "end_position": "55593605",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.W557C",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "55593605",
      "variant_annotation": "Missense",
      "feature": "KIT p.W557C (Missense)"
    },
    {
      "id": 348,
      "alternate_allele": "G",
      "cdna_change": "c.1669T>G",
      "chromosome": "4",
      "end_position": "55593603",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.W557G",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "55593603",
      "variant_annotation": "Missense",
      "feature": "KIT p.W557G (Missense)"
    },
    {
      "id": 349,
      "alternate_allele": "C",
      "cdna_change": "c.1669T>C",
      "chromosome": "4",
      "end_position": "55593603",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.W557R",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "55593603",
      "variant_annotation": "Missense",
      "feature": "KIT p.W557R (Missense)"
    },
    {
      "id": 350,
      "alternate_allele": "C",
      "cdna_change": "c.1676T>C",
      "chromosome": "4",
      "end_position": "55593610",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.V559A",
      "reference_allele": "T",
      "rsid": "rs121913517",
      "start_position": "55593610",
      "variant_annotation": "Missense",
      "feature": "KIT p.V559A (Missense)"
    },
    {
      "id": 351,
      "alternate_allele": "G",
      "cdna_change": "c.1676T>G",
      "chromosome": "4",
      "end_position": "55593610",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.V559G",
      "reference_allele": "T",
      "rsid": "rs121913517",
      "start_position": "55593610",
      "variant_annotation": "Missense",
      "feature": "KIT p.V559G (Missense)"
    },
    {
      "id": 352,
      "alternate_allele": "C",
      "cdna_change": "c.1727T>C",
      "chromosome": "4",
      "end_position": "55593661",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.L576P",
      "reference_allele": "T",
      "rsid": "rs121913513",
      "start_position": "55593661",
      "variant_annotation": "Missense",
      "feature": "KIT p.L576P (Missense)"
    },
    {
      "id": 353,
      "alternate_allele": "G",
      "cdna_change": "c.1924A>G",
      "chromosome": "4",
      "end_position": "55594221",
      "exon": "13",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.K642E",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "55594221",
      "variant_annotation": "Missense",
      "feature": "KIT p.K642E (Missense)"
    },
    {
      "id": 354,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": "17",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KIT"
    },
    {
      "id": 355,
      "alternate_allele": "C",
      "cdna_change": "c.2446G>C",
      "chromosome": "4",
      "end_position": "55599320",
      "exon": "17",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.D816H",
      "reference_allele": "G",
      "rsid": "rs121913506",
      "start_position": "55599320",
      "variant_annotation": "Missense",
      "feature": "KIT p.D816H (Missense)"
    },
    {
      "id": 358,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": "9",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KIT"
    },
    {
      "id": 360,
      "alternate_allele": "T",
      "cdna_change": "c.2447A>T",
      "chromosome": "4",
      "end_position": "55599321",
      "exon": "17",
      "feature_type": "somatic_variant",
      "gene": "KIT",
      "protein_change": "p.D816V",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "55599321",
      "variant_annotation": "Missense",
      "feature": "KIT p.D816V (Missense)"
    },
    {
      "id": 364,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KRAS"
    },
    {
      "id": 366,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KRAS"
    },
    {
      "id": 368,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KRAS"
    },
    {
      "id": 370,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "KRAS"
    },
    {
      "id": 372,
      "alternate_allele": "A",
      "cdna_change": "c.34G>T",
      "chromosome": "12",
      "end_position": "25398285",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": "p.G12C",
      "reference_allele": "C",
      "rsid": "rs121913530",
      "start_position": "25398285",
      "variant_annotation": "Missense",
      "feature": "KRAS p.G12C (Missense)"
    },
    {
      "id": 374,
      "alternate_allele": "T",
      "cdna_change": "c.35G>A",
      "chromosome": "12",
      "end_position": "25398284",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": "p.G12D",
      "reference_allele": "C",
      "rsid": "rs121913529",
      "start_position": "25398284",
      "variant_annotation": "Missense",
      "feature": "KRAS p.G12D (Missense)"
    },
    {
      "id": 375,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": "p.G12",
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "KRAS p.G12 (Missense)"
    },
    {
      "id": 376,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": "p.G13",
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "KRAS p.G13 (Missense)"
    },
    {
      "id": 377,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "KRAS",
      "protein_change": "p.Q61",
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "KRAS p.Q61 (Missense)"
    },
    {
      "id": 386,
      "alternate_allele": "T",
      "cdna_change": "c.371C>T",
      "chromosome": "15",
      "end_position": "66729163",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "MAP2K1",
      "protein_change": "p.P124L",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "66729163",
      "variant_annotation": "Missense",
      "feature": "MAP2K1 p.P124L (Missense)"
    },
    {
      "id": 387,
      "alternate_allele": "C",
      "cdna_change": "c.167A>C",
      "chromosome": "15",
      "end_position": "66727451",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "MAP2K1",
      "protein_change": "p.Q56P",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "66727451",
      "variant_annotation": "Missense",
      "feature": "MAP2K1 p.Q56P (Missense)"
    },
    {
      "id": 392,
      "alternate_allele": "A",
      "cdna_change": "c.361T>A",
      "chromosome": "15",
      "end_position": "66729153",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "MAP2K1",
      "protein_change": "p.C121S",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "66729153",
      "variant_annotation": "Missense",
      "feature": "MAP2K1 p.C121S (Missense)"
    },
    {
      "id": 394,
      "alternate_allele": "G",
      "cdna_change": "c.179A>C",
      "chromosome": "19",
      "end_position": "4117541",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "MAP2K2",
      "protein_change": "p.Q60P",
      "reference_allele": "T",
      "rsid": "rs1057519808",
      "start_position": "4117541",
      "variant_annotation": "Missense",
      "feature": "MAP2K2 p.Q60P (Missense)"
    },
    {
      "id": 395,
      "alternate_allele": "T",
      "cdna_change": "c.964G>A",
      "chromosome": "22",
      "end_position": "22127164",
      "exon": "7",
      "feature_type": "somatic_variant",
      "gene": "MAPK1",
      "protein_change": "p.E322K",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "22127164",
      "variant_annotation": "Missense",
      "feature": "MAPK1 p.E322K (Missense)"
    },
    {
      "id": 396,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MC1R",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MC1R"
    },
    {
      "id": 397,
      "alternate_allele": "T",
      "cdna_change": "c.3029C>T",
      "chromosome": "7",
      "end_position": "116411990",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "MET",
      "protein_change": "p.T1010I",
      "reference_allele": "C",
      "rsid": "rs56391007",
      "start_position": "116411990",
      "variant_annotation": "Missense",
      "feature": "MET p.T1010I (Missense)"
    },
    {
      "id": 398,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "MET",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "MET (Splice Site)"
    },
    {
      "id": 399,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "7",
      "end_position": null,
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "MET",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Deletion",
      "feature": "MET (Deletion)"
    },
    {
      "id": 402,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MLH3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MLH3"
    },
    {
      "id": 403,
      "alternate_allele": "T",
      "cdna_change": "c.1544G>T",
      "chromosome": "1",
      "end_position": "43815009",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "MPL",
      "protein_change": "p.W515L",
      "reference_allele": "G",
      "rsid": "rs121913615",
      "start_position": "43815009",
      "variant_annotation": "Missense",
      "feature": "MPL p.W515L (Missense)"
    },
    {
      "id": 404,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MSH2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MSH2"
    },
    {
      "id": 405,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MSH6",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MSH6"
    },
    {
      "id": 406,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MTOR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MTOR"
    },
    {
      "id": 407,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MYH",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MYH"
    },
    {
      "id": 408,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "NFE2L2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Activating mutation",
      "feature": "NFE2L2 (Activating mutation)"
    },
    {
      "id": 409,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "1",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "NRAS"
    },
    {
      "id": 411,
      "alternate_allele": "G",
      "cdna_change": "c.35G>C",
      "chromosome": "1",
      "end_position": "115258747",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G12A",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258747",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G12A (Missense)"
    },
    {
      "id": 412,
      "alternate_allele": "A",
      "cdna_change": "c.34G>T",
      "chromosome": "1",
      "end_position": "115258748",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G12C",
      "reference_allele": "C",
      "rsid": "rs121913250",
      "start_position": "115258748",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G12C (Missense)"
    },
    {
      "id": 413,
      "alternate_allele": "T",
      "cdna_change": "c.35G>A",
      "chromosome": "1",
      "end_position": "115258747",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G12D",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258747",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G12D (Missense)"
    },
    {
      "id": 414,
      "alternate_allele": "G",
      "cdna_change": "p.34G>C",
      "chromosome": "1",
      "end_position": "115258748",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G12R",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258748",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G12R (Missense)"
    },
    {
      "id": 415,
      "alternate_allele": "T",
      "cdna_change": "p.34G>A",
      "chromosome": "1",
      "end_position": "115258748",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G12S",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258748",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G12S (Missense)"
    },
    {
      "id": 416,
      "alternate_allele": "A",
      "cdna_change": "p.35G>T",
      "chromosome": "1",
      "end_position": "115258747",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G12V",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258747",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G12V (Missense)"
    },
    {
      "id": 417,
      "alternate_allele": "G",
      "cdna_change": "c.38G>C",
      "chromosome": "1",
      "end_position": "115258744",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G13A",
      "reference_allele": "C",
      "rsid": "rs121434596",
      "start_position": "115258744",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G13A (Missense)"
    },
    {
      "id": 418,
      "alternate_allele": "T",
      "cdna_change": "c.38G>A",
      "chromosome": "1",
      "end_position": "115258744",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G13D",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258744",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G13D (Missense)"
    },
    {
      "id": 419,
      "alternate_allele": "G",
      "cdna_change": "c.37G>C",
      "chromosome": "1",
      "end_position": "115258745",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G13R",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "115258745",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G13R (Missense)"
    },
    {
      "id": 420,
      "alternate_allele": "A",
      "cdna_change": "c.38G>T",
      "chromosome": "1",
      "end_position": "115258744",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.G13V",
      "reference_allele": "C",
      "rsid": "rs121434596",
      "start_position": "115258744",
      "variant_annotation": "Missense",
      "feature": "NRAS p.G13V (Missense)"
    },
    {
      "id": 421,
      "alternate_allele": "C",
      "cdna_change": "c.181C>G",
      "chromosome": "1",
      "end_position": "115256530",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.Q61E",
      "reference_allele": "G",
      "rsid": "rs121913254",
      "start_position": "115256530",
      "variant_annotation": "Missense",
      "feature": "NRAS p.Q61E (Missense)"
    },
    {
      "id": 422,
      "alternate_allele": "A",
      "cdna_change": "c.183A>T",
      "chromosome": "1",
      "end_position": "115256528",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.Q61H",
      "reference_allele": "T",
      "rsid": "rs121913255",
      "start_position": "115256528",
      "variant_annotation": "Missense",
      "feature": "NRAS p.Q61H (Missense)"
    },
    {
      "id": 423,
      "alternate_allele": "A",
      "cdna_change": "c.182A>T",
      "chromosome": "1",
      "end_position": "115256529",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.Q61L",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "115256529",
      "variant_annotation": "Missense",
      "feature": "NRAS p.Q61L (Missense)"
    },
    {
      "id": 424,
      "alternate_allele": "G",
      "cdna_change": "c.182A>C",
      "chromosome": "1",
      "end_position": "115256529",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.Q61P",
      "reference_allele": "T",
      "rsid": "rs11554290",
      "start_position": "115256529",
      "variant_annotation": "Missense",
      "feature": "NRAS p.Q61P (Missense)"
    },
    {
      "id": 425,
      "alternate_allele": "C",
      "cdna_change": "c.182A>G",
      "chromosome": "1",
      "end_position": "115256529",
      "exon": "3",
      "feature_type": "somatic_variant",
      "gene": "NRAS",
      "protein_change": "p.Q61R",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "115256529",
      "variant_annotation": "Missense",
      "feature": "NRAS p.Q61R (Missense)"
    },
    {
      "id": 441,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PALB2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PALB2"
    },
    {
      "id": 449,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PBRM1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "PBRM1 (Nonsense)"
    },
    {
      "id": 450,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PDGFRA",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PDGFRA"
    },
    {
      "id": 451,
      "alternate_allele": "T",
      "cdna_change": "c.2525A>T",
      "chromosome": "4",
      "end_position": "55152093",
      "exon": "18",
      "feature_type": "somatic_variant",
      "gene": "PDGFRA",
      "protein_change": "p.D842V",
      "reference_allele": "A",
      "rsid": "rs121908585",
      "start_position": "55152093",
      "variant_annotation": "Missense",
      "feature": "PDGFRA p.D842V (Missense)"
    },
    {
      "id": 453,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "4",
      "end_position": null,
      "exon": "18",
      "feature_type": "somatic_variant",
      "gene": "PDGFRA",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PDGFRA"
    },
    {
      "id": 455,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PBRM1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "PBRM1 (Frameshift)"
    },
    {
      "id": 456,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PIK3CA"
    },
    {
      "id": 457,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "3",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PIK3CA"
    },
    {
      "id": 459,
      "alternate_allele": "C",
      "cdna_change": "c.1633G>C",
      "chromosome": "3",
      "end_position": "178936091",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E545Q",
      "reference_allele": "G",
      "rsid": "rs104886003",
      "start_position": "178936091",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E545Q (Missense)"
    },
    {
      "id": 460,
      "alternate_allele": "C",
      "cdna_change": "c.1258T>C",
      "chromosome": "3",
      "end_position": "178927980",
      "exon": "8",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.C420R",
      "reference_allele": "T",
      "rsid": "rs121913272",
      "start_position": "178927980",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.C420R (Missense)"
    },
    {
      "id": 461,
      "alternate_allele": "A",
      "cdna_change": "c.1624G>A",
      "chromosome": "3",
      "end_position": "178936082",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E542K",
      "reference_allele": "G",
      "rsid": "rs121913273",
      "start_position": "178936082",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E542K (Missense)"
    },
    {
      "id": 462,
      "alternate_allele": "C",
      "cdna_change": "c.1624G>C",
      "chromosome": "3",
      "end_position": "178936082",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E542Q",
      "reference_allele": "G",
      "rsid": "rs121913273",
      "start_position": "178936082",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E542Q (Missense)"
    },
    {
      "id": 463,
      "alternate_allele": "C",
      "cdna_change": "c.1634A>C",
      "chromosome": "3",
      "end_position": "178936092",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E545A",
      "reference_allele": "A",
      "rsid": "rs121913274",
      "start_position": "178936092",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E545A (Missense)"
    },
    {
      "id": 464,
      "alternate_allele": "T",
      "cdna_change": "c.1635G>T",
      "chromosome": "3",
      "end_position": "178936093",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E545D",
      "reference_allele": "G",
      "rsid": "rs121913275",
      "start_position": "178936093",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E545D (Missense)"
    },
    {
      "id": 466,
      "alternate_allele": "G",
      "cdna_change": "c.1634A>G",
      "chromosome": "3",
      "end_position": "178936092",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E545G",
      "reference_allele": "A",
      "rsid": "rs121913274",
      "start_position": "178936092",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E545G (Missense)"
    },
    {
      "id": 467,
      "alternate_allele": "A",
      "cdna_change": "c.1633G>A",
      "chromosome": "3",
      "end_position": "178936091",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.E545K",
      "reference_allele": "G",
      "rsid": "rs104886003",
      "start_position": "178936091",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.E545K (Missense)"
    },
    {
      "id": 468,
      "alternate_allele": "C",
      "cdna_change": "c.3145G>C",
      "chromosome": "3",
      "end_position": "178952090",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.G1049R",
      "reference_allele": "G",
      "rsid": "rs121913277",
      "start_position": "178952090",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.G1049R (Missense)"
    },
    {
      "id": 469,
      "alternate_allele": "A",
      "cdna_change": "c.3145G>A",
      "chromosome": "3",
      "end_position": "178952090",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.G1049S",
      "reference_allele": "G",
      "rsid": "rs121913277",
      "start_position": "178952090",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.G1049S (Missense)"
    },
    {
      "id": 470,
      "alternate_allele": "T",
      "cdna_change": "c.3140A>T",
      "chromosome": "3",
      "end_position": "178952085",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.H1047L",
      "reference_allele": "A",
      "rsid": "rs121913279",
      "start_position": "178952085",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.H1047L (Missense)"
    },
    {
      "id": 471,
      "alternate_allele": "G",
      "cdna_change": "c.3140A>G",
      "chromosome": "3",
      "end_position": "178952085",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.H1047R",
      "reference_allele": "A",
      "rsid": "rs121913279",
      "start_position": "178952085",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.H1047R (Missense)"
    },
    {
      "id": 472,
      "alternate_allele": "T",
      "cdna_change": "c.3139C>T",
      "chromosome": "3",
      "end_position": "178952084",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.H1047Y",
      "reference_allele": "C",
      "rsid": "rs121913281",
      "start_position": "178952084",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.H1047Y (Missense)"
    },
    {
      "id": 473,
      "alternate_allele": "C",
      "cdna_change": "c.2102A>C",
      "chromosome": "3",
      "end_position": "178938860",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.H701P",
      "reference_allele": "A",
      "rsid": "rs121913282",
      "start_position": "178938860",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.H701P (Missense)"
    },
    {
      "id": 474,
      "alternate_allele": "A",
      "cdna_change": "c.3129G>A",
      "chromosome": "3",
      "end_position": "178952074",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.M1043I",
      "reference_allele": "G",
      "rsid": "rs121913283",
      "start_position": "178952074",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.M1043I (Missense)"
    },
    {
      "id": 476,
      "alternate_allele": "G",
      "cdna_change": "c.1616C>G",
      "chromosome": "3",
      "end_position": "178936074",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.P539R",
      "reference_allele": "C",
      "rsid": "rs121913285",
      "start_position": "178936074",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.P539R (Missense)"
    },
    {
      "id": 477,
      "alternate_allele": "A",
      "cdna_change": "c.1636C>A",
      "chromosome": "3",
      "end_position": "178936094",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.Q546K",
      "reference_allele": "C",
      "rsid": "rs121913286",
      "start_position": "178936094",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.Q546K (Missense)"
    },
    {
      "id": 478,
      "alternate_allele": "G",
      "cdna_change": "c.3062A>G",
      "chromosome": "3",
      "end_position": "178952007",
      "exon": "21",
      "feature_type": "somatic_variant",
      "gene": "PIK3CA",
      "protein_change": "p.Y1021C",
      "reference_allele": "A",
      "rsid": "rs121913288",
      "start_position": "178952007",
      "variant_annotation": "Missense",
      "feature": "PIK3CA p.Y1021C (Missense)"
    },
    {
      "id": 479,
      "alternate_allele": "C",
      "cdna_change": "c.946G>C",
      "chromosome": "19",
      "end_position": "50905974",
      "exon": "8",
      "feature_type": "somatic_variant",
      "gene": "POLD1",
      "protein_change": "p.D316H",
      "reference_allele": "G",
      "rsid": "rs746087148",
      "start_position": "50905974",
      "variant_annotation": "Missense",
      "feature": "POLD1 p.D316H (Missense)"
    },
    {
      "id": 480,
      "alternate_allele": "G",
      "cdna_change": "c.947A>G",
      "chromosome": "19",
      "end_position": "50905975",
      "exon": "8",
      "feature_type": "somatic_variant",
      "gene": "POLD1",
      "protein_change": "p.D316G",
      "reference_allele": "A",
      "rsid": "rs746087148",
      "start_position": "50905975",
      "variant_annotation": "Missense",
      "feature": "POLD1 p.D316G (Missense)"
    },
    {
      "id": 481,
      "alternate_allele": "T",
      "cdna_change": "c.1225C>T",
      "chromosome": "19",
      "end_position": "50906837",
      "exon": "10",
      "feature_type": "somatic_variant",
      "gene": "POLD1",
      "protein_change": "p.R409W",
      "reference_allele": "C",
      "rsid": "rs778135510",
      "start_position": "50906837",
      "variant_annotation": "Missense",
      "feature": "POLD1 p.R409W (Missense)"
    },
    {
      "id": 482,
      "alternate_allele": "C",
      "cdna_change": "c.1421T>C",
      "chromosome": "19",
      "end_position": "50909701",
      "exon": "12",
      "feature_type": "somatic_variant",
      "gene": "POLD1",
      "protein_change": "p.L474P",
      "reference_allele": "T",
      "rsid": "rs587777627",
      "start_position": "50909701",
      "variant_annotation": "Missense",
      "feature": "POLD1 p.L474P (Missense)"
    },
    {
      "id": 483,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "19",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "POLD1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "POLD1"
    },
    {
      "id": 486,
      "alternate_allele": "C",
      "cdna_change": "c.1270C>G",
      "chromosome": "12",
      "end_position": "133250250",
      "exon": "13",
      "feature_type": "somatic_variant",
      "gene": "POLE",
      "protein_change": "p.L424V",
      "reference_allele": "G",
      "rsid": "rs483352909",
      "start_position": "133250250",
      "variant_annotation": "Missense",
      "feature": "POLE p.L424V (Missense)"
    },
    {
      "id": 487,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "12",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "POLE",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "POLE"
    },
    {
      "id": 490,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "PTEN (Nonsense)"
    },
    {
      "id": 491,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "PTEN (Frameshift)"
    },
    {
      "id": 492,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "PTEN (Splice Site)"
    },
    {
      "id": 496,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PTEN"
    },
    {
      "id": 501,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTPN11",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PTPN11"
    },
    {
      "id": 502,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RAD51B",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RAD51B"
    },
    {
      "id": 503,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RAD51C",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RAD51C"
    },
    {
      "id": 510,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RAD51D",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RAD51D"
    },
    {
      "id": 517,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RAD54L",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RAD54L"
    },
    {
      "id": 518,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RBM10",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RBM10"
    },
    {
      "id": 519,
      "alternate_allele": "A",
      "cdna_change": "c.2410G>A",
      "chromosome": "10",
      "end_position": "43614996",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "RET",
      "protein_change": "p.V804M",
      "reference_allele": "G",
      "rsid": "rs79658334",
      "start_position": "43614996",
      "variant_annotation": "Missense",
      "feature": "RET p.V804M (Missense)"
    },
    {
      "id": 520,
      "alternate_allele": "C",
      "cdna_change": "c.2753T>C",
      "chromosome": "10",
      "end_position": "43617416",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "RET",
      "protein_change": "p.M918T",
      "reference_allele": "T",
      "rsid": "rs74799832",
      "start_position": "43617416",
      "variant_annotation": "Missense",
      "feature": "RET p.M918T (Missense)"
    },
    {
      "id": 521,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RET",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RET"
    },
    {
      "id": 522,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RUNX1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "RUNX1 (Nonsense)"
    },
    {
      "id": 523,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RUNX1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "RUNX1 (Frameshift)"
    },
    {
      "id": 524,
      "alternate_allele": "A",
      "cdna_change": "c.2572G>A",
      "chromosome": "18",
      "end_position": "42531877",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.E858K",
      "reference_allele": "G",
      "rsid": null,
      "start_position": "42531877",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.E858K (Missense)"
    },
    {
      "id": 525,
      "alternate_allele": "T",
      "cdna_change": "c.2591C>T",
      "chromosome": "18",
      "end_position": "42531896",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.T864M",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "42531896",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.T864M (Missense)"
    },
    {
      "id": 526,
      "alternate_allele": "A",
      "cdna_change": "c.2594T>A",
      "chromosome": "18",
      "end_position": "42531899",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.I865N",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "42531899",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.I865N (Missense)"
    },
    {
      "id": 527,
      "alternate_allele": "A",
      "cdna_change": "c.2602G>A",
      "chromosome": "18",
      "end_position": "42531907",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.D868N",
      "reference_allele": "G",
      "rsid": "rs267607042",
      "start_position": "42531907",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.D868N (Missense)"
    },
    {
      "id": 528,
      "alternate_allele": "T",
      "cdna_change": "c.2602G>T",
      "chromosome": "18",
      "end_position": "42531907",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.D868Y",
      "reference_allele": "G",
      "rsid": "rs267607042",
      "start_position": "42531907",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.D868Y (Missense)"
    },
    {
      "id": 529,
      "alternate_allele": "T",
      "cdna_change": "c.2605A>T",
      "chromosome": "18",
      "end_position": "42531910",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.S869C",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "42531910",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.S869C (Missense)"
    },
    {
      "id": 530,
      "alternate_allele": "A",
      "cdna_change": "c.2608G>A",
      "chromosome": "18",
      "end_position": "42531913",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "SETBP1",
      "protein_change": "p.G870S",
      "reference_allele": "G",
      "rsid": "rs267607040",
      "start_position": "42531913",
      "variant_annotation": "Missense",
      "feature": "SETBP1 p.G870S (Missense)"
    },
    {
      "id": 531,
      "alternate_allele": "G",
      "cdna_change": "c.1864G>C",
      "chromosome": "2",
      "end_position": "198267493",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.E622Q",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "198267493",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.E622Q (Missense)"
    },
    {
      "id": 532,
      "alternate_allele": "G",
      "cdna_change": "c.1866G>C",
      "chromosome": "2",
      "end_position": "198267491",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.E622D",
      "reference_allele": "C",
      "rsid": "rs763149798",
      "start_position": "198267491",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.E622D (Missense)"
    },
    {
      "id": 533,
      "alternate_allele": "C",
      "cdna_change": "c.1868A>G",
      "chromosome": "2",
      "end_position": "198267489",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.Y623C",
      "reference_allele": "T",
      "rsid": "rs1039242157",
      "start_position": "198267489",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.Y623C (Missense)"
    },
    {
      "id": 534,
      "alternate_allele": "A",
      "cdna_change": "c.1873C>T",
      "chromosome": "2",
      "end_position": "198267484",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.R625C",
      "reference_allele": "G",
      "rsid": "rs775623976",
      "start_position": "198267484",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.R625C (Missense)"
    },
    {
      "id": 535,
      "alternate_allele": "T",
      "cdna_change": "c.1874G>A",
      "chromosome": "2",
      "end_position": "198267483",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.R625H",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "198267483",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.R625H (Missense)"
    },
    {
      "id": 536,
      "alternate_allele": "G",
      "cdna_change": "c.1876A>C",
      "chromosome": "2",
      "end_position": "198267481",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.N626H",
      "reference_allele": "T",
      "rsid": "rs769888451",
      "start_position": "198267481",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.N626H (Missense)"
    },
    {
      "id": 537,
      "alternate_allele": "A",
      "cdna_change": "c.1876A>T",
      "chromosome": "2",
      "end_position": "198267481",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.N626Y",
      "reference_allele": "T",
      "rsid": "rs769888451",
      "start_position": "198267481",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.N626Y (Missense)"
    },
    {
      "id": 538,
      "alternate_allele": "C",
      "cdna_change": "c.1876A>G",
      "chromosome": "2",
      "end_position": "198267481",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.N626D",
      "reference_allele": "T",
      "rsid": "rs769888451",
      "start_position": "198267481",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.N626D (Missense)"
    },
    {
      "id": 539,
      "alternate_allele": "C",
      "cdna_change": "c.1985A>G",
      "chromosome": "2",
      "end_position": "198267372",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.H662R",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "198267372",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.H662R (Missense)"
    },
    {
      "id": 540,
      "alternate_allele": "G",
      "cdna_change": "c.1987A>C",
      "chromosome": "2",
      "end_position": "198267370",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.T663P",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "198267370",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.T663P (Missense)"
    },
    {
      "id": 541,
      "alternate_allele": "G",
      "cdna_change": "c.1998G>C",
      "chromosome": "2",
      "end_position": "198267359",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.K666N",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "198267359",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.K666N (Missense)"
    },
    {
      "id": 542,
      "alternate_allele": "G",
      "cdna_change": "c.1997A>C",
      "chromosome": "2",
      "end_position": "198267360",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.K666T",
      "reference_allele": "T",
      "rsid": null,
      "start_position": "198267360",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.K666T (Missense)"
    },
    {
      "id": 543,
      "alternate_allele": "C",
      "cdna_change": "c.1996A>G",
      "chromosome": "2",
      "end_position": "198267361",
      "exon": "14",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.K666E",
      "reference_allele": "T",
      "rsid": "rs754688962",
      "start_position": "198267361",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.K666E (Missense)"
    },
    {
      "id": 544,
      "alternate_allele": "C",
      "cdna_change": "c.2098A>G",
      "chromosome": "2",
      "end_position": "198266834",
      "exon": "15",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.K700E",
      "reference_allele": "T",
      "rsid": "rs559063155",
      "start_position": "198266834",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.K700E (Missense)"
    },
    {
      "id": 545,
      "alternate_allele": "C",
      "cdna_change": "c.2111T>G",
      "chromosome": "2",
      "end_position": "198266821",
      "exon": "15",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.I704S",
      "reference_allele": "A",
      "rsid": "rs1574528840",
      "start_position": "198266821",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.I704S (Missense)"
    },
    {
      "id": 546,
      "alternate_allele": "T",
      "cdna_change": "c.2219G>A",
      "chromosome": "2",
      "end_position": "198266713",
      "exon": "15",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.G740E",
      "reference_allele": "C",
      "rsid": "rs776846119",
      "start_position": "198266713",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.G740E (Missense)"
    },
    {
      "id": 547,
      "alternate_allele": "A",
      "cdna_change": "c.2219G>T",
      "chromosome": "2",
      "end_position": "198266713",
      "exon": "15",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.G740V",
      "reference_allele": "C",
      "rsid": "rs776846119",
      "start_position": "198266713",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.G740V (Missense)"
    },
    {
      "id": 548,
      "alternate_allele": "T",
      "cdna_change": "c.2225G>A",
      "chromosome": "2",
      "end_position": "198266611",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.G742D",
      "reference_allele": "C",
      "rsid": "rs755415626",
      "start_position": "198266611",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.G742D (Missense)"
    },
    {
      "id": 549,
      "alternate_allele": "T",
      "cdna_change": "c.2343T>A",
      "chromosome": "2",
      "end_position": "198266493",
      "exon": "16",
      "feature_type": "somatic_variant",
      "gene": "SF3B1",
      "protein_change": "p.D781E",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "198266493",
      "variant_annotation": "Missense",
      "feature": "SF3B1 p.D781E (Missense)"
    },
    {
      "id": 550,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "SMARCA4",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "SMARCA4 (Nonsense)"
    },
    {
      "id": 551,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "SMARCA4",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "SMARCA4 (Frameshift)"
    },
    {
      "id": 552,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "SMARCA4",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "SMARCA4 (Splice Site)"
    },
    {
      "id": 553,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "17",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "SPOP",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "SPOP (Missense)"
    },
    {
      "id": 556,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "STAG2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "STAG2 (Nonsense)"
    },
    {
      "id": 557,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "STAG2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "STAG2 (Frameshift)"
    },
    {
      "id": 558,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "STAG2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "STAG2 (Splice Site)"
    },
    {
      "id": 559,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TET2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "TET2"
    },
    {
      "id": 560,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TP53",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "TP53 (Missense)"
    },
    {
      "id": 561,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TP53",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "TP53 (Nonsense)"
    },
    {
      "id": 562,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TP53",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "TP53 (Frameshift)"
    },
    {
      "id": 563,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TP53",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "TP53 (Splice Site)"
    },
    {
      "id": 568,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TP53",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "TP53"
    },
    {
      "id": 571,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TSC1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "TSC1"
    },
    {
      "id": 572,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TSC1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "TSC1 (Nonsense)"
    },
    {
      "id": 573,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TSC1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "TSC1 (Frameshift)"
    },
    {
      "id": 577,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TSC2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "TSC2"
    },
    {
      "id": 579,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TSC2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "TSC2 (Nonsense)"
    },
    {
      "id": 580,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "TSC2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "TSC2 (Frameshift)"
    },
    {
      "id": 583,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ZRSR2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "ZRSR2 (Nonsense)"
    },
    {
      "id": 584,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ZRSR2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "ZRSR2 (Frameshift)"
    },
    {
      "id": 585,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "ATM",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ATM"
    },
    {
      "id": 586,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "ATM",
      "pathogenic": "1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ATM"
    },
    {
      "id": 587,
      "alternate_allele": "G",
      "cdna_change": "c.2251-10T>G",
      "chromosome": "11",
      "end_position": "108128198",
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "ATM",
      "pathogenic": "1",
      "protein_change": null,
      "reference_allele": "T",
      "rsid": "rs730881346",
      "start_position": "108128198",
      "variant_annotation": null,
      "feature": "ATM"
    },
    {
      "id": 588,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "BARD1",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BARD1"
    },
    {
      "id": 594,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "BRCA1",
      "pathogenic": "1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRCA1"
    },
    {
      "id": 602,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "BRCA1",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRCA1"
    },
    {
      "id": 612,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "BRCA2",
      "pathogenic": "1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRCA2"
    },
    {
      "id": 624,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "BRCA2",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "BRCA2"
    },
    {
      "id": 628,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "CHEK1",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CHEK1"
    },
    {
      "id": 634,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "CHEK2",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CHEK2"
    },
    {
      "id": 640,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "CHEK2",
      "pathogenic": "1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "CHEK2"
    },
    {
      "id": 641,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "EPCAM",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "EPCAM"
    },
    {
      "id": 642,
      "alternate_allele": "A",
      "cdna_change": "c.94C>T",
      "chromosome": "19",
      "end_position": "18194272",
      "exon": "2",
      "feature_type": "germline_variant",
      "gene": "IL12RB1",
      "pathogenic": null,
      "protein_change": "p.Q32*",
      "reference_allele": "G",
      "rsid": "rs121434492",
      "start_position": "18194272",
      "variant_annotation": "Nonsense",
      "feature": "IL12RB1"
    },
    {
      "id": 643,
      "alternate_allele": "A",
      "cdna_change": "c.1624C>T",
      "chromosome": "19",
      "end_position": "18173082",
      "exon": "15",
      "feature_type": "germline_variant",
      "gene": "IL12RB1",
      "pathogenic": null,
      "protein_change": "p.Q542*",
      "reference_allele": "G",
      "rsid": "rs372833507",
      "start_position": "18173082",
      "variant_annotation": "Nonsense",
      "feature": "IL12RB1"
    },
    {
      "id": 644,
      "alternate_allele": "C",
      "cdna_change": "c.1719dup",
      "chromosome": "22",
      "end_position": "31672776",
      "exon": "15",
      "feature_type": "germline_variant",
      "gene": "LIMK2",
      "pathogenic": null,
      "protein_change": "p.G574Rfs*12",
      "reference_allele": "-",
      "rsid": "rs540206607",
      "start_position": "31672776",
      "variant_annotation": "Frameshift",
      "feature": "LIMK2"
    },
    {
      "id": 645,
      "alternate_allele": "G",
      "cdna_change": "c.1742dup",
      "chromosome": "22",
      "end_position": "31672807",
      "exon": "15",
      "feature_type": "germline_variant",
      "gene": "LIMK2",
      "pathogenic": null,
      "protein_change": "p.C582Lfs*4",
      "reference_allele": "-",
      "rsid": null,
      "start_position": "31672807",
      "variant_annotation": "Frameshift",
      "feature": "LIMK2"
    },
    {
      "id": 646,
      "alternate_allele": "A",
      "cdna_change": "c.2049_2050insA",
      "chromosome": "22",
      "end_position": "31673114",
      "exon": "15",
      "feature_type": "germline_variant",
      "gene": "LIMK2",
      "pathogenic": null,
      "protein_change": "p.G684Tfs*16",
      "reference_allele": "-",
      "rsid": null,
      "start_position": "31673114",
      "variant_annotation": "Frameshift",
      "feature": "LIMK2"
    },
    {
      "id": 647,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "MLH1",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MLH1"
    },
    {
      "id": 648,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "MLH3",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MLH3"
    },
    {
      "id": 649,
      "alternate_allele": "A",
      "cdna_change": "c.1726C>T",
      "chromosome": "11",
      "end_position": "94180442",
      "exon": "15",
      "feature_type": "germline_variant",
      "gene": "MRE11",
      "pathogenic": null,
      "protein_change": "p.R576*",
      "reference_allele": "G",
      "rsid": "rs774277300",
      "start_position": "94180442",
      "variant_annotation": "Nonsense",
      "feature": "MRE11"
    },
    {
      "id": 650,
      "alternate_allele": "-",
      "cdna_change": "c.1066del",
      "chromosome": "11",
      "end_position": "94201011",
      "exon": "10",
      "feature_type": "germline_variant",
      "gene": "MRE11",
      "pathogenic": null,
      "protein_change": "p.H356Tfs*34",
      "reference_allele": "C",
      "rsid": null,
      "start_position": "94201010",
      "variant_annotation": "Frameshift",
      "feature": "MRE11"
    },
    {
      "id": 651,
      "alternate_allele": null,
      "cdna_change": "c.21-6_26del",
      "chromosome": "11",
      "end_position": "94224137",
      "exon": "3",
      "feature_type": "germline_variant",
      "gene": "MRE11",
      "pathogenic": null,
      "protein_change": "p.L7fs*18",
      "reference_allele": null,
      "rsid": "rs587780138",
      "start_position": "94224125",
      "variant_annotation": "Frameshift",
      "feature": "MRE11"
    },
    {
      "id": 652,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "MSH2",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MSH2"
    },
    {
      "id": 654,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "MSH6",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MSH6"
    },
    {
      "id": 656,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "NF1",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "NF1"
    },
    {
      "id": 657,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "PALB2",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PALB2"
    },
    {
      "id": 664,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "PALB2",
      "pathogenic": "1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PALB2"
    },
    {
      "id": 665,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "PMS2",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "PMS2"
    },
    {
      "id": 666,
      "alternate_allele": "A",
      "cdna_change": "c.1406dup",
      "chromosome": "14",
      "end_position": "50117073",
      "exon": "17",
      "feature_type": "germline_variant",
      "gene": "POLE2",
      "pathogenic": null,
      "protein_change": "p.L469Ffs*17",
      "reference_allele": "-",
      "rsid": "rs776517397",
      "start_position": "50117073",
      "variant_annotation": "Frameshift",
      "feature": "POLE2"
    },
    {
      "id": 667,
      "alternate_allele": "T",
      "cdna_change": "c.1851_1852del",
      "chromosome": "7",
      "end_position": "124464070",
      "exon": "19",
      "feature_type": "germline_variant",
      "gene": "POT1",
      "pathogenic": null,
      "protein_change": "p.D617Efs*9",
      "reference_allele": "TTA",
      "rsid": "rs758673417",
      "start_position": "124464068",
      "variant_annotation": "Frameshift",
      "feature": "POT1"
    },
    {
      "id": 668,
      "alternate_allele": "A",
      "cdna_change": "c.1087C>T",
      "chromosome": "7",
      "end_position": "124482937",
      "exon": "13",
      "feature_type": "germline_variant",
      "gene": "POT1",
      "pathogenic": null,
      "protein_change": "p.R363*",
      "reference_allele": "G",
      "rsid": "rs756198077",
      "start_position": "124482937",
      "variant_annotation": "Nonsense",
      "feature": "POT1"
    },
    {
      "id": 669,
      "alternate_allele": "A",
      "cdna_change": "c.224dup",
      "chromosome": "7",
      "end_position": "124511000",
      "exon": "7",
      "feature_type": "germline_variant",
      "gene": "POT1",
      "pathogenic": null,
      "protein_change": "p.N75Kfs*16",
      "reference_allele": "-",
      "rsid": null,
      "start_position": "124511000",
      "variant_annotation": "Frameshift",
      "feature": "POT1"
    },
    {
      "id": 670,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "RAD51C",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RAD51C"
    },
    {
      "id": 676,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "RAD51D",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RAD51D"
    },
    {
      "id": 682,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "RB1",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RB1"
    },
    {
      "id": 683,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "germline_variant",
      "gene": "TP53",
      "pathogenic": null,
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "TP53"
    },
    {
      "id": 684,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "AR",
      "feature": "AR Amplification"
    },
    {
      "id": 688,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "ARID1A",
      "feature": "ARID1A Deletion"
    },
    {
      "id": 689,
      "cytoband": "20q13.2",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "AURKA",
      "feature": "AURKA Amplification"
    },
    {
      "id": 691,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "AURKB",
      "feature": "AURKB Amplification"
    },
    {
      "id": 692,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "BRAF",
      "feature": "BRAF Amplification"
    },
    {
      "id": 694,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "BRCA2",
      "feature": "BRCA2 Deletion"
    },
    {
      "id": 695,
      "cytoband": "11p13",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CCND1",
      "feature": "CCND1 Amplification"
    },
    {
      "id": 696,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CCND1",
      "feature": "CCND1 Amplification"
    },
    {
      "id": 697,
      "cytoband": "19q12",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CCNE1",
      "feature": "CCNE1 Amplification"
    },
    {
      "id": 698,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CD274",
      "feature": "CD274 Amplification"
    },
    {
      "id": 704,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CDK4",
      "feature": "CDK4 Amplification"
    },
    {
      "id": 708,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "CDKN2A",
      "feature": "CDKN2A Deletion"
    },
    {
      "id": 710,
      "cytoband": "1p32.3",
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "CDKN2C",
      "feature": "CDKN2C Deletion"
    },
    {
      "id": 711,
      "cytoband": "1p",
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "CDKN2C",
      "feature": "CDKN2C Deletion"
    },
    {
      "id": 712,
      "cytoband": "22q11.21",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CRKL",
      "feature": "CRKL Amplification"
    },
    {
      "id": 713,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "EGFR",
      "feature": "EGFR Amplification"
    },
    {
      "id": 714,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "ERBB2",
      "feature": "ERBB2 Amplification"
    },
    {
      "id": 732,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "ESR1",
      "feature": "ESR1 Amplification"
    },
    {
      "id": 733,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "FBXW7",
      "feature": "FBXW7 Deletion"
    },
    {
      "id": 734,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "FGFR1",
      "feature": "FGFR1 Amplification"
    },
    {
      "id": 738,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "FGFR2",
      "feature": "FGFR2 Amplification"
    },
    {
      "id": 742,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "HIF1a",
      "feature": "HIF1a Amplification"
    },
    {
      "id": 743,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "KEAP1",
      "feature": "KEAP1 Deletion"
    },
    {
      "id": 744,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "KIT",
      "feature": "KIT Amplification"
    },
    {
      "id": 745,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MDM2",
      "feature": "MDM2 Amplification"
    },
    {
      "id": 746,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MET",
      "feature": "MET Amplification"
    },
    {
      "id": 750,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MIR17HG",
      "feature": "MIR17HG Amplification"
    },
    {
      "id": 751,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "MIR17HG",
      "feature": "MIR17HG Deletion"
    },
    {
      "id": 752,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MRE11",
      "feature": "MRE11 Amplification"
    },
    {
      "id": 753,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MYC",
      "feature": "MYC Amplification"
    },
    {
      "id": 754,
      "cytoband": "8q24",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MYC",
      "feature": "MYC Amplification"
    },
    {
      "id": 755,
      "cytoband": "11p13",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "PAK1",
      "feature": "PAK1 Amplification"
    },
    {
      "id": 757,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "PBRM1",
      "feature": "PBRM1 Deletion"
    },
    {
      "id": 758,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "PIK3CA",
      "feature": "PIK3CA Amplification"
    },
    {
      "id": 759,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "PTEN",
      "feature": "PTEN Deletion"
    },
    {
      "id": 765,
      "cytoband": "13",
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "RB1",
      "feature": "RB1 Deletion"
    },
    {
      "id": 766,
      "cytoband": "17p13",
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "TP53",
      "feature": "TP53 Deletion"
    },
    {
      "id": 767,
      "cytoband": "20q11",
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "TPX2",
      "feature": "TPX2 Amplification"
    },
    {
      "id": 768,
      "feature_type": "microsatellite_stability",
      "status": "MSI-High",
      "feature": "MSI-High"
    },
    {
      "id": 774,
      "cosmic_signature": "SBS10a",
      "feature_type": "mutational_signature",
      "feature": "COSMIC Signature"
    },
    {
      "id": 775,
      "cosmic_signature": "SBS10b",
      "feature_type": "mutational_signature",
      "feature": "COSMIC Signature"
    },
    {
      "id": 780,
      "cosmic_signature": "SBS2",
      "feature_type": "mutational_signature",
      "feature": "COSMIC Signature"
    },
    {
      "id": 782,
      "cosmic_signature": "SBS3",
      "feature_type": "mutational_signature",
      "feature": "COSMIC Signature"
    },
    {
      "id": 788,
      "cosmic_signature": "SBS4",
      "feature_type": "mutational_signature",
      "feature": "COSMIC Signature"
    },
    {
      "id": 790,
      "cosmic_signature": "SBS5",
      "feature_type": "mutational_signature",
      "feature": "COSMIC Signature"
    },
    {
      "id": 794,
      "classification": "High",
      "feature_type": "mutational_burden",
      "minimum_mutations": null,
      "mutations_per_mb": null,
      "feature": "High"
    },
    {
      "id": 796,
      "classification": "High",
      "feature_type": "mutational_burden",
      "minimum_mutations": "178",
      "mutations_per_mb": null,
      "feature": "High (>= 178 mutations)"
    },
    {
      "id": 797,
      "classification": "High",
      "feature_type": "mutational_burden",
      "minimum_mutations": "100",
      "mutations_per_mb": null,
      "feature": "High (>= 100 mutations)"
    },
    {
      "id": 799,
      "classification": "High",
      "feature_type": "mutational_burden",
      "minimum_mutations": null,
      "mutations_per_mb": "10",
      "feature": "High (>= 10 mutations/Mb)"
    },
    {
      "id": 800,
      "feature_type": "knockdown",
      "gene": "ATM",
      "technique": "shRNA",
      "feature": "ATM (shRNA)"
    },
    {
      "id": 801,
      "feature_type": "knockdown",
      "gene": "B2M",
      "technique": "CRISPR-Cas9",
      "feature": "B2M (CRISPR-Cas9)"
    },
    {
      "id": 802,
      "feature_type": "knockdown",
      "gene": "CDK12",
      "technique": "shRNA",
      "feature": "CDK12 (shRNA)"
    },
    {
      "id": 803,
      "feature_type": "knockdown",
      "gene": "CDK12",
      "technique": "siRNA",
      "feature": "CDK12 (siRNA)"
    },
    {
      "id": 804,
      "feature_type": "knockdown",
      "gene": "CPT1A",
      "technique": "shRNA",
      "feature": "CPT1A (shRNA)"
    },
    {
      "id": 805,
      "feature_type": "knockdown",
      "gene": "RAD17",
      "technique": "shRNA",
      "feature": "RAD17 (shRNA)"
    },
    {
      "id": 807,
      "feature_type": "knockdown",
      "gene": "RAD50",
      "technique": "shRNA",
      "feature": "RAD50 (shRNA)"
    },
    {
      "id": 808,
      "feature_type": "knockdown",
      "gene": "TAP2",
      "technique": "CRISPR-Cas9",
      "feature": "TAP2 (CRISPR-Cas9)"
    },
    {
      "id": 809,
      "feature_type": "knockdown",
      "gene": "PPARGC1A",
      "technique": "CRSPR-Cas9",
      "feature": "PPARGC1A (CRSPR-Cas9)"
    },
    {
      "id": 810,
      "event": "Whole genome doubling",
      "feature_type": "aneuploidy",
      "feature": "Whole genome doubling"
    },
    {
      "id": 824,
      "feature_type": "knockdown",
      "gene": "RB1",
      "technique": "shRNA",
      "feature": "RB1 (shRNA)"
    },
    {
      "id": 825,
      "feature_type": "knockdown",
      "gene": "USP11",
      "technique": "siRNA",
      "feature": "USP11 (siRNA)"
    },
    {
      "id": 827,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRCA1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "BRCA1 (Nonsense)"
    },
    {
      "id": 828,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRCA1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "BRCA1 (Frameshift)"
    },
    {
      "id": 832,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "BRCA2",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "BRCA2 (Frameshift)"
    },
    {
      "id": 837,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RB1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "RB1 (Nonsense)"
    },
    {
      "id": 838,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RB1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "RB1 (Frameshift)"
    },
    {
      "id": 839,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "ATRX",
      "feature": "ATRX Deletion"
    },
    {
      "id": 840,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "BRCA1",
      "feature": "BRCA1 Deletion"
    },
    {
      "id": 844,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "CDKN2C",
      "feature": "CDKN2C Deletion"
    },
    {
      "id": 845,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MAP2K4",
      "feature": "MAP2K4 Amplification"
    },
    {
      "id": 848,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MAPK7",
      "feature": "MAPK7 Amplification"
    },
    {
      "id": 849,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "MYOCD",
      "feature": "MYOCD Amplification"
    },
    {
      "id": 850,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "PDGFRA",
      "feature": "PDGFRA Amplification"
    },
    {
      "id": 853,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "RB1",
      "feature": "RB1 Deletion"
    },
    {
      "id": 854,
      "feature_type": "rearrangement",
      "gene1": "FGFR1",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "FGFR1"
    },
    {
      "id": 859,
      "alternate_allele": "C",
      "cdna_change": "c.394C>G",
      "chromosome": "2",
      "end_position": "209113113",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": "p.R132G",
      "reference_allele": "G",
      "rsid": "rs121913499",
      "start_position": "209113113",
      "variant_annotation": "Missense",
      "feature": "IDH1 p.R132G (Missense)"
    },
    {
      "id": 860,
      "alternate_allele": "T",
      "cdna_change": "c.394C>A",
      "chromosome": "2",
      "end_position": "209113113",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": "p.R132S",
      "reference_allele": "G",
      "rsid": "rs121913499",
      "start_position": "209113113",
      "variant_annotation": "Missense",
      "feature": "IDH1 p.R132S (Missense)"
    },
    {
      "id": 861,
      "alternate_allele": "A",
      "cdna_change": "c.395G>T",
      "chromosome": "2",
      "end_position": "209113112",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": "p.R132L",
      "reference_allele": "C",
      "rsid": "rs121913500",
      "start_position": "209113112",
      "variant_annotation": "Missense",
      "feature": "IDH1 p.R132L (Missense)"
    },
    {
      "id": 864,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "6",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ESR1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ESR1"
    },
    {
      "id": 875,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "ATR",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "ATR"
    },
    {
      "id": 880,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FANCA",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "FANCA"
    },
    {
      "id": 881,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MLH1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MLH1"
    },
    {
      "id": 883,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "NBN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "NBN"
    },
    {
      "id": 892,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "RB1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "RB1"
    },
    {
      "id": 897,
      "cytoband": null,
      "direction": "Amplification",
      "feature_type": "copy_number",
      "gene": "CCNE1",
      "feature": "CCNE1 Amplification"
    },
    {
      "id": 901,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "BAP1",
      "feature": "BAP1 Deletion"
    },
    {
      "id": 902,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "FANCA",
      "feature": "FANCA Deletion"
    },
    {
      "id": 903,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "BARD1",
      "feature": "BARD1 Deletion"
    },
    {
      "id": 904,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "CHEK2",
      "feature": "CHEK2 Deletion"
    },
    {
      "id": 905,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "TP53",
      "feature": "TP53 Deletion"
    },
    {
      "id": 906,
      "cytoband": null,
      "direction": "Deletion",
      "feature_type": "copy_number",
      "gene": "ATM",
      "feature": "ATM Deletion"
    },
    {
      "id": 908,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "2",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "IDH1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "IDH1"
    },
    {
      "id": 912,
      "alternate_allele": "G",
      "cdna_change": "c.2504A>C",
      "chromosome": "13",
      "end_position": "28592641",
      "exon": "20",
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": "p.D835A",
      "reference_allele": "T",
      "rsid": "rs121909646",
      "start_position": "28592641",
      "variant_annotation": "Missense",
      "feature": "FLT3 p.D835A (Missense)"
    },
    {
      "id": 913,
      "alternate_allele": "G",
      "cdna_change": "c.2505T>A",
      "chromosome": "13",
      "end_position": "28592640",
      "exon": "20",
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": "p.D835E",
      "reference_allele": "T",
      "rsid": "rs121913487",
      "start_position": "28592640",
      "variant_annotation": "Missense",
      "feature": "FLT3 p.D835E (Missense)"
    },
    {
      "id": 914,
      "alternate_allele": "G",
      "cdna_change": "c.2503G>C",
      "chromosome": "13",
      "end_position": "28592642",
      "exon": "20",
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": "p.D835H",
      "reference_allele": "C",
      "rsid": "rs121913488",
      "start_position": "28592642",
      "variant_annotation": "Missense",
      "feature": "FLT3 p.D835H (Missense)"
    },
    {
      "id": 915,
      "alternate_allele": "A",
      "cdna_change": "c.2503G>T",
      "chromosome": "13",
      "end_position": "28592642",
      "exon": "20",
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": "p.D835Y",
      "reference_allele": "C",
      "rsid": "rs121913488",
      "start_position": "28592642",
      "variant_annotation": "Missense",
      "feature": "FLT3 p.D835Y (Missense)"
    },
    {
      "id": 916,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "3",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Missense",
      "feature": "FLT3 (Missense)"
    },
    {
      "id": 917,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "3",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "FLT3 (Nonsense)"
    },
    {
      "id": 918,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "3",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "FLT3 (Frameshift)"
    },
    {
      "id": 919,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "3",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "FLT3",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "FLT3 (Splice Site)"
    },
    {
      "id": 920,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "3",
      "end_position": "170837544",
      "exon": "11",
      "feature_type": "somatic_variant",
      "gene": "NPM1",
      "protein_change": "p.W288Cfs*12",
      "reference_allele": null,
      "rsid": null,
      "start_position": "170837543",
      "variant_annotation": "Frameshift",
      "feature": "NPM1 p.W288Cfs*12 (Frameshift)"
    },
    {
      "id": 921,
      "alternate_allele": "T",
      "cdna_change": "c.284C>A",
      "chromosome": "17",
      "end_position": "74732959",
      "exon": "1",
      "feature_type": "somatic_variant",
      "gene": "SRSF2",
      "protein_change": "p.P95H",
      "reference_allele": "G",
      "rsid": "rs751713049",
      "start_position": "74732959",
      "variant_annotation": "Missense",
      "feature": "SRSF2 p.P95H (Missense)"
    },
    {
      "id": 922,
      "alternate_allele": "A",
      "cdna_change": "c.284C>T",
      "chromosome": "17",
      "end_position": "74732959",
      "exon": "1",
      "feature_type": "somatic_variant",
      "gene": "SRSF2",
      "protein_change": "p.P95L",
      "reference_allele": "G",
      "rsid": "rs751713049",
      "start_position": "74732959",
      "variant_annotation": "Missense",
      "feature": "SRSF2 p.P95L (Missense)"
    },
    {
      "id": 923,
      "alternate_allele": "C",
      "cdna_change": "c.284C>G",
      "chromosome": "17",
      "end_position": "74732959",
      "exon": "1",
      "feature_type": "somatic_variant",
      "gene": "SRSF2",
      "protein_change": "p.P95R",
      "reference_allele": "G",
      "rsid": "rs751713049",
      "start_position": "74732959",
      "variant_annotation": "Missense",
      "feature": "SRSF2 p.P95R (Missense)"
    },
    {
      "id": 924,
      "alternate_allele": "C",
      "cdna_change": "c.283C>G",
      "chromosome": "17",
      "end_position": "74732960",
      "exon": "1",
      "feature_type": "somatic_variant",
      "gene": "SRSF2",
      "protein_change": "p.P95A",
      "reference_allele": "G",
      "rsid": "rs752405402",
      "start_position": "74732960",
      "variant_annotation": "Missense",
      "feature": "SRSF2 p.P95A (Missense)"
    },
    {
      "id": 925,
      "alternate_allele": "-",
      "cdna_change": "c.284_307del",
      "chromosome": "17",
      "end_position": "74732959",
      "exon": "1",
      "feature_type": "somatic_variant",
      "gene": "SRSF2",
      "protein_change": "p.P95_R102del",
      "reference_allele": "GGCGGCTGTGGTGTGAGTCCGGGG",
      "rsid": null,
      "start_position": "74732936",
      "variant_annotation": "Deletion",
      "feature": "SRSF2 p.P95_R102del (Deletion)"
    },
    {
      "id": 926,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "WT1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "WT1 (Nonsense)"
    },
    {
      "id": 927,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "WT1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "WT1 (Frameshift)"
    },
    {
      "id": 928,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "WT1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "WT1 (Splice Site)"
    },
    {
      "id": 929,
      "alternate_allele": "C",
      "cdna_change": "c.100T>G",
      "chromosome": "21",
      "end_position": "44524457",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.S34A",
      "reference_allele": "A",
      "rsid": null,
      "start_position": "44524457",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.S34A (Missense)"
    },
    {
      "id": 930,
      "alternate_allele": "A",
      "cdna_change": "c.101C>T",
      "chromosome": "21",
      "end_position": "44524456",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.S34F",
      "reference_allele": "G",
      "rsid": "rs371769427",
      "start_position": "44524456",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.S34F (Missense)"
    },
    {
      "id": 931,
      "alternate_allele": "GA",
      "cdna_change": "c.101_102delinsTC",
      "chromosome": "21",
      "end_position": "44524456",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.S34F",
      "reference_allele": "AG",
      "rsid": null,
      "start_position": "44524455",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.S34F (Missense)"
    },
    {
      "id": 932,
      "alternate_allele": "T",
      "cdna_change": "c.101C>A",
      "chromosome": "21",
      "end_position": "44524456",
      "exon": "2",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.S34Y",
      "reference_allele": "G",
      "rsid": "rs371769427",
      "start_position": "44524456",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.S34Y (Missense)"
    },
    {
      "id": 933,
      "alternate_allele": "AG",
      "cdna_change": "c.470_471inv",
      "chromosome": "21",
      "end_position": "44514777",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.Q157P",
      "reference_allele": "CT",
      "rsid": null,
      "start_position": "44514776",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.Q157P (Missense)"
    },
    {
      "id": 934,
      "alternate_allele": "G",
      "cdna_change": "c.470A>C",
      "chromosome": "21",
      "end_position": "44514777",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.Q157P",
      "reference_allele": "T",
      "rsid": "rs371246226",
      "start_position": "44514777",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.Q157P (Missense)"
    },
    {
      "id": 935,
      "alternate_allele": "C",
      "cdna_change": "c.470A>G",
      "chromosome": "21",
      "end_position": "44514777",
      "exon": "6",
      "feature_type": "somatic_variant",
      "gene": "U2AF1",
      "protein_change": "p.Q157R",
      "reference_allele": "T",
      "rsid": "rs371246226",
      "start_position": "44514777",
      "variant_annotation": "Missense",
      "feature": "U2AF1 p.Q157R (Missense)"
    },
    {
      "id": 938,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "14",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "AKT1",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "AKT1"
    },
    {
      "id": 939,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "10",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Nonsense",
      "feature": "PTEN (Nonsense)"
    },
    {
      "id": 940,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "10",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Frameshift",
      "feature": "PTEN (Frameshift)"
    },
    {
      "id": 941,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": "10",
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "PTEN",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": "Splice Site",
      "feature": "PTEN (Splice Site)"
    },
    {
      "id": 955,
      "feature_type": "rearrangement",
      "gene1": "ROS1",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "ROS1"
    },
    {
      "id": 956,
      "alternate_allele": null,
      "cdna_change": null,
      "chromosome": null,
      "end_position": null,
      "exon": null,
      "feature_type": "somatic_variant",
      "gene": "MRE11",
      "protein_change": null,
      "reference_allele": null,
      "rsid": null,
      "start_position": null,
      "variant_annotation": null,
      "feature": "MRE11"
    },
    {
      "id": 964,
      "feature_type": "rearrangement",
      "gene1": "BRAF",
      "gene2": null,
      "locus": null,
      "rearrangement_type": null,
      "feature": "BRAF"
    },
    {
      "id": 965,
      "feature_type": "rearrangement",
      "gene1": "BRAF",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "BRAF Fusion"
    },
    {
      "id": 982,
      "alternate_allele": "C",
      "cdna_change": "c.514A>G",
      "chromosome": "15",
      "end_position": "90631839",
      "exon": "4",
      "feature_type": "somatic_variant",
      "gene": "IDH2",
      "protein_change": "p.R172G",
      "reference_allele": "T",
      "rsid": "rs1057519906",
      "start_position": "90631839",
      "variant_annotation": "Missense",
      "feature": "IDH2 p.R172G (Missense)"
    },
    {
      "id": 1001,
      "feature_type": "rearrangement",
      "gene1": "KMT2A",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Translocation",
      "feature": "KMT2A Translocation"
    },
    {
      "id": 1003,
      "feature_type": "rearrangement",
      "gene1": "NRG1",
      "gene2": null,
      "locus": null,
      "rearrangement_type": "Fusion",
      "feature": "NRG1 Fusion"
    }
  ],
  "genes": [
    "ABL1",
    "AKT1",
    "AKT2",
    "AKT3",
    "ALK",
    "AR",
    "ARAF",
    "ARID1A",
    "ASXL1",
    "ATM",
    "ATR",
    "ATRX",
    "AURKA",
    "AURKB",
    "B2M",
    "BAP1",
    "BARD1",
    "BCOR",
    "BCR",
    "BLM",
    "BRAF",
    "BRCA1",
    "BRCA2",
    "BRD4",
    "BRIP1",
    "CCND1",
    "CCND3",
    "CCNE1",
    "CD274",
    "CDK12",
    "CDK4",
    "CDKN2A",
    "CDKN2C",
    "CHEK1",
    "CHEK2",
    "COL1A1",
    "CPT1A",
    "CRKL",
    "CTNNB1",
    "EGFR",
    "EML4",
    "EPCAM",
    "ERBB2",
    "ERBB3",
    "ERCC2",
    "ERG",
    "ERRFI1",
    "ESR1",
    "ESRP1",
    "ETV6",
    "EWSR1",
    "EZH2",
    "FANCA",
    "FANCL",
    "FBXW7",
    "FGFR1",
    "FGFR2",
    "FGFR3",
    "FIP1L1",
    "FLCN",
    "FLI1",
    "FLT3",
    "GATA3",
    "HIF1a",
    "IDH1",
    "IDH2",
    "IGH",
    "IL12RB1",
    "JAK1",
    "JAK2",
    "JAK3",
    "KEAP1",
    "KIT",
    "KMT2A",
    "KRAS",
    "LIMK2",
    "MAP2K1",
    "MAP2K2",
    "MAP2K4",
    "MAPK1",
    "MAPK7",
    "MC1R",
    "MDM2",
    "MET",
    "MIR17HG",
    "MLH1",
    "MLH3",
    "MPL",
    "MRE11",
    "MSH2",
    "MSH6",
    "MTOR",
    "MYC",
    "MYH",
    "MYOCD",
    "NBN",
    "NF1",
    "NFE2L2",
    "NPM1",
    "NRAS",
    "NRG1",
    "NSD2",
    "NTRK1",
    "NTRK2",
    "NTRK3",
    "PAK1",
    "PALB2",
    "PBRM1",
    "PDGFB",
    "PDGFRA",
    "PDGFRB",
    "PIK3CA",
    "PMS2",
    "POLD1",
    "POLE",
    "POLE2",
    "POT1",
    "PPARGC1A",
    "PTEN",
    "PTPN11",
    "RAD17",
    "RAD50",
    "RAD51B",
    "RAD51C",
    "RAD51D",
    "RAD54L",
    "RAF1",
    "RB1",
    "RBM10",
    "RET",
    "ROS1",
    "RUNX1",
    "RUNX1T1",
    "SETBP1",
    "SF3B1",
    "SLC45A3",
    "SMARCA4",
    "SPOP",
    "SRSF2",
    "STAG2",
    "TACC3",
    "TAP2",
    "TET2",
    "TMPRSS2",
    "TP53",
    "TPX2",
    "TSC1",
    "TSC2",
    "U2AF1",
    "USP11",
    "WT1",
    "ZRSR2"
  ],
  "assertions": [
    {
      "id": 1,
      "context": "Chronic, accelerated, or blast phase",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 1,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 2,
      "context": "Chronic phase",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for newly diagnosed patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. It is also approved for adults with chronic, accelerated, myeloid, or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 2,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 3,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 2,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 4,
      "context": "Chronic phase",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for newly diagnosed adult and pediatric patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 5,
      "context": "Relapsed or refactory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL).",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 6,
      "context": "Chronic phase",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase or in the setting of resistance or intolerance to prior therapy, including imatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 4,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 7,
      "context": "Newly diagnosed chronic phase",
      "deprecated": false,
      "description": "Nilotinib was superior to imatinib in patients (n=846) with newly diagnosed chronic-phase Ph+ CML.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 5,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 8,
      "context": "Chronic phase",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administraton (FDA) granted approval to asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) that have been previously treated.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Asciminib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 6,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 9,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Alectinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 7,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 10,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 8,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 11,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Lorlatinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 9,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 12,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 10,
      "variant": {
        "id": 12,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "ALK"
      }
    },
    {
      "id": 13,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Alectinib (Alecensa) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option as a first or subsequent line of therapy for patients with metastatic non-small cell lung cancer whose tumors harbor an ALK rearrangement",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Alectinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 14,
      "context": "Advanced",
      "deprecated": false,
      "description": "Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 12,
      "variant": {
        "id": 12,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "ALK"
      }
    },
    {
      "id": 15,
      "context": "",
      "deprecated": false,
      "description": "Crizotinib (Xalkori) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with inflammatory myofibroblastic tumors and ALK translocations.",
      "disease": {
        "name": "Inflammatory Myofibroblastic Tumor",
        "oncotree_code": "IMT",
        "oncotree_term": "Inflammatory Myofibroblastic Tumor"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 13,
      "variant": {
        "id": 15,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Translocation",
        "feature": "ALK Translocation"
      }
    },
    {
      "id": 16,
      "context": "",
      "deprecated": false,
      "description": "Ceritinib (Zykadia) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with inflammatory myofibroblastic tumors and ALK translocations.",
      "disease": {
        "name": "Inflammatory Myofibroblastic Tumor",
        "oncotree_code": "IMT",
        "oncotree_term": "Inflammatory Myofibroblastic Tumor"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 13,
      "variant": {
        "id": 15,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Translocation",
        "feature": "ALK Translocation"
      }
    },
    {
      "id": 17,
      "context": "",
      "deprecated": false,
      "description": "A sustained partial response is observed ot the ALK inhibitor crizotinib in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation.",
      "disease": {
        "name": "Inflammatory Myofibroblastic Tumor",
        "oncotree_code": "IMT",
        "oncotree_term": "Inflammatory Myofibroblastic Tumor"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 14,
      "variant": {
        "id": 15,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Translocation",
        "feature": "ALK Translocation"
      }
    },
    {
      "id": 18,
      "context": "",
      "deprecated": false,
      "description": "BET inhibition was found to have an antitumor effect in a murine model of squamous cell carcinoma.",
      "disease": {
        "name": "Squamous Cell Carcinoma, NOS",
        "oncotree_code": "SCCNOS",
        "oncotree_term": "Squamous Cell Carcinoma, NOS"
      },
      "therapy": {
        "name": "JQ1",
        "type": "Targeted therapy",
        "strategy": "BET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 15,
      "variant": {
        "id": 18,
        "feature_type": "rearrangement",
        "gene1": "BRD4",
        "gene2": null,
        "locus": "t(15;19)",
        "rearrangement_type": "Translocation",
        "feature": "BRD4 Translocation"
      }
    },
    {
      "id": 19,
      "context": "",
      "deprecated": false,
      "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 16,
      "variant": {
        "id": 19,
        "feature_type": "rearrangement",
        "gene1": "CCND1",
        "gene2": null,
        "locus": "t(11;14)",
        "rearrangement_type": "Translocation",
        "feature": "CCND1 Translocation"
      }
    },
    {
      "id": 20,
      "context": "",
      "deprecated": false,
      "description": "In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 17,
      "variant": {
        "id": 19,
        "feature_type": "rearrangement",
        "gene1": "CCND1",
        "gene2": null,
        "locus": "t(11;14)",
        "rearrangement_type": "Translocation",
        "feature": "CCND1 Translocation"
      }
    },
    {
      "id": 21,
      "context": "",
      "deprecated": false,
      "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(6;14) resulting in CCND3 overexpression.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 16,
      "variant": {
        "id": 21,
        "feature_type": "rearrangement",
        "gene1": "CCND3",
        "gene2": null,
        "locus": "t(6;14)",
        "rearrangement_type": "Translocation",
        "feature": "CCND3 Translocation"
      }
    },
    {
      "id": 22,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with localized or metastatic dermatofibrosarcoma tumors containing t(17;22)(q22;q13).",
      "disease": {
        "name": "Dermatofibrosarcoma Protuberans",
        "oncotree_code": "DFSP",
        "oncotree_term": "Dermatofibrosarcoma Protuberans"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 18,
      "variant": {
        "id": 22,
        "feature_type": "rearrangement",
        "gene1": "COL1A1",
        "gene2": "PDGFB",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "COL1A1--PDGFB Fusion"
      }
    },
    {
      "id": 23,
      "context": "Intracranial metastases",
      "deprecated": false,
      "description": "In a retrospective study of patients with NSCLC, tumors with EGFR mutations or EML4-ALK locations had improved in-field local control of brain metastases treated with gamma knife.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gamma knife",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-09",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 19,
      "variant": {
        "id": 23,
        "feature_type": "rearrangement",
        "gene1": "EML4",
        "gene2": "ALK",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "EML4--ALK Fusion"
      }
    },
    {
      "id": 24,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Crizotinib (Xalkori) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option as a first or subsequent line of therapy for patients with metastatic non-small cell lung cancer whose tumors harbor an ALK rearrangement, notable with EML4.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 23,
        "feature_type": "rearrangement",
        "gene1": "EML4",
        "gene2": "ALK",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "EML4--ALK Fusion"
      }
    },
    {
      "id": 25,
      "context": "",
      "deprecated": false,
      "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Sorafenib",
        "type": "Targeted therapy",
        "strategy": "RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 21,
      "variant": {
        "id": 25,
        "feature_type": "rearrangement",
        "gene1": "ESRP1",
        "gene2": "RAF1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ESRP1--RAF1 Fusion"
      }
    },
    {
      "id": 26,
      "context": "",
      "deprecated": false,
      "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "U0126",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 21,
      "variant": {
        "id": 25,
        "feature_type": "rearrangement",
        "gene1": "ESRP1",
        "gene2": "RAF1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ESRP1--RAF1 Fusion"
      }
    },
    {
      "id": 27,
      "context": "",
      "deprecated": false,
      "description": "EWS-FLI1 translocations may be associated with improved prognosis in Ewing's Sarcoma; however, current treatments result in patient outcomes indistinguishable by EWS-FLI1 status.",
      "disease": {
        "name": "Ewing Sarcoma",
        "oncotree_code": "ES",
        "oncotree_term": "Ewing Sarcoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 22,
      "variant": {
        "id": 27,
        "feature_type": "rearrangement",
        "gene1": "EWSR1",
        "gene2": "FLI1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "EWSR1--FLI1 Fusion"
      }
    },
    {
      "id": 28,
      "context": "",
      "deprecated": false,
      "description": "After progressing on previous treatments, a patient with a FGFR2-TACC3 fusion obtained stable disease after being treated with ponatinib.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Ponatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 23,
      "variant": {
        "id": 28,
        "feature_type": "rearrangement",
        "gene1": "FGFR2",
        "gene2": "TACC3",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "FGFR2--TACC3 Fusion"
      }
    },
    {
      "id": 29,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Pemigatinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 24,
      "variant": {
        "id": 29,
        "feature_type": "rearrangement",
        "gene1": "FGFR2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "FGFR2 Fusion"
      }
    },
    {
      "id": 30,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Pemigatinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 24,
      "variant": {
        "id": 30,
        "feature_type": "rearrangement",
        "gene1": "FGFR2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "FGFR2"
      }
    },
    {
      "id": 31,
      "context": "Adults with previously treated, unresectable locally advanced or metastatic disease",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.). Infigratinib is a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-06-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 25,
      "variant": {
        "id": 29,
        "feature_type": "rearrangement",
        "gene1": "FGFR2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "FGFR2 Fusion"
      }
    },
    {
      "id": 32,
      "context": "Locally advanced or metastatic.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Erdafitinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-25",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 26,
      "variant": {
        "id": 32,
        "feature_type": "rearrangement",
        "gene1": "FGFR3",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "FGFR3 Fusion"
      }
    },
    {
      "id": 33,
      "context": "",
      "deprecated": false,
      "description": "The combination of bortezomib with tandem transplant therapy was associated with increased event-free survival and complete remission duration in multiple myeloma patients.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "Bortezomib",
        "type": "Targeted therapy",
        "strategy": "Proteasome inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 27,
      "variant": {
        "id": 33,
        "feature_type": "rearrangement",
        "gene1": "FGFR3",
        "gene2": "NSD2",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "FGFR3--NSD2 Fusion"
      }
    },
    {
      "id": 34,
      "context": "",
      "deprecated": false,
      "description": "A translocation between 11 and 14 [t(11;14)] has been reported to be associated with improved survival.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 28,
      "variant": {
        "id": 34,
        "feature_type": "rearrangement",
        "gene1": "IGH",
        "gene2": null,
        "locus": "t(11;14)(q13;q32)",
        "rearrangement_type": "Translocation",
        "feature": "IGH Translocation"
      }
    },
    {
      "id": 35,
      "context": "",
      "deprecated": false,
      "description": "A translocation between 4 and 14 [t(4;14)] has been reported in several studies to be associated with poor prognosis.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 28,
      "variant": {
        "id": 35,
        "feature_type": "rearrangement",
        "gene1": "IGH",
        "gene2": null,
        "locus": "t(4;14)(q16;q32)",
        "rearrangement_type": "Translocation",
        "feature": "IGH Translocation"
      }
    },
    {
      "id": 36,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Larotrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 29,
      "variant": {
        "id": 36,
        "feature_type": "rearrangement",
        "gene1": "NTRK1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK1 Fusion"
      }
    },
    {
      "id": 37,
      "context": "",
      "deprecated": false,
      "description": "NTRK fusions may respond to NTRK inhibitors",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-03-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 30,
      "variant": {
        "id": 36,
        "feature_type": "rearrangement",
        "gene1": "NTRK1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK1 Fusion"
      }
    },
    {
      "id": 38,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 31,
      "variant": {
        "id": 36,
        "feature_type": "rearrangement",
        "gene1": "NTRK1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK1 Fusion"
      }
    },
    {
      "id": 39,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Larotrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 29,
      "variant": {
        "id": 39,
        "feature_type": "rearrangement",
        "gene1": "NTRK2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK2 Fusion"
      }
    },
    {
      "id": 40,
      "context": "",
      "deprecated": false,
      "description": "NTRK fusions may respond to NTRK inhibitors.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-03-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 30,
      "variant": {
        "id": 39,
        "feature_type": "rearrangement",
        "gene1": "NTRK2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK2 Fusion"
      }
    },
    {
      "id": 41,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 31,
      "variant": {
        "id": 39,
        "feature_type": "rearrangement",
        "gene1": "NTRK2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK2 Fusion"
      }
    },
    {
      "id": 42,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Larotrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 29,
      "variant": {
        "id": 42,
        "feature_type": "rearrangement",
        "gene1": "NTRK3",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK3 Fusion"
      }
    },
    {
      "id": 43,
      "context": "",
      "deprecated": false,
      "description": "NTRK fusions may respond to NTRK inhibitors.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-03-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 30,
      "variant": {
        "id": 42,
        "feature_type": "rearrangement",
        "gene1": "NTRK3",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK3 Fusion"
      }
    },
    {
      "id": 44,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 31,
      "variant": {
        "id": 42,
        "feature_type": "rearrangement",
        "gene1": "NTRK3",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK3 Fusion"
      }
    },
    {
      "id": 45,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 45,
        "feature_type": "rearrangement",
        "gene1": "PDGFRA",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "PDGFRA"
      }
    },
    {
      "id": 46,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions.",
      "disease": {
        "name": "Chronic Eosinophilic Leukemia, NOS",
        "oncotree_code": "CELNOS",
        "oncotree_term": "Chronic Eosinophilic Leukemia, NOS"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 46,
        "feature_type": "rearrangement",
        "gene1": "FIP1L1",
        "gene2": "PDGFRA",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "FIP1L1--PDGFRA Fusion"
      }
    },
    {
      "id": 47,
      "context": "",
      "deprecated": false,
      "description": "A patient with a BCR--PDGFRA fusion observed rapid clinical and molecular response to imatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition + PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 32,
      "variant": {
        "id": 47,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "PDGFRA",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--PDGFRA Fusion"
      }
    },
    {
      "id": 48,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 48,
        "feature_type": "rearrangement",
        "gene1": "PDGFRB",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "PDGFRB"
      }
    },
    {
      "id": 49,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with Chronic Myelomonocytic Leukemia harboring an ETV6::PDGFRB translocation.",
      "disease": {
        "name": "Chronic Myelomonocytic Leukemia",
        "oncotree_code": "CMML",
        "oncotree_term": "Chronic Myelomonocytic Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 49,
        "feature_type": "rearrangement",
        "gene1": "ETV6",
        "gene2": "PDGFRB",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ETV6--PDGFRB Fusion"
      }
    },
    {
      "id": 50,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Cabozantinib (Xalkori) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic non-small cell lung cancer whose tumors harbor a RET rearrangement.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Cabozantinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 50,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "RET"
      }
    },
    {
      "id": 51,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Vandetanib (Caprelsa) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic non-small cell lung cancer whose tumors harbor a RET rearrangement.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Vandetanib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 50,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "RET"
      }
    },
    {
      "id": 52,
      "context": "",
      "deprecated": false,
      "description": "Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated for efficacy in patients with RET fusion-positive tumors.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Cabozantinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 34,
      "variant": {
        "id": 52,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RET Fusion"
      }
    },
    {
      "id": 53,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Selpercatinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 35,
      "variant": {
        "id": 52,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RET Fusion"
      }
    },
    {
      "id": 54,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA approved test, who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate).",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Selpercatinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 36,
      "variant": {
        "id": 52,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RET Fusion"
      }
    },
    {
      "id": 55,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Pralsetinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-09-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 37,
      "variant": {
        "id": 52,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RET Fusion"
      }
    },
    {
      "id": 56,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Pralsetinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-12-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 38,
      "variant": {
        "id": 52,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RET Fusion"
      }
    },
    {
      "id": 57,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC).",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 39,
      "variant": {
        "id": 57,
        "feature_type": "rearrangement",
        "gene1": "ROS1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ROS1 Fusion"
      }
    },
    {
      "id": 59,
      "context": "",
      "deprecated": false,
      "description": "Azacitidine (Vidaza) in combination with Panobinostat (Farydak) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with myelodysplasia syndromes harboring a t(8;21)(q22;q22) translocation. t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Azacitidine + Panobinostat",
        "type": "Combination therapy",
        "strategy": "Hypomethylating agent chemotherapy + HDAC inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 41,
      "variant": {
        "id": 59,
        "feature_type": "rearrangement",
        "gene1": "RUNX1",
        "gene2": "RUNX1T1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RUNX1--RUNX1T1 Fusion"
      }
    },
    {
      "id": 60,
      "context": "",
      "deprecated": false,
      "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Sorafenib",
        "type": "Targeted therapy",
        "strategy": "RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 21,
      "variant": {
        "id": 60,
        "feature_type": "rearrangement",
        "gene1": "SLC45A3",
        "gene2": "BRAF",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "SLC45A3--BRAF Fusion"
      }
    },
    {
      "id": 61,
      "context": "",
      "deprecated": false,
      "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "U0126",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 21,
      "variant": {
        "id": 60,
        "feature_type": "rearrangement",
        "gene1": "SLC45A3",
        "gene2": "BRAF",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "SLC45A3--BRAF Fusion"
      }
    },
    {
      "id": 62,
      "context": "",
      "deprecated": false,
      "description": "Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 42,
      "variant": {
        "id": 62,
        "feature_type": "rearrangement",
        "gene1": "TMPRSS2",
        "gene2": "ERG",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "TMPRSS2--ERG Fusion"
      }
    },
    {
      "id": 63,
      "context": "",
      "deprecated": false,
      "description": "A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 43,
      "variant": {
        "id": 62,
        "feature_type": "rearrangement",
        "gene1": "TMPRSS2",
        "gene2": "ERG",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "TMPRSS2--ERG Fusion"
      }
    },
    {
      "id": 64,
      "context": "",
      "deprecated": false,
      "description": "ETS fusions did not have a better response to AR suppression and PARP inhibition.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 44,
      "variant": {
        "id": 62,
        "feature_type": "rearrangement",
        "gene1": "TMPRSS2",
        "gene2": "ERG",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "TMPRSS2--ERG Fusion"
      }
    },
    {
      "id": 65,
      "context": "",
      "deprecated": false,
      "description": "ETS fusions did not have a better response to AR suppression and PARP inhibition.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Veliparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 44,
      "variant": {
        "id": 62,
        "feature_type": "rearrangement",
        "gene1": "TMPRSS2",
        "gene2": "ERG",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "TMPRSS2--ERG Fusion"
      }
    },
    {
      "id": 66,
      "context": "",
      "deprecated": false,
      "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 45,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 67,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 67,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "9",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "ABL1 (Missense)"
      }
    },
    {
      "id": 68,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 68,
        "alternate_allele": "G",
        "cdna_change": "c.943A>G",
        "chromosome": "9",
        "end_position": "133747582",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315A",
        "reference_allele": "A",
        "rsid": "rs1057519772",
        "start_position": "133747582",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315A (Missense)"
      }
    },
    {
      "id": 69,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 70,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 70,
        "alternate_allele": "G",
        "cdna_change": "c.951C>G",
        "chromosome": "9",
        "end_position": "133748290",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317L",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "133748290",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317L (Missense)"
      }
    },
    {
      "id": 71,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 71,
        "alternate_allele": "G",
        "cdna_change": "c.949T>G",
        "chromosome": "9",
        "end_position": "133748288",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317V",
        "reference_allele": "T",
        "rsid": "rs1057519773",
        "start_position": "133748288",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317V (Missense)"
      }
    },
    {
      "id": 72,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 72,
        "alternate_allele": "A",
        "cdna_change": "c.949T>A",
        "chromosome": "9",
        "end_position": "133748288",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317I",
        "reference_allele": "T",
        "rsid": "rs1057519773",
        "start_position": "133748288",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317I (Missense)"
      }
    },
    {
      "id": 73,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 73,
        "alternate_allele": "G",
        "cdna_change": "c.950T>G",
        "chromosome": "9",
        "end_position": "133747586",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317C",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "133747586",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317C (Missense)"
      }
    },
    {
      "id": 74,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 74,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "9",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ABL1"
      }
    },
    {
      "id": 75,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 75,
        "alternate_allele": "A",
        "cdna_change": "c.763G>A",
        "chromosome": "9",
        "end_position": "133738306",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.E255K",
        "reference_allele": "G",
        "rsid": "rs387906517",
        "start_position": "133738306",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.E255K (Missense)"
      }
    },
    {
      "id": 76,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 76,
        "alternate_allele": "T",
        "cdna_change": "c.764A>T",
        "chromosome": "9",
        "end_position": "133738307",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.E255V",
        "reference_allele": "A",
        "rsid": "rs387906516",
        "start_position": "133738307",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.E255V (Missense)"
      }
    },
    {
      "id": 77,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 77,
        "alternate_allele": "C",
        "cdna_change": "c.757T>C",
        "chromosome": "9",
        "end_position": "133738357",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.Y253H",
        "reference_allele": "T",
        "rsid": "rs121913461",
        "start_position": "133738357",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.Y253H (Missense)"
      }
    },
    {
      "id": 78,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 78,
        "alternate_allele": "G",
        "cdna_change": "c.1075T>G",
        "chromosome": "9",
        "end_position": "133748414",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359V",
        "reference_allele": "T",
        "rsid": "rs121913452",
        "start_position": "133748414",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359V (Missense)"
      }
    },
    {
      "id": 79,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 79,
        "alternate_allele": "G",
        "cdna_change": "c.1076T>G",
        "chromosome": "9",
        "end_position": "133748358",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359C",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "133748358",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359C (Missense)"
      }
    },
    {
      "id": 80,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 80,
        "alternate_allele": "A",
        "cdna_change": "c.1075T>A",
        "chromosome": "9",
        "end_position": "133748414",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359I",
        "reference_allele": "T",
        "rsid": "rs121913452",
        "start_position": "133748414",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359I (Missense)"
      }
    },
    {
      "id": 81,
      "context": "Advanced",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 77,
        "alternate_allele": "C",
        "cdna_change": "c.757T>C",
        "chromosome": "9",
        "end_position": "133738357",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.Y253H",
        "reference_allele": "T",
        "rsid": "rs121913461",
        "start_position": "133738357",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.Y253H (Missense)"
      }
    },
    {
      "id": 82,
      "context": "",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 75,
        "alternate_allele": "A",
        "cdna_change": "c.763G>A",
        "chromosome": "9",
        "end_position": "133738306",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.E255K",
        "reference_allele": "G",
        "rsid": "rs387906517",
        "start_position": "133738306",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.E255K (Missense)"
      }
    },
    {
      "id": 83,
      "context": "",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 76,
        "alternate_allele": "T",
        "cdna_change": "c.764A>T",
        "chromosome": "9",
        "end_position": "133738307",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.E255V",
        "reference_allele": "A",
        "rsid": "rs387906516",
        "start_position": "133738307",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.E255V (Missense)"
      }
    },
    {
      "id": 84,
      "context": "",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 78,
        "alternate_allele": "G",
        "cdna_change": "c.1075T>G",
        "chromosome": "9",
        "end_position": "133748414",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359V",
        "reference_allele": "T",
        "rsid": "rs121913452",
        "start_position": "133748414",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359V (Missense)"
      }
    },
    {
      "id": 85,
      "context": "",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 79,
        "alternate_allele": "G",
        "cdna_change": "c.1076T>G",
        "chromosome": "9",
        "end_position": "133748358",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359C",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "133748358",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359C (Missense)"
      }
    },
    {
      "id": 86,
      "context": "",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 80,
        "alternate_allele": "A",
        "cdna_change": "c.1075T>A",
        "chromosome": "9",
        "end_position": "133748414",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359I",
        "reference_allele": "T",
        "rsid": "rs121913452",
        "start_position": "133748414",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359I (Missense)"
      }
    },
    {
      "id": 87,
      "context": "",
      "deprecated": false,
      "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 70,
        "alternate_allele": "G",
        "cdna_change": "c.951C>G",
        "chromosome": "9",
        "end_position": "133748290",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317L",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "133748290",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317L (Missense)"
      }
    },
    {
      "id": 88,
      "context": "",
      "deprecated": false,
      "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 71,
        "alternate_allele": "G",
        "cdna_change": "c.949T>G",
        "chromosome": "9",
        "end_position": "133748288",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317V",
        "reference_allele": "T",
        "rsid": "rs1057519773",
        "start_position": "133748288",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317V (Missense)"
      }
    },
    {
      "id": 89,
      "context": "",
      "deprecated": false,
      "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 72,
        "alternate_allele": "A",
        "cdna_change": "c.949T>A",
        "chromosome": "9",
        "end_position": "133748288",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317I",
        "reference_allele": "T",
        "rsid": "rs1057519773",
        "start_position": "133748288",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317I (Missense)"
      }
    },
    {
      "id": 90,
      "context": "",
      "deprecated": false,
      "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 73,
        "alternate_allele": "G",
        "cdna_change": "c.950T>G",
        "chromosome": "9",
        "end_position": "133747586",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317C",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "133747586",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317C (Missense)"
      }
    },
    {
      "id": 91,
      "context": "",
      "deprecated": false,
      "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 68,
        "alternate_allele": "G",
        "cdna_change": "c.943A>G",
        "chromosome": "9",
        "end_position": "133747582",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315A",
        "reference_allele": "A",
        "rsid": "rs1057519772",
        "start_position": "133747582",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315A (Missense)"
      }
    },
    {
      "id": 92,
      "context": "",
      "deprecated": false,
      "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Nilotinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 92,
        "alternate_allele": "T",
        "cdna_change": "c.895G>T",
        "chromosome": "9",
        "end_position": "133747531",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.V299L",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "133747531",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.V299L (Missense)"
      }
    },
    {
      "id": 93,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 75,
        "alternate_allele": "A",
        "cdna_change": "c.763G>A",
        "chromosome": "9",
        "end_position": "133738306",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.E255K",
        "reference_allele": "G",
        "rsid": "rs387906517",
        "start_position": "133738306",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.E255K (Missense)"
      }
    },
    {
      "id": 94,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 76,
        "alternate_allele": "T",
        "cdna_change": "c.764A>T",
        "chromosome": "9",
        "end_position": "133738307",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.E255V",
        "reference_allele": "A",
        "rsid": "rs387906516",
        "start_position": "133738307",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.E255V (Missense)"
      }
    },
    {
      "id": 95,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 70,
        "alternate_allele": "G",
        "cdna_change": "c.951C>G",
        "chromosome": "9",
        "end_position": "133748290",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317L",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "133748290",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317L (Missense)"
      }
    },
    {
      "id": 96,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 71,
        "alternate_allele": "G",
        "cdna_change": "c.949T>G",
        "chromosome": "9",
        "end_position": "133748288",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317V",
        "reference_allele": "T",
        "rsid": "rs1057519773",
        "start_position": "133748288",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317V (Missense)"
      }
    },
    {
      "id": 97,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 72,
        "alternate_allele": "A",
        "cdna_change": "c.949T>A",
        "chromosome": "9",
        "end_position": "133748288",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317I",
        "reference_allele": "T",
        "rsid": "rs1057519773",
        "start_position": "133748288",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317I (Missense)"
      }
    },
    {
      "id": 98,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 73,
        "alternate_allele": "G",
        "cdna_change": "c.950T>G",
        "chromosome": "9",
        "end_position": "133747586",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F317C",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "133747586",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F317C (Missense)"
      }
    },
    {
      "id": 99,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 78,
        "alternate_allele": "G",
        "cdna_change": "c.1075T>G",
        "chromosome": "9",
        "end_position": "133748414",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359V",
        "reference_allele": "T",
        "rsid": "rs121913452",
        "start_position": "133748414",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359V (Missense)"
      }
    },
    {
      "id": 100,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 79,
        "alternate_allele": "G",
        "cdna_change": "c.1076T>G",
        "chromosome": "9",
        "end_position": "133748358",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359C",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "133748358",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359C (Missense)"
      }
    },
    {
      "id": 101,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 68,
        "alternate_allele": "G",
        "cdna_change": "c.943A>G",
        "chromosome": "9",
        "end_position": "133747582",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315A",
        "reference_allele": "A",
        "rsid": "rs1057519772",
        "start_position": "133747582",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315A (Missense)"
      }
    },
    {
      "id": 102,
      "context": "",
      "deprecated": false,
      "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 77,
        "alternate_allele": "C",
        "cdna_change": "c.757T>C",
        "chromosome": "9",
        "end_position": "133738357",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.Y253H",
        "reference_allele": "T",
        "rsid": "rs121913461",
        "start_position": "133738357",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.Y253H (Missense)"
      }
    },
    {
      "id": 103,
      "context": "",
      "deprecated": false,
      "description": "Ponatinib (Iclusig) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Ponatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 104,
      "context": "",
      "deprecated": false,
      "description": "Omacetaxine is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Omacetaxine",
        "type": "Chemotherapy",
        "strategy": "Chemotherapy",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 105,
      "context": "",
      "deprecated": false,
      "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Dasatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 47,
      "variant": {
        "id": 80,
        "alternate_allele": "A",
        "cdna_change": "c.1075T>A",
        "chromosome": "9",
        "end_position": "133748414",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.F359I",
        "reference_allele": "T",
        "rsid": "rs121913452",
        "start_position": "133748414",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.F359I (Missense)"
      }
    },
    {
      "id": 106,
      "context": "",
      "deprecated": false,
      "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway. This study observed that AKT inhibitors MK-2206 and AZD5363 both caused significant growth inhibition of breast cancer explant models with AKT1 E17K mutations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Akt Inhibitor MK2206",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 48,
      "variant": {
        "id": 106,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "14",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "AKT1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "AKT1 (Missense)"
      }
    },
    {
      "id": 107,
      "context": "",
      "deprecated": false,
      "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway. This study observed that AKT inhibitors MK-2206 and AZD5363 both caused significant growth inhibition of breast cancer explant models with AKT1 E17K mutations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Akt Inhibitor MK2206",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 48,
      "variant": {
        "id": 107,
        "alternate_allele": "T",
        "cdna_change": "c.49G>A",
        "chromosome": "14",
        "end_position": "105246551",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "AKT1",
        "protein_change": "p.E17K",
        "reference_allele": "C",
        "rsid": "rs34409589",
        "start_position": "105246551",
        "variant_annotation": "Missense",
        "feature": "AKT1 p.E17K (Missense)"
      }
    },
    {
      "id": 108,
      "context": "",
      "deprecated": false,
      "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway",
      "disease": {
        "name": "",
        "oncotree_code": "",
        "oncotree_term": ""
      },
      "therapy": {
        "name": "Akt Inhibitor MK2206",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 49,
      "variant": {
        "id": 108,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "AKT2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "AKT2 (Missense)"
      }
    },
    {
      "id": 109,
      "context": "",
      "deprecated": false,
      "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway",
      "disease": {
        "name": "",
        "oncotree_code": "",
        "oncotree_term": ""
      },
      "therapy": {
        "name": "Akt Inhibitor MK2206",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 49,
      "variant": {
        "id": 109,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "AKT3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "AKT3 (Missense)"
      }
    },
    {
      "id": 110,
      "context": "",
      "deprecated": false,
      "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 50,
      "variant": {
        "id": 110,
        "alternate_allele": "T",
        "cdna_change": "c.3604G>A",
        "chromosome": "2",
        "end_position": "29443613",
        "exon": "23",
        "feature_type": "somatic_variant",
        "gene": "ALK",
        "protein_change": "p.G1202R",
        "reference_allele": "C",
        "rsid": "rs1057519783",
        "start_position": "29443613",
        "variant_annotation": "Missense",
        "feature": "ALK p.G1202R (Missense)"
      }
    },
    {
      "id": 111,
      "context": "",
      "deprecated": false,
      "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 50,
      "variant": {
        "id": 111,
        "alternate_allele": "C",
        "cdna_change": "c.3521T>G",
        "chromosome": "2",
        "end_position": "29443696",
        "exon": "23",
        "feature_type": "somatic_variant",
        "gene": "ALK",
        "protein_change": "p.F1174C",
        "reference_allele": "A",
        "rsid": "rs1057519697",
        "start_position": "29443696",
        "variant_annotation": "Missense",
        "feature": "ALK p.F1174C (Missense)"
      }
    },
    {
      "id": 112,
      "context": "",
      "deprecated": false,
      "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 50,
      "variant": {
        "id": 112,
        "alternate_allele": "T",
        "cdna_change": "c.3586C>A",
        "chromosome": "2",
        "end_position": "29443631",
        "exon": "23",
        "feature_type": "somatic_variant",
        "gene": "ALK",
        "protein_change": "p.L1196M",
        "reference_allele": "G",
        "rsid": "rs1057519784",
        "start_position": "29443631",
        "variant_annotation": "Missense",
        "feature": "ALK p.L1196M (Missense)"
      }
    },
    {
      "id": 113,
      "context": "",
      "deprecated": false,
      "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 50,
      "variant": {
        "id": 113,
        "alternate_allele": "G",
        "cdna_change": "c.3806G>C",
        "chromosome": "2",
        "end_position": "29432682",
        "exon": "25",
        "feature_type": "somatic_variant",
        "gene": "ALK",
        "protein_change": "p.G1269A",
        "reference_allele": "C",
        "rsid": "rs1057519781",
        "start_position": "29432682",
        "variant_annotation": "Missense",
        "feature": "ALK p.G1269A (Missense)"
      }
    },
    {
      "id": 114,
      "context": "",
      "deprecated": false,
      "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ceritinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 50,
      "variant": {
        "id": 114,
        "alternate_allele": "T",
        "cdna_change": "c.3617C>A",
        "chromosome": "2",
        "end_position": "29443600",
        "exon": "23",
        "feature_type": "somatic_variant",
        "gene": "ALK",
        "protein_change": "p.S1206Y",
        "reference_allele": "G",
        "rsid": "rs1057519782",
        "start_position": "29443600",
        "variant_annotation": "Missense",
        "feature": "ALK p.S1206Y (Missense)"
      }
    },
    {
      "id": 115,
      "context": "Castration Resistant Prostate Cancer",
      "deprecated": false,
      "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 51,
      "variant": {
        "id": 115,
        "alternate_allele": "G",
        "cdna_change": "c.2632A>G",
        "chromosome": "X",
        "end_position": "66943552",
        "exon": "8",
        "feature_type": "somatic_variant",
        "gene": "AR",
        "protein_change": "p.T878A",
        "reference_allele": "A",
        "rsid": "rs137852578",
        "start_position": "66943552",
        "variant_annotation": "Missense",
        "feature": "AR p.T878A (Missense)"
      }
    },
    {
      "id": 116,
      "context": "Castration Resistant Prostate Cancer",
      "deprecated": false,
      "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 51,
      "variant": {
        "id": 116,
        "alternate_allele": "A",
        "cdna_change": "c.2105T>A",
        "chromosome": "X",
        "end_position": "66931463",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "AR",
        "protein_change": "p.L702H",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "66931463",
        "variant_annotation": "Missense",
        "feature": "AR p.L702H (Missense)"
      }
    },
    {
      "id": 117,
      "context": "Advanced",
      "deprecated": false,
      "description": "Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Sorafenib",
        "type": "Targeted therapy",
        "strategy": "RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 52,
      "variant": {
        "id": 117,
        "alternate_allele": "G",
        "cdna_change": "c.641C>G",
        "chromosome": "X",
        "end_position": "47426121",
        "exon": "7",
        "feature_type": "somatic_variant",
        "gene": "ARAF",
        "protein_change": "p.S214C",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "47426121",
        "variant_annotation": "Missense",
        "feature": "ARAF p.S214C (Missense)"
      }
    },
    {
      "id": 118,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-02-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 53,
      "variant": {
        "id": 118,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ARID1A",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "ARID1A (Nonsense)"
      }
    },
    {
      "id": 119,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-02-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 53,
      "variant": {
        "id": 119,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ARID1A",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "ARID1A (Frameshift)"
      }
    },
    {
      "id": 120,
      "context": "",
      "deprecated": false,
      "description": "ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 120,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ARID1A",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ARID1A"
      }
    },
    {
      "id": 121,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights ASXL1 frameshift and nonsense variants as associated with poor prognosis in myelodysplastic syndromes, and is mutated most frequently in chronic myelomonocytic leukemia (CMML).",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 121,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ASXL1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "ASXL1 (Nonsense)"
      }
    },
    {
      "id": 122,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights ASXL1 frameshift and nonsense variants as associated with poor prognosis in myelodysplastic syndromes, and is mutated most frequently in chronic myelomonocytic leukemia (CMML).",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 122,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ASXL1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "ASXL1 (Frameshift)"
      }
    },
    {
      "id": 123,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The ATR inhibitor BAY 1895344 was tolerated in a dose-escalation phase 1 trial (NCT03188965) across 21 patients with advanced solid tumors. Responders had ATM protein loss and/or deleterious ATM variants.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Elimusertib",
        "type": "Targeted therapy",
        "strategy": "ATR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 55,
      "variant": {
        "id": 123,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "ATM (Frameshift)"
      }
    },
    {
      "id": 124,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The ATR inhibitor BAY 1895344 was tolerated in a dose-escalation phase 1 trial (NCT03188965) across 21 patients with advanced solid tumors. Responders had ATM protein loss and/or deleterious ATM variants.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Elimusertib",
        "type": "Targeted therapy",
        "strategy": "ATR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 55,
      "variant": {
        "id": 124,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "ATM (Splice Site)"
      }
    },
    {
      "id": 125,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The ATR inhibitor BAY 1895344 was tolerated in a dose-escalation phase 1 trial (NCT03188965) across 21 patients with advanced solid tumors. Responders had ATM protein loss and/or deleterious ATM variants.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Elimusertib",
        "type": "Targeted therapy",
        "strategy": "ATR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 55,
      "variant": {
        "id": 125,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "ATM (Nonsense)"
      }
    },
    {
      "id": 126,
      "context": "",
      "deprecated": false,
      "description": "In a retrospective review of 8 patients with somatic truncating ATM mutations receiving palliative radiation therapy, excellent responses were seen with a median local control period of 4.62 years.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 56,
      "variant": {
        "id": 123,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "ATM (Frameshift)"
      }
    },
    {
      "id": 127,
      "context": "",
      "deprecated": false,
      "description": "In a retrospective review of 8 patients with somatic truncating ATM mutations receiving palliative radiation therapy, excellent responses were seen with a median local control period of 4.62 years.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 56,
      "variant": {
        "id": 124,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "ATM (Splice Site)"
      }
    },
    {
      "id": 128,
      "context": "",
      "deprecated": false,
      "description": "In a retrospective review of 8 patients with somatic truncating ATM mutations receiving palliative radiation therapy, excellent responses were seen with a median local control period of 4.62 years.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 56,
      "variant": {
        "id": 125,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "ATM (Nonsense)"
      }
    },
    {
      "id": 129,
      "context": "",
      "deprecated": false,
      "description": "HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 57,
      "variant": {
        "id": 129,
        "alternate_allele": "A",
        "cdna_change": "c.3380C>A",
        "chromosome": "11",
        "end_position": "108150313",
        "exon": "23",
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": "p.A1127D",
        "reference_allele": "C",
        "rsid": "rs1555090340",
        "start_position": "108150313",
        "variant_annotation": "Missense",
        "feature": "ATM p.A1127D (Missense)"
      }
    },
    {
      "id": 130,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 130,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ATM"
      }
    },
    {
      "id": 131,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 132,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 133,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 134,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 135,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 136,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 137,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 131,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BARD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 138,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights BCOR frameshift, splice site, and nonsense variants as associated with poor prognosis in myelodysplastic syndromes, and is mutated most frequently in chronic myelomonocytic leukemia (CMML).",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 138,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BCOR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BCOR (Nonsense)"
      }
    },
    {
      "id": 139,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights BCOR frameshift, splice site, and nonsense variants as associated with poor prognosis in myelodysplastic syndromes, and is mutated most frequently in chronic myelomonocytic leukemia (CMML).",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 139,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BCOR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "BCOR (Frameshift)"
      }
    },
    {
      "id": 140,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights BCOR frameshift, splice site, and nonsense variants as associated with poor prognosis in myelodysplastic syndromes, and is mutated most frequently in chronic myelomonocytic leukemia (CMML).",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 140,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BCOR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "BCOR (Splice Site)"
      }
    },
    {
      "id": 141,
      "context": "",
      "deprecated": false,
      "description": "More frequent in Chronic Myelomonocytic Leukemia.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 141,
        "alternate_allele": "C",
        "cdna_change": "c.4376A>G",
        "chromosome": "X",
        "end_position": "39921444",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "BCOR",
        "protein_change": "p.N1425S",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "39921444",
        "variant_annotation": "Missense",
        "feature": "BCOR p.N1425S (Missense)"
      }
    },
    {
      "id": 142,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 46,
      "variant": {
        "id": 142,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BCR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BCR"
      }
    },
    {
      "id": 143,
      "context": "",
      "deprecated": false,
      "description": "BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 61,
      "variant": {
        "id": 143,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BLM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BLM"
      }
    },
    {
      "id": 144,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 62,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 145,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 62,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 146,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 62,
      "variant": {
        "id": 146,
        "alternate_allele": "TT",
        "cdna_change": "c.1798_1799GT>AA",
        "chromosome": "7",
        "end_position": "140453137",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600K",
        "reference_allele": "AC",
        "rsid": "rs121913227",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600K (Missense)"
      }
    },
    {
      "id": 147,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 62,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 148,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 62,
      "variant": {
        "id": 146,
        "alternate_allele": "TT",
        "cdna_change": "c.1798_1799GT>AA",
        "chromosome": "7",
        "end_position": "140453137",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600K",
        "reference_allele": "AC",
        "rsid": "rs121913227",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600K (Missense)"
      }
    },
    {
      "id": 149,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 62,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 150,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Trametinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 63,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 151,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Trametinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 63,
      "variant": {
        "id": 146,
        "alternate_allele": "TT",
        "cdna_change": "c.1798_1799GT>AA",
        "chromosome": "7",
        "end_position": "140453137",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600K",
        "reference_allele": "AC",
        "rsid": "rs121913227",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600K (Missense)"
      }
    },
    {
      "id": 152,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Encorafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 64,
      "variant": {
        "id": 146,
        "alternate_allele": "TT",
        "cdna_change": "c.1798_1799GT>AA",
        "chromosome": "7",
        "end_position": "140453137",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600K",
        "reference_allele": "AC",
        "rsid": "rs121913227",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600K (Missense)"
      }
    },
    {
      "id": 153,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Encorafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 64,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 154,
      "context": "Metastatic, after prior therapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab + Encorafenib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 64,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 155,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 65,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 156,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic colorectal cancer, BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor. ",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Panitumumab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 157,
      "context": "Metastatic",
      "deprecated": false,
      "description": "BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 67,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 158,
      "context": "",
      "deprecated": false,
      "description": "Vemurafenib (Zelboraf) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 68,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 159,
      "context": "",
      "deprecated": false,
      "description": "Dabrafenib (Tafinlar) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 68,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 160,
      "context": "",
      "deprecated": false,
      "description": "Vemurafenib (Zelboraf) in combination with Cobimetinib (Coltellic) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Cobimetinib + Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 68,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 161,
      "context": "",
      "deprecated": false,
      "description": "Dabrafenib (Tafinlar) in combination with Trametinib (Mekinist) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 68,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 162,
      "context": "",
      "deprecated": false,
      "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Ipilimumab + Vemurafenib",
        "type": "Combination therapy",
        "strategy": "CTLA-4 inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 69,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 163,
      "context": "",
      "deprecated": false,
      "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Ipilimumab + Vemurafenib",
        "type": "Combination therapy",
        "strategy": "CTLA-4 inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 69,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 164,
      "context": "Resistance to BRAFi monotherapy",
      "deprecated": false,
      "description": "Administration of bevacizumab in a dabrafenib-resistant melanoma cancer cell line (A375R) counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance. This study suggests that a regime which combines BRAFi with bevacizumab or inhibitors of PI3K/Akt/mTOR may be more effective than BRAFi monotherapy in the setting of resistance.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Bevacizumab + Dabrafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + VEGF/VEGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 70,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 165,
      "context": "Resistance to BRAFi monotherapy",
      "deprecated": false,
      "description": "Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance. This study suggests that a regime which combines BRAFi with bevacizumab or inhibitors of PI3K/Akt/mTOR may be more effective than BRAFi monotherapy in the setting of resistance.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Omipalisib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 70,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 166,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Treating mutant BRAF melanoma cell with both Selumetinib and PLX4720, a predecessor to Vemurafenib, prevented emergence of resistant clones.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib + Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 71,
      "variant": {
        "id": 166,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRAF"
      }
    },
    {
      "id": 167,
      "context": "",
      "deprecated": false,
      "description": "Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Bleomycin",
        "type": "Chemotherapy",
        "strategy": "Intercalated chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 72,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 168,
      "context": "",
      "deprecated": false,
      "description": "Mitochondria-targeted metabolism-interferring agent mito-CP (mitochondria-targeted carboxy-proxyl) demonstrated a tumor-suppressing effect in BRAF V600E-mutated melanoma mouse models, including models that had developed resistance to vemurafenib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Mito-CP",
        "type": "Targeted therapy",
        "strategy": "Metabolism interference",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 73,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 169,
      "context": "",
      "deprecated": false,
      "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Langerhans Cell Histiocytosis",
        "oncotree_code": "LCH",
        "oncotree_term": "Langerhans Cell Histiocytosis"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 74,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 170,
      "context": "",
      "deprecated": false,
      "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease",
        "oncotree_code": "ECD",
        "oncotree_term": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 74,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 171,
      "context": "",
      "deprecated": false,
      "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 74,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 172,
      "context": "",
      "deprecated": false,
      "description": "Study of a patient-derived orthotopic xenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Trametinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 75,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 173,
      "context": "Poorly differentiatied high-grade",
      "deprecated": false,
      "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting over 7 months when treated with dabrafenib and trametinib in combination.",
      "disease": {
        "name": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum",
        "oncotree_code": "HGNEC",
        "oncotree_term": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 76,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 174,
      "context": "Locally advanced high-grade",
      "deprecated": false,
      "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting 9 months when treated with vemurafenib and trametinib in combination.",
      "disease": {
        "name": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum",
        "oncotree_code": "HGNEC",
        "oncotree_term": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum"
      },
      "therapy": {
        "name": "Trametinib + Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 76,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 175,
      "context": "",
      "deprecated": false,
      "description": "Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Interferon Alpha + Ixazomib",
        "type": "Targeted therapy",
        "strategy": "Interferon-alpha + Proteasome inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 77,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 176,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Targeted agents, such as dabrafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 78,
      "variant": {
        "id": 166,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRAF"
      }
    },
    {
      "id": 177,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Targeted agents, such as vemurafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 78,
      "variant": {
        "id": 166,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRAF"
      }
    },
    {
      "id": 178,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Combination therapy of dabrafenib and tremetinib improved progression-free survival, objective response, and duration of response relative to dabrafenib monotherapy in a phase I/II trial.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 78,
      "variant": {
        "id": 166,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRAF"
      }
    },
    {
      "id": 179,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Targeted agents, such as tremetinib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including MEK1 and MEK2, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Trametinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 78,
      "variant": {
        "id": 166,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRAF"
      }
    },
    {
      "id": 180,
      "context": "",
      "deprecated": false,
      "description": "BRAF V600E mutations were associated with sensitivity to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 181,
      "context": "",
      "deprecated": false,
      "description": "Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.",
      "disease": {
        "name": "Glioma",
        "oncotree_code": "GNOS",
        "oncotree_term": "Glioma"
      },
      "therapy": {
        "name": "Neratinib + Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 79,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 182,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic colorectal cancer, BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor. ",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 183,
      "context": "Metastatic",
      "deprecated": false,
      "description": "BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 184,
      "context": "",
      "deprecated": false,
      "description": "Vemurafenib alone had insufficient activity in BRAF V600E mutant colorectal cancer patients. Of patients who received vemurafenib and cetuximab, one response was observed; however, approximately half of the patients had tumor regression that did not meet the standard criteria of partial response.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab + Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-10-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 74,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 185,
      "context": "Advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 186,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 187,
      "context": "Primary",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 188,
      "context": "Previously treated with 2 or more chemotherapies",
      "deprecated": false,
      "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 82,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 189,
      "context": "",
      "deprecated": false,
      "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 82,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 190,
      "context": "Previously treated with 2 or more chemotherapies",
      "deprecated": false,
      "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 82,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 191,
      "context": "",
      "deprecated": false,
      "description": "Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-20",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 83,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 192,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-20",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 84,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 193,
      "context": "",
      "deprecated": false,
      "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 194,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 195,
      "context": "Treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 196,
      "context": "Primary, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 197,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 198,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 199,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 200,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 201,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 202,
      "context": "Treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 203,
      "context": "Primary, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 204,
      "context": "Advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 205,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 206,
      "context": "Primary",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 207,
      "context": "Previously treated with 2 or more chemotherapies",
      "deprecated": false,
      "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 82,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 208,
      "context": "Previously treated with 2 or more chemotherapies",
      "deprecated": false,
      "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 82,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 209,
      "context": "Previously treated with 2 or more chemotherapies",
      "deprecated": false,
      "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Rucaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 82,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 210,
      "context": "",
      "deprecated": false,
      "description": "Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 83,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 211,
      "context": "",
      "deprecated": false,
      "description": "Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 84,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 212,
      "context": "",
      "deprecated": false,
      "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 88,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 213,
      "context": "",
      "deprecated": false,
      "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 214,
      "context": "",
      "deprecated": false,
      "description": "Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Nivolumab + Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 89,
      "variant": {
        "id": 214,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BRCA2 (Nonsense)"
      }
    },
    {
      "id": 215,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 216,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 217,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 218,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 219,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 220,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 221,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 222,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 223,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 224,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 225,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 219,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRIP1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRIP1"
      }
    },
    {
      "id": 226,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 226,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CDK12",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CDK12"
      }
    },
    {
      "id": 227,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 228,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 229,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 230,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 231,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 232,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 233,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 227,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 234,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 235,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 236,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 237,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 238,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 239,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 240,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 241,
      "context": "",
      "deprecated": false,
      "description": "Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.",
      "disease": {
        "name": "Medulloblastoma",
        "oncotree_code": "MBL",
        "oncotree_term": "Medulloblastoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2019-09-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 90,
      "variant": {
        "id": 241,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CTNNB1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CTNNB1"
      }
    },
    {
      "id": 242,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to osimertinib, a kinase inhibitor, for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDA approved test, whose disease has progressed on or after EGFR TKI therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-10-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 91,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 243,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Erlotinib (Tarceva) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with EGFR mutant metastatic non-small cell lung cancer. Mutant EGFR may suggest sensitivity to Erlotinib as a first or subsequent line of therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Erlotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 244,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Gefitinib (Iressa) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with EGFR mutant metastatic non-small cell lung cancer as a first or subsequent line of therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 245,
      "context": "",
      "deprecated": false,
      "description": "Gefitinib (Iressa) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with second-site mutations within the EGFR kinase domain, such as p.T790M, as they are associated with acquired resistance to EGFR TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 246,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Afatinib (Gilotrif) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with EGFR mutant metastatic non-small cell lung cancer as a first or subsequent line of therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Afatinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 247,
      "context": "",
      "deprecated": false,
      "description": "Gefitinib (Iressa) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with EGFR mutant non-small cell lung cancer. There is significant association between EGFR mutants and sensitivity to EGFR TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 248,
      "context": "",
      "deprecated": false,
      "description": "Gefitinib (Iressa) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with non-small cell lung cancer whose tumors harbor EGFR exon 20 insertion variants, as these mutations may predict resistance to TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 248,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Insertion",
        "feature": "EGFR (Insertion)"
      }
    },
    {
      "id": 249,
      "context": "",
      "deprecated": false,
      "description": "Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Durvalumab + Osimertinib",
        "type": "Combination therapy",
        "strategy": "PD-1/PD-L1 inhibition + EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 92,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 250,
      "context": "",
      "deprecated": false,
      "description": "HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Olmutinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 93,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 251,
      "context": "",
      "deprecated": false,
      "description": "Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated in patents with EGFR mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Cabozantinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 94,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 252,
      "context": "",
      "deprecated": false,
      "description": "Capmatinib (a cMET inhibitor) is being evaluated in patients with EGFR mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Capmatinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 94,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 253,
      "context": "",
      "deprecated": false,
      "description": "AZD3759, a CNS-penetrant EGFR-TKI, is being evaluated in patients with activating EGFR mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Zorifertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 94,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 254,
      "context": "",
      "deprecated": false,
      "description": "Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Dacomitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 94,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 255,
      "context": "",
      "deprecated": false,
      "description": "Mutant EGFR may suggest sensitivity to Icotinib as a first or subsequent line of therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Icotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 94,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 256,
      "context": "",
      "deprecated": false,
      "description": "Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 94,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 257,
      "context": "",
      "deprecated": false,
      "description": "Rociletinib was found to be effective in some patients in a 130-patient trial.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Rociletinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 95,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 258,
      "context": "",
      "deprecated": false,
      "description": "Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 96,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 259,
      "context": "",
      "deprecated": false,
      "description": "Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 97,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 260,
      "context": "",
      "deprecated": false,
      "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Nazartinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 97,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 261,
      "context": "",
      "deprecated": false,
      "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Nazartinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 97,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 262,
      "context": "",
      "deprecated": false,
      "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Mavelertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 97,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 263,
      "context": "",
      "deprecated": false,
      "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Mavelertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 97,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 264,
      "context": "",
      "deprecated": false,
      "description": "TKI therapy for patients with T790M has limited benefit.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Erlotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 98,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 265,
      "context": "",
      "deprecated": false,
      "description": "TKI therapy for patients with T790M has limited benefit.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Afatinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 98,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 266,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Afatinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 99,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 267,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Afatinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 99,
      "variant": {
        "id": 267,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "EGFR (Nonsense)"
      }
    },
    {
      "id": 268,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Afatinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 99,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 269,
      "context": "Intracranial metastases",
      "deprecated": false,
      "description": "In a retrospective study of patients with NSCLC, tumors with EGFR mutations or EML4-ALK locations had improved in-field local control of brain metastases treated with gamma knife.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gamma knife",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-09",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 19,
      "variant": {
        "id": 243,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EGFR"
      }
    },
    {
      "id": 270,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 100,
      "variant": {
        "id": 270,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "EGFR (Nonsense)"
      }
    },
    {
      "id": 271,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 100,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 272,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 101,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 273,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 101,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 274,
      "context": "Locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to amivantamab-vmjw for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Amivantamab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 102,
      "variant": {
        "id": 248,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Insertion",
        "feature": "EGFR (Insertion)"
      }
    },
    {
      "id": 275,
      "context": "Locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Mobocertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 103,
      "variant": {
        "id": 248,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Insertion",
        "feature": "EGFR (Insertion)"
      }
    },
    {
      "id": 276,
      "context": "",
      "deprecated": false,
      "description": "Missesnse mutations may predict sensitivity to HER2 inhibitors",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Neratinib",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 104,
      "variant": {
        "id": 276,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ERBB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "ERBB2 (Missense)"
      }
    },
    {
      "id": 277,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Ado-trasuzumab emtansine (Kadcyla) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with non-small cell lung cancer whose tumors harbor variants in ERBB2.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Trastuzumab Emtansine",
        "type": "Hormone therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 277,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ERBB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ERBB2"
      }
    },
    {
      "id": 278,
      "context": "",
      "deprecated": false,
      "description": "Missesnse mutations may predict sensitivity to HER2 inhibitors",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Neratinib",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 104,
      "variant": {
        "id": 278,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ERBB3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "ERBB3 (Missense)"
      }
    },
    {
      "id": 279,
      "context": "Muscle-Invasive",
      "deprecated": false,
      "description": "Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Cisplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 105,
      "variant": {
        "id": 279,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ERCC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "ERCC2 (Missense)"
      }
    },
    {
      "id": 280,
      "context": "Muscle-Invasive",
      "deprecated": false,
      "description": "Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Cisplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 106,
      "variant": {
        "id": 279,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ERCC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "ERCC2 (Missense)"
      }
    },
    {
      "id": 281,
      "context": "",
      "deprecated": false,
      "description": "Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Erlotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 23,
      "variant": {
        "id": 281,
        "alternate_allele": "A",
        "cdna_change": "c.1150G>T",
        "chromosome": "1",
        "end_position": "8073509",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "ERRFI1",
        "protein_change": "p.E384*",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "8073509",
        "variant_annotation": "Nonsense",
        "feature": "ERRFI1 p.E384* (Nonsense)"
      }
    },
    {
      "id": 282,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Letrozole + Tamoxifen",
        "type": "Combination therapy",
        "strategy": "Aromatase inhibition + ER signaling inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 107,
      "variant": {
        "id": 282,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ESR1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ESR1"
      }
    },
    {
      "id": 283,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights nonsense and frameshift variants in ETV6 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 283,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ETV6",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "ETV6 (Nonsense)"
      }
    },
    {
      "id": 284,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights nonsense and frameshift variants in ETV6 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 284,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ETV6",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "ETV6 (Frameshift)"
      }
    },
    {
      "id": 285,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights nonsense and frameshift variants in EZH2 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 285,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "EZH2 (Nonsense)"
      }
    },
    {
      "id": 286,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights nonsense and frameshift variants in EZH2 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 286,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "EZH2 (Frameshift)"
      }
    },
    {
      "id": 287,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Follicular Lymphoma",
        "oncotree_code": "FL",
        "oncotree_term": "Follicular Lymphoma"
      },
      "therapy": {
        "name": "Tazemetostat",
        "type": "Targeted therapy",
        "strategy": "EZH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 108,
      "variant": {
        "id": 287,
        "alternate_allele": "T",
        "cdna_change": "c.1938C>A",
        "chromosome": "7",
        "end_position": "148508726",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": "p.Y646*",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "148508726",
        "variant_annotation": "Nonsense",
        "feature": "EZH2 p.Y646* (Nonsense)"
      }
    },
    {
      "id": 288,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Follicular Lymphoma",
        "oncotree_code": "FL",
        "oncotree_term": "Follicular Lymphoma"
      },
      "therapy": {
        "name": "Tazemetostat",
        "type": "Targeted therapy",
        "strategy": "EZH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 108,
      "variant": {
        "id": 288,
        "alternate_allele": "A",
        "cdna_change": "c.1937A>T",
        "chromosome": "7",
        "end_position": "148508727",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": "p.Y646F",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "148508727",
        "variant_annotation": "Missense",
        "feature": "EZH2 p.Y646F (Missense)"
      }
    },
    {
      "id": 289,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Follicular Lymphoma",
        "oncotree_code": "FL",
        "oncotree_term": "Follicular Lymphoma"
      },
      "therapy": {
        "name": "Tazemetostat",
        "type": "Targeted therapy",
        "strategy": "EZH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 108,
      "variant": {
        "id": 289,
        "alternate_allele": "T",
        "cdna_change": "c.1936T>A",
        "chromosome": "7",
        "end_position": "148508728",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": "p.Y646N",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "148508728",
        "variant_annotation": "Missense",
        "feature": "EZH2 p.Y646N (Missense)"
      }
    },
    {
      "id": 290,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Follicular Lymphoma",
        "oncotree_code": "FL",
        "oncotree_term": "Follicular Lymphoma"
      },
      "therapy": {
        "name": "Tazemetostat",
        "type": "Targeted therapy",
        "strategy": "EZH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 108,
      "variant": {
        "id": 290,
        "alternate_allele": "C",
        "cdna_change": "c.2045C>G",
        "chromosome": "7",
        "end_position": "148506467",
        "exon": "18",
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": "p.A682G",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "148506467",
        "variant_annotation": "Missense",
        "feature": "EZH2 p.A682G (Missense)"
      }
    },
    {
      "id": 291,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Follicular Lymphoma",
        "oncotree_code": "FL",
        "oncotree_term": "Follicular Lymphoma"
      },
      "therapy": {
        "name": "Tazemetostat",
        "type": "Targeted therapy",
        "strategy": "EZH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-10",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 108,
      "variant": {
        "id": 291,
        "alternate_allele": "A",
        "cdna_change": "c.2075C>T",
        "chromosome": "7",
        "end_position": "148506437",
        "exon": "18",
        "feature_type": "somatic_variant",
        "gene": "EZH2",
        "protein_change": "p.A692V",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "148506437",
        "variant_annotation": "Missense",
        "feature": "EZH2 p.A692V (Missense)"
      }
    },
    {
      "id": 292,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 292,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FANCL",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "FANCL"
      }
    },
    {
      "id": 293,
      "context": "",
      "deprecated": false,
      "description": "Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.",
      "disease": {
        "name": "Breast Invasive Ductal Carcinoma",
        "oncotree_code": "IDC",
        "oncotree_term": "Breast Invasive Ductal Carcinoma"
      },
      "therapy": {
        "name": "Sirolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 109,
      "variant": {
        "id": 293,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FBXW7",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "FBXW7 (Missense)"
      }
    },
    {
      "id": 294,
      "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Erdafitinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-25",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 26,
      "variant": {
        "id": 294,
        "alternate_allele": "T",
        "cdna_change": "c.742C>T",
        "chromosome": "4",
        "end_position": "1803564",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "FGFR3",
        "protein_change": "p.R248C",
        "reference_allele": "C",
        "rsid": "rs121913482",
        "start_position": "1803564",
        "variant_annotation": "Missense",
        "feature": "FGFR3 p.R248C (Missense)"
      }
    },
    {
      "id": 295,
      "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Erdafitinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-25",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 26,
      "variant": {
        "id": 295,
        "alternate_allele": "G",
        "cdna_change": "c.746C>G",
        "chromosome": "4",
        "end_position": "1803568",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "FGFR3",
        "protein_change": "p.S249C",
        "reference_allele": "C",
        "rsid": "rs121913483",
        "start_position": "1803568",
        "variant_annotation": "Missense",
        "feature": "FGFR3 p.S249C (Missense)"
      }
    },
    {
      "id": 296,
      "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Erdafitinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-25",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 26,
      "variant": {
        "id": 296,
        "alternate_allele": "T",
        "cdna_change": "c.1180G>T",
        "chromosome": "4",
        "end_position": "1806089",
        "exon": "8",
        "feature_type": "somatic_variant",
        "gene": "FGFR3",
        "protein_change": "p.G370C",
        "reference_allele": "G",
        "rsid": "rs121913479",
        "start_position": "1806089",
        "variant_annotation": "Missense",
        "feature": "FGFR3 p.G370C (Missense)"
      }
    },
    {
      "id": 297,
      "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Erdafitinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-25",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 26,
      "variant": {
        "id": 297,
        "alternate_allele": "G",
        "cdna_change": "c.1118A>G",
        "chromosome": "4",
        "end_position": "1806099",
        "exon": "8",
        "feature_type": "somatic_variant",
        "gene": "FGFR3",
        "protein_change": "p.Y373C",
        "reference_allele": "A",
        "rsid": "rs121913485",
        "start_position": "1806099",
        "variant_annotation": "Missense",
        "feature": "FGFR3 p.Y373C (Missense)"
      }
    },
    {
      "id": 298,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 110,
      "variant": {
        "id": 298,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLCN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "FLCN (Nonsense)"
      }
    },
    {
      "id": 299,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 110,
      "variant": {
        "id": 298,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLCN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "FLCN (Nonsense)"
      }
    },
    {
      "id": 300,
      "context": "",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 298,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLCN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "FLCN (Nonsense)"
      }
    },
    {
      "id": 301,
      "context": "",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 301,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLCN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "FLCN (Frameshift)"
      }
    },
    {
      "id": 302,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 301,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLCN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "FLCN (Frameshift)"
      }
    },
    {
      "id": 303,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 301,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLCN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "FLCN (Frameshift)"
      }
    },
    {
      "id": 304,
      "context": "",
      "deprecated": false,
      "description": "A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Quizartinib",
        "type": "Targeted therapy",
        "strategy": "targets FLT3",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 112,
      "variant": {
        "id": 304,
        "alternate_allele": "G",
        "cdna_change": "c.2071T>C",
        "chromosome": "13",
        "end_position": "28601361",
        "exon": "17",
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": "p.F691L",
        "reference_allele": "A",
        "rsid": "rs759272576",
        "start_position": "28601361",
        "variant_annotation": "Missense",
        "feature": "FLT3 p.F691L (Missense)"
      }
    },
    {
      "id": 305,
      "context": "",
      "deprecated": false,
      "description": "Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Sunitinib",
        "type": "Targeted therapy",
        "strategy": "targets FLT3",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 113,
      "variant": {
        "id": 305,
        "alternate_allele": "G",
        "cdna_change": "c.1987A>C",
        "chromosome": "13",
        "end_position": "28602381",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": "p.K663Q",
        "reference_allele": "T",
        "rsid": "rs1057520026",
        "start_position": "28602381",
        "variant_annotation": "Missense",
        "feature": "FLT3 p.K663Q (Missense)"
      }
    },
    {
      "id": 306,
      "context": "",
      "deprecated": false,
      "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Letrozole",
        "type": "Targeted therapy",
        "strategy": "Aromatase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 114,
      "variant": {
        "id": 306,
        "alternate_allele": "A",
        "cdna_change": "c.881T>A",
        "chromosome": "10",
        "end_position": "8106058",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "GATA3",
        "protein_change": "p.M294K",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "8106058",
        "variant_annotation": "Missense",
        "feature": "GATA3 p.M294K (Missense)"
      }
    },
    {
      "id": 307,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 115,
      "variant": {
        "id": 307,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 308,
      "context": "",
      "deprecated": false,
      "description": "Alkylating chemotherapy is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with glioma harboring mutation of IDH1, as mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy, but not untreated patients.",
      "disease": {
        "name": "Glioma",
        "oncotree_code": "GNOS",
        "oncotree_term": "Glioma"
      },
      "therapy": {
        "name": "Antineoplastic Alkylating Agent",
        "type": "Chemotherapy",
        "strategy": "Alkylating chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 116,
      "variant": {
        "id": 307,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 309,
      "context": "",
      "deprecated": false,
      "description": "Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).",
      "disease": {
        "name": "Glioma",
        "oncotree_code": "GNOS",
        "oncotree_term": "Glioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 116,
      "variant": {
        "id": 307,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 310,
      "context": "Newly diagnosed AML who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. Relapsed or refractory AML.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 117,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 311,
      "context": "Newly diagnosed AML who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. Relapsed or refractory AML.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 117,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 312,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 117,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 313,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 117,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 314,
      "context": "Newly diagnosed AML who are greater than or equal to 75 years of age and who have comorbidities that preclude the use of intensive induction chemotherapy. Relapsed or refractory AML.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 117,
      "variant": {
        "id": 307,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 315,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
      "disease": {
        "name": "Cholangiocarcinoma",
        "oncotree_code": "CHOL",
        "oncotree_term": "Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 117,
      "variant": {
        "id": 307,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 316,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Enasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 118,
      "variant": {
        "id": 316,
        "alternate_allele": "T",
        "cdna_change": "c.419G>A",
        "chromosome": "15",
        "end_position": "90631934",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R140Q",
        "reference_allele": "C",
        "rsid": "rs121913502",
        "start_position": "90631934",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R140Q (Missense)"
      }
    },
    {
      "id": 317,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Enasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 118,
      "variant": {
        "id": 317,
        "alternate_allele": "A",
        "cdna_change": "c.516G>T",
        "chromosome": "15",
        "end_position": "90631837",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172S",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "90631837",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172S (Missense)"
      }
    },
    {
      "id": 318,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Enasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 118,
      "variant": {
        "id": 318,
        "alternate_allele": "T",
        "cdna_change": "c.515G>A",
        "chromosome": "15",
        "end_position": "90631837",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172K",
        "reference_allele": "C",
        "rsid": "rs121913503",
        "start_position": "90631837",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172K (Missense)"
      }
    },
    {
      "id": 319,
      "context": "",
      "deprecated": false,
      "description": "Alkylating chemotherapy is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with glioma harboring mutation of IDH2, as mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy, but not untreated patients.",
      "disease": {
        "name": "Glioma",
        "oncotree_code": "GNOS",
        "oncotree_term": "Glioma"
      },
      "therapy": {
        "name": "Antineoplastic Alkylating Agent",
        "type": "Chemotherapy",
        "strategy": "Alkylating chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 116,
      "variant": {
        "id": 319,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "15",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH2"
      }
    },
    {
      "id": 320,
      "context": "",
      "deprecated": false,
      "description": "Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy, but not untreated patients.",
      "disease": {
        "name": "Glioma",
        "oncotree_code": "GNOS",
        "oncotree_term": "Glioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 116,
      "variant": {
        "id": 319,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "15",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH2"
      }
    },
    {
      "id": 321,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights IDH2 p.R140Q and p.R172 variants as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 321,
        "alternate_allele": "T",
        "cdna_change": "c.419G>A",
        "chromosome": "15",
        "end_position": "90631934",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R140Q",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "90631934",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R140Q (Missense)"
      }
    },
    {
      "id": 322,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights IDH2 p.R140Q and p.R172 variants as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 317,
        "alternate_allele": "A",
        "cdna_change": "c.516G>T",
        "chromosome": "15",
        "end_position": "90631837",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172S",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "90631837",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172S (Missense)"
      }
    },
    {
      "id": 323,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights IDH2 p.R140Q and p.R172 variants as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 318,
        "alternate_allele": "T",
        "cdna_change": "c.515G>A",
        "chromosome": "15",
        "end_position": "90631837",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172K",
        "reference_allele": "C",
        "rsid": "rs121913503",
        "start_position": "90631837",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172K (Missense)"
      }
    },
    {
      "id": 324,
      "context": "",
      "deprecated": false,
      "description": "A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.",
      "disease": {
        "name": "B-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "BALL",
        "oncotree_term": "B-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 119,
      "variant": {
        "id": 324,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "1",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "JAK1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "JAK1"
      }
    },
    {
      "id": 325,
      "context": "",
      "deprecated": false,
      "description": "MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Zelavespib",
        "type": "Targeted therapy",
        "strategy": "HSP90 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 120,
      "variant": {
        "id": 325,
        "alternate_allele": "A",
        "cdna_change": "c.1966G>T",
        "chromosome": "1",
        "end_position": "65312353",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "JAK1",
        "protein_change": "p.V656F",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "65312353",
        "variant_annotation": "Missense",
        "feature": "JAK1 p.V656F (Missense)"
      }
    },
    {
      "id": 326,
      "context": "",
      "deprecated": false,
      "description": "MOHITO JAK1 A634D transplated mice were highly sensitive to growth inhibition by PU-H71.",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Zelavespib",
        "type": "Targeted therapy",
        "strategy": "HSP90 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 120,
      "variant": {
        "id": 326,
        "alternate_allele": "T",
        "cdna_change": "c.1901C>A",
        "chromosome": "1",
        "end_position": "65312418",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "JAK1",
        "protein_change": "p.A634D",
        "reference_allele": "G",
        "rsid": "rs869312953",
        "start_position": "65312418",
        "variant_annotation": "Missense",
        "feature": "JAK1 p.A634D (Missense)"
      }
    },
    {
      "id": 327,
      "context": "",
      "deprecated": false,
      "description": "A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.",
      "disease": {
        "name": "B-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "BALL",
        "oncotree_term": "B-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 119,
      "variant": {
        "id": 327,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "JAK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "JAK2"
      }
    },
    {
      "id": 328,
      "context": "",
      "deprecated": false,
      "description": "In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.",
      "disease": {
        "name": "Myeloproliferative Neoplasm",
        "oncotree_code": "MPN",
        "oncotree_term": "Myeloproliferative Neoplasm"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 121,
      "variant": {
        "id": 328,
        "alternate_allele": "T",
        "cdna_change": "c.1849G>T",
        "chromosome": "9",
        "end_position": "5073770",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "JAK2",
        "protein_change": "p.V617F",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "5073770",
        "variant_annotation": "Missense",
        "feature": "JAK2 p.V617F (Missense)"
      }
    },
    {
      "id": 329,
      "context": "",
      "deprecated": false,
      "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.",
      "disease": {
        "name": "T-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "TALL",
        "oncotree_term": "T-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Ruxolitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 122,
      "variant": {
        "id": 329,
        "alternate_allele": "T",
        "cdna_change": "c.1714G>A",
        "chromosome": "19",
        "end_position": "17948010",
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "JAK3",
        "protein_change": "p.A572T",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "17948010",
        "variant_annotation": "Missense",
        "feature": "JAK3 p.A572T (Missense)"
      }
    },
    {
      "id": 330,
      "context": "",
      "deprecated": false,
      "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.",
      "disease": {
        "name": "T-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "TALL",
        "oncotree_term": "T-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Ruxolitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 122,
      "variant": {
        "id": 330,
        "alternate_allele": "T",
        "cdna_change": "c.1533G>A",
        "chromosome": "19",
        "end_position": "17949108",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "JAK3",
        "protein_change": "p.M511I",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "17949108",
        "variant_annotation": "Missense",
        "feature": "JAK3 p.M511I (Missense)"
      }
    },
    {
      "id": 331,
      "context": "",
      "deprecated": false,
      "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.",
      "disease": {
        "name": "T-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "TALL",
        "oncotree_term": "T-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Ruxolitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 122,
      "variant": {
        "id": 331,
        "alternate_allele": "T",
        "cdna_change": "c.2570T>A",
        "chromosome": "19",
        "end_position": "17943438",
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "JAK3",
        "protein_change": "p.L857Q",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "17943438",
        "variant_annotation": "Missense",
        "feature": "JAK3 p.L857Q (Missense)"
      }
    },
    {
      "id": 332,
      "context": "",
      "deprecated": false,
      "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.",
      "disease": {
        "name": "T-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "TALL",
        "oncotree_term": "T-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Tofacitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 122,
      "variant": {
        "id": 329,
        "alternate_allele": "T",
        "cdna_change": "c.1714G>A",
        "chromosome": "19",
        "end_position": "17948010",
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "JAK3",
        "protein_change": "p.A572T",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "17948010",
        "variant_annotation": "Missense",
        "feature": "JAK3 p.A572T (Missense)"
      }
    },
    {
      "id": 333,
      "context": "",
      "deprecated": false,
      "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.",
      "disease": {
        "name": "T-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "TALL",
        "oncotree_term": "T-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Tofacitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 122,
      "variant": {
        "id": 330,
        "alternate_allele": "T",
        "cdna_change": "c.1533G>A",
        "chromosome": "19",
        "end_position": "17949108",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "JAK3",
        "protein_change": "p.M511I",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "17949108",
        "variant_annotation": "Missense",
        "feature": "JAK3 p.M511I (Missense)"
      }
    },
    {
      "id": 334,
      "context": "",
      "deprecated": false,
      "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.",
      "disease": {
        "name": "T-Cell Acute Lymphoid Leukemia",
        "oncotree_code": "TALL",
        "oncotree_term": "T-Cell Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Tofacitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 122,
      "variant": {
        "id": 331,
        "alternate_allele": "T",
        "cdna_change": "c.2570T>A",
        "chromosome": "19",
        "end_position": "17943438",
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "JAK3",
        "protein_change": "p.L857Q",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "17943438",
        "variant_annotation": "Missense",
        "feature": "JAK3 p.L857Q (Missense)"
      }
    },
    {
      "id": 335,
      "context": "Unresectable and/or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 336,
      "context": "",
      "deprecated": false,
      "description": "FDA-approved for (1) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) and (2) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 3,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 337,
      "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "deprecated": false,
      "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Regorafenib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 123,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 338,
      "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "deprecated": false,
      "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Regorafenib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 123,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 339,
      "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "deprecated": false,
      "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Regorafenib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 123,
      "variant": {
        "id": 339,
        "alternate_allele": "T",
        "cdna_change": "c.2009C>T",
        "chromosome": "4",
        "end_position": "55595519",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.T670I",
        "reference_allele": "C",
        "rsid": "rs121913516",
        "start_position": "55595519",
        "variant_annotation": "Missense",
        "feature": "KIT p.T670I (Missense)"
      }
    },
    {
      "id": 340,
      "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "deprecated": false,
      "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Regorafenib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 123,
      "variant": {
        "id": 340,
        "alternate_allele": "C",
        "cdna_change": "c.1961T>C",
        "chromosome": "4",
        "end_position": "55594258",
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.V654A",
        "reference_allele": "T",
        "rsid": "rs121913523",
        "start_position": "55594258",
        "variant_annotation": "Missense",
        "feature": "KIT p.V654A (Missense)"
      }
    },
    {
      "id": 341,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Sunitinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 124,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 342,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Sunitinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 124,
      "variant": {
        "id": 339,
        "alternate_allele": "T",
        "cdna_change": "c.2009C>T",
        "chromosome": "4",
        "end_position": "55595519",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.T670I",
        "reference_allele": "C",
        "rsid": "rs121913516",
        "start_position": "55595519",
        "variant_annotation": "Missense",
        "feature": "KIT p.T670I (Missense)"
      }
    },
    {
      "id": 343,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Sunitinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 124,
      "variant": {
        "id": 340,
        "alternate_allele": "C",
        "cdna_change": "c.1961T>C",
        "chromosome": "4",
        "end_position": "55594258",
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.V654A",
        "reference_allele": "T",
        "rsid": "rs121913523",
        "start_position": "55594258",
        "variant_annotation": "Missense",
        "feature": "KIT p.V654A (Missense)"
      }
    },
    {
      "id": 344,
      "context": "Mucosal Melanoma",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with head and neck mucosal melanoma. Mucosal melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.",
      "disease": {
        "name": "Head and Neck Mucosal Melanoma",
        "oncotree_code": "HNMUCM",
        "oncotree_term": "Head and Neck Mucosal Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 125,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 345,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 345,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 346,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 346,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 347,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 347,
        "alternate_allele": "T",
        "cdna_change": "c.1671G>T",
        "chromosome": "4",
        "end_position": "55593605",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.W557C",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "55593605",
        "variant_annotation": "Missense",
        "feature": "KIT p.W557C (Missense)"
      }
    },
    {
      "id": 348,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 348,
        "alternate_allele": "G",
        "cdna_change": "c.1669T>G",
        "chromosome": "4",
        "end_position": "55593603",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.W557G",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "55593603",
        "variant_annotation": "Missense",
        "feature": "KIT p.W557G (Missense)"
      }
    },
    {
      "id": 349,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 349,
        "alternate_allele": "C",
        "cdna_change": "c.1669T>C",
        "chromosome": "4",
        "end_position": "55593603",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.W557R",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "55593603",
        "variant_annotation": "Missense",
        "feature": "KIT p.W557R (Missense)"
      }
    },
    {
      "id": 350,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 350,
        "alternate_allele": "C",
        "cdna_change": "c.1676T>C",
        "chromosome": "4",
        "end_position": "55593610",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.V559A",
        "reference_allele": "T",
        "rsid": "rs121913517",
        "start_position": "55593610",
        "variant_annotation": "Missense",
        "feature": "KIT p.V559A (Missense)"
      }
    },
    {
      "id": 351,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 351,
        "alternate_allele": "G",
        "cdna_change": "c.1676T>G",
        "chromosome": "4",
        "end_position": "55593610",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.V559G",
        "reference_allele": "T",
        "rsid": "rs121913517",
        "start_position": "55593610",
        "variant_annotation": "Missense",
        "feature": "KIT p.V559G (Missense)"
      }
    },
    {
      "id": 352,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 352,
        "alternate_allele": "C",
        "cdna_change": "c.1727T>C",
        "chromosome": "4",
        "end_position": "55593661",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.L576P",
        "reference_allele": "T",
        "rsid": "rs121913513",
        "start_position": "55593661",
        "variant_annotation": "Missense",
        "feature": "KIT p.L576P (Missense)"
      }
    },
    {
      "id": 353,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 353,
        "alternate_allele": "G",
        "cdna_change": "c.1924A>G",
        "chromosome": "4",
        "end_position": "55594221",
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.K642E",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "55594221",
        "variant_annotation": "Missense",
        "feature": "KIT p.K642E (Missense)"
      }
    },
    {
      "id": 354,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 17 variants (p.D816H), these variants appear to have minimal or no sensitivity to KIT inhibitiors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 354,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "17",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 355,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 17 variants (p.D816H), these variants appear to have minimal or no sensitivity to KIT inhibitiors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 355,
        "alternate_allele": "C",
        "cdna_change": "c.2446G>C",
        "chromosome": "4",
        "end_position": "55599320",
        "exon": "17",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.D816H",
        "reference_allele": "G",
        "rsid": "rs121913506",
        "start_position": "55599320",
        "variant_annotation": "Missense",
        "feature": "KIT p.D816H (Missense)"
      }
    },
    {
      "id": 356,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with KIT mutant melanoma. Activating KIT mutations are associated with an increased sensitvity to imatinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 68,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 357,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with gastrointestinal stromal tumors and mutations in KIT exon 11. Approximately 90% of patients have diseases that respond to imatinib when their tumors have a KIT exon 11 mutation.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 127,
      "variant": {
        "id": 345,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 358,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with gastrointestinal stromal tumors and mutations in KIT exon 9. Approximately 50% of patients have diseases that respond to imatinib when their tumors have a KIT exon 9 mutation, and the likelihood of response improves with use of 800 mg dosage rather than the standard 400 mg.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 127,
      "variant": {
        "id": 358,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "9",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 359,
      "context": "",
      "deprecated": false,
      "description": "Sunitinib (Sutent) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with thymic carcinomas and c-KIT mutations.",
      "disease": {
        "name": "Thymic Carcinoma",
        "oncotree_code": "THYC",
        "oncotree_term": "Thymic Carcinoma"
      },
      "therapy": {
        "name": "Sunitinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 128,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 360,
      "context": "",
      "deprecated": false,
      "description": "Avapritnib inhibited the autophosphorylation of KIT p.D816V in cellular assays relative to wild-type KIT.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 360,
        "alternate_allele": "T",
        "cdna_change": "c.2447A>T",
        "chromosome": "4",
        "end_position": "55599321",
        "exon": "17",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": "p.D816V",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "55599321",
        "variant_annotation": "Missense",
        "feature": "KIT p.D816V (Missense)"
      }
    },
    {
      "id": 361,
      "context": "",
      "deprecated": false,
      "description": "Avapritnib inhibited the the profileration of KIT mutant cell lines. Avapritnib also had anti-tumor activity in mice implanted with an imatinib-resistant patient-derived xenograft model of human GIST with an activating KIT exon 11 or 17 variant.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 354,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "17",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 362,
      "context": "",
      "deprecated": false,
      "description": "Avapritnib inhibited the the profileration of KIT mutant cell lines.",
      "disease": {
        "name": "Mast Cell Leukemia",
        "oncotree_code": "SMMCL",
        "oncotree_term": "Mast Cell Leukemia"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 335,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 363,
      "context": "",
      "deprecated": false,
      "description": "Avapritnib had anti-tumor activity in mice implanted with an imatinib-resistant patient-derived xenograft model of human GIST with an activating KIT exon 11 or 17 variant.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 345,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "KIT",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KIT"
      }
    },
    {
      "id": 364,
      "context": "",
      "deprecated": false,
      "description": "The combination of palbociclib and trametinib has shown antitumor and radiosensitizing activity in preclinical models of non-small cell lung cancer, and is currently in a phase III clinical trial for non-small cell lung cancer.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Palbociclib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 130,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 365,
      "context": "",
      "deprecated": false,
      "description": "A phase 1b trial including 21 ovarian cancer patients demonstrated increased survival and an average PFS of 7 months when treated with a combination of buparlisib and trametinib (RP2D of buparlisib 60mg and trametinib 1.5mg daily).",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Buparlisib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 131,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 366,
      "context": "Primary or Metastatic",
      "deprecated": false,
      "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 366,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 367,
      "context": "Primary or Metastatic",
      "deprecated": false,
      "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Panitumumab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 366,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 368,
      "context": "Primary or Metastatic",
      "deprecated": false,
      "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 368,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 369,
      "context": "Primary or Metastatic",
      "deprecated": false,
      "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Panitumumab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 368,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 370,
      "context": "Primary or Metastatic",
      "deprecated": false,
      "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 370,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 371,
      "context": "Primary or Metastatic",
      "deprecated": false,
      "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Panitumumab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 370,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 372,
      "context": "Locally advanced or metastatic disease",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Sotorasib",
        "type": "Targeted therapy",
        "strategy": "RAS inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 132,
      "variant": {
        "id": 372,
        "alternate_allele": "A",
        "cdna_change": "c.34G>T",
        "chromosome": "12",
        "end_position": "25398285",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G12C",
        "reference_allele": "C",
        "rsid": "rs121913530",
        "start_position": "25398285",
        "variant_annotation": "Missense",
        "feature": "KRAS p.G12C (Missense)"
      }
    },
    {
      "id": 373,
      "context": "",
      "deprecated": false,
      "description": "Gefitinib (Iressa) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with non-small cell lung cancer whose tumors harbor variants in KRAS, as these mutations are associated with intrinsic resistance to EGFR TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 374,
      "context": "",
      "deprecated": false,
      "description": "KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 133,
      "variant": {
        "id": 374,
        "alternate_allele": "T",
        "cdna_change": "c.35G>A",
        "chromosome": "12",
        "end_position": "25398284",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G12D",
        "reference_allele": "C",
        "rsid": "rs121913529",
        "start_position": "25398284",
        "variant_annotation": "Missense",
        "feature": "KRAS p.G12D (Missense)"
      }
    },
    {
      "id": 375,
      "context": "Liver metastases from solid tumors",
      "deprecated": false,
      "description": "In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Proton Stereotactic Body Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 134,
      "variant": {
        "id": 375,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G12",
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "KRAS p.G12 (Missense)"
      }
    },
    {
      "id": 376,
      "context": "Liver metastases from solid tumors",
      "deprecated": false,
      "description": "In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Proton Stereotactic Body Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 134,
      "variant": {
        "id": 376,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G13",
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "KRAS p.G13 (Missense)"
      }
    },
    {
      "id": 377,
      "context": "Liver metastases from solid tumors",
      "deprecated": false,
      "description": "In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Proton Stereotactic Body Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 134,
      "variant": {
        "id": 377,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.Q61",
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "KRAS p.Q61 (Missense)"
      }
    },
    {
      "id": 378,
      "context": "",
      "deprecated": false,
      "description": "The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "FGFR1 inhibitor + Trametinib",
        "type": "Targeted therapy",
        "strategy": "FGFR1 inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 135,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 379,
      "context": "",
      "deprecated": false,
      "description": "The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "FGFR1 inhibitor + Trametinib",
        "type": "Targeted therapy",
        "strategy": "FGFR1 inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 135,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 380,
      "context": "",
      "deprecated": false,
      "description": "In a cohort of 34 non-small cell lung cancer patients treated with pembrolizumab, the presence of a KRAS mutation was associated with an increased chance of DCB.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 136,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 381,
      "context": "",
      "deprecated": false,
      "description": "KRAS mutations were associated with resistance to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 382,
      "context": "",
      "deprecated": false,
      "description": "Preclinical study suggests that TBK1/IKKepsilon promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKepsilon, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS",
      "disease": {
        "name": "Leukemia",
        "oncotree_code": "LEUK",
        "oncotree_term": "Leukemia"
      },
      "therapy": {
        "name": "Momelotinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 137,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 383,
      "context": "",
      "deprecated": false,
      "description": "Preclinical study suggests that TBK1/IKKepsilon promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKepsilon, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS",
      "disease": {
        "name": "Leukemia",
        "oncotree_code": "LEUK",
        "oncotree_term": "Leukemia"
      },
      "therapy": {
        "name": "Ruxolitinib",
        "type": "Targeted therapy",
        "strategy": "JAK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 137,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 384,
      "context": "",
      "deprecated": false,
      "description": "In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.",
      "disease": {
        "name": "Rectal Adenocarcinoma",
        "oncotree_code": "READ",
        "oncotree_term": "Rectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Chemoradiotherapy",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 138,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 385,
      "context": "Early stage",
      "deprecated": false,
      "description": "In a retrosepctive series of early-stage NSCLC patients treated with SBRT, KRAS mutation was associated with decreased FFR and CSS.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Stereotactic Body Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 139,
      "variant": {
        "id": 364,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "KRAS"
      }
    },
    {
      "id": 386,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 71,
      "variant": {
        "id": 386,
        "alternate_allele": "T",
        "cdna_change": "c.371C>T",
        "chromosome": "15",
        "end_position": "66729163",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.P124L",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "66729163",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.P124L (Missense)"
      }
    },
    {
      "id": 387,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 71,
      "variant": {
        "id": 387,
        "alternate_allele": "C",
        "cdna_change": "c.167A>C",
        "chromosome": "15",
        "end_position": "66727451",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.Q56P",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "66727451",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.Q56P (Missense)"
      }
    },
    {
      "id": 388,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest resistance to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 71,
      "variant": {
        "id": 386,
        "alternate_allele": "T",
        "cdna_change": "c.371C>T",
        "chromosome": "15",
        "end_position": "66729163",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.P124L",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "66729163",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.P124L (Missense)"
      }
    },
    {
      "id": 389,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 140,
      "variant": {
        "id": 387,
        "alternate_allele": "C",
        "cdna_change": "c.167A>C",
        "chromosome": "15",
        "end_position": "66727451",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.Q56P",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "66727451",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.Q56P (Missense)"
      }
    },
    {
      "id": 390,
      "context": "Metastatic",
      "deprecated": false,
      "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 141,
      "variant": {
        "id": 387,
        "alternate_allele": "C",
        "cdna_change": "c.167A>C",
        "chromosome": "15",
        "end_position": "66727451",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.Q56P",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "66727451",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.Q56P (Missense)"
      }
    },
    {
      "id": 391,
      "context": "Metastatic",
      "deprecated": false,
      "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 141,
      "variant": {
        "id": 387,
        "alternate_allele": "C",
        "cdna_change": "c.167A>C",
        "chromosome": "15",
        "end_position": "66727451",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.Q56P",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "66727451",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.Q56P (Missense)"
      }
    },
    {
      "id": 392,
      "context": "Metastatic",
      "deprecated": false,
      "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 142,
      "variant": {
        "id": 392,
        "alternate_allele": "A",
        "cdna_change": "c.361T>A",
        "chromosome": "15",
        "end_position": "66729153",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.C121S",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "66729153",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.C121S (Missense)"
      }
    },
    {
      "id": 393,
      "context": "Metastatic",
      "deprecated": false,
      "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 142,
      "variant": {
        "id": 392,
        "alternate_allele": "A",
        "cdna_change": "c.361T>A",
        "chromosome": "15",
        "end_position": "66729153",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "MAP2K1",
        "protein_change": "p.C121S",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "66729153",
        "variant_annotation": "Missense",
        "feature": "MAP2K1 p.C121S (Missense)"
      }
    },
    {
      "id": 394,
      "context": "Metastatic",
      "deprecated": false,
      "description": "MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Trametinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 78,
      "variant": {
        "id": 394,
        "alternate_allele": "G",
        "cdna_change": "c.179A>C",
        "chromosome": "19",
        "end_position": "4117541",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "MAP2K2",
        "protein_change": "p.Q60P",
        "reference_allele": "T",
        "rsid": "rs1057519808",
        "start_position": "4117541",
        "variant_annotation": "Missense",
        "feature": "MAP2K2 p.Q60P (Missense)"
      }
    },
    {
      "id": 395,
      "context": "",
      "deprecated": false,
      "description": "In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC",
      "disease": {
        "name": "Head and Neck Squamous Cell Carcinoma",
        "oncotree_code": "HNSC",
        "oncotree_term": "Head and Neck Squamous Cell Carcinoma"
      },
      "therapy": {
        "name": "Erlotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 143,
      "variant": {
        "id": 395,
        "alternate_allele": "T",
        "cdna_change": "c.964G>A",
        "chromosome": "22",
        "end_position": "22127164",
        "exon": "7",
        "feature_type": "somatic_variant",
        "gene": "MAPK1",
        "protein_change": "p.E322K",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "22127164",
        "variant_annotation": "Missense",
        "feature": "MAPK1 p.E322K (Missense)"
      }
    },
    {
      "id": 396,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 144,
      "variant": {
        "id": 396,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MC1R",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MC1R"
      }
    },
    {
      "id": 397,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to SU11274.",
      "disease": {
        "name": "Head and Neck Squamous Cell Carcinoma",
        "oncotree_code": "HNSC",
        "oncotree_term": "Head and Neck Squamous Cell Carcinoma"
      },
      "therapy": {
        "name": "SU11274",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 145,
      "variant": {
        "id": 397,
        "alternate_allele": "T",
        "cdna_change": "c.3029C>T",
        "chromosome": "7",
        "end_position": "116411990",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": "p.T1010I",
        "reference_allele": "C",
        "rsid": "rs56391007",
        "start_position": "116411990",
        "variant_annotation": "Missense",
        "feature": "MET p.T1010I (Missense)"
      }
    },
    {
      "id": 398,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Crizotinib (Xalkori) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping variants.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 398,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "MET (Splice Site)"
      }
    },
    {
      "id": 399,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Crizotinib (Xalkori) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping variants.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 399,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "MET (Deletion)"
      }
    },
    {
      "id": 400,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Capmatinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 146,
      "variant": {
        "id": 398,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "MET (Splice Site)"
      }
    },
    {
      "id": 401,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Capmatinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 146,
      "variant": {
        "id": 399,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "MET (Deletion)"
      }
    },
    {
      "id": 402,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 402,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MLH3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MLH3"
      }
    },
    {
      "id": 403,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.",
      "disease": {
        "name": "Myeloproliferative Neoplasm",
        "oncotree_code": "MPN",
        "oncotree_term": "Myeloproliferative Neoplasm"
      },
      "therapy": {
        "name": "EXEL-8232",
        "type": "Targeted therapy",
        "strategy": "JAK2 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 148,
      "variant": {
        "id": 403,
        "alternate_allele": "T",
        "cdna_change": "c.1544G>T",
        "chromosome": "1",
        "end_position": "43815009",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "MPL",
        "protein_change": "p.W515L",
        "reference_allele": "G",
        "rsid": "rs121913615",
        "start_position": "43815009",
        "variant_annotation": "Missense",
        "feature": "MPL p.W515L (Missense)"
      }
    },
    {
      "id": 404,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 404,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MSH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MSH2"
      }
    },
    {
      "id": 405,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 405,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MSH6",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MSH6"
      }
    },
    {
      "id": 406,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a study of 184 everolimus-treated patients with RCC from a phase 2 randomized trial,  PFS neither differed on univariate analysis nor on multivariate testing based on variant status in TSC1, TSC2, or MTOR.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "RCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 149,
      "variant": {
        "id": 406,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MTOR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MTOR"
      }
    },
    {
      "id": 407,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 407,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MYH",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MYH"
      }
    },
    {
      "id": 408,
      "context": "",
      "deprecated": false,
      "description": "In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.",
      "disease": {
        "name": "Lung Squamous Cell Carcinoma",
        "oncotree_code": "LUSC",
        "oncotree_term": "Lung Squamous Cell Carcinoma"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 150,
      "variant": {
        "id": 408,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "NFE2L2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Activating mutation",
        "feature": "NFE2L2 (Activating mutation)"
      }
    },
    {
      "id": 409,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 409,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "1",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "NRAS"
      }
    },
    {
      "id": 410,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4).",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Panitumumab",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 66,
      "variant": {
        "id": 409,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "1",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "NRAS"
      }
    },
    {
      "id": 411,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 411,
        "alternate_allele": "G",
        "cdna_change": "c.35G>C",
        "chromosome": "1",
        "end_position": "115258747",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12A",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258747",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12A (Missense)"
      }
    },
    {
      "id": 412,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 412,
        "alternate_allele": "A",
        "cdna_change": "c.34G>T",
        "chromosome": "1",
        "end_position": "115258748",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12C",
        "reference_allele": "C",
        "rsid": "rs121913250",
        "start_position": "115258748",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12C (Missense)"
      }
    },
    {
      "id": 413,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 413,
        "alternate_allele": "T",
        "cdna_change": "c.35G>A",
        "chromosome": "1",
        "end_position": "115258747",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12D",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258747",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12D (Missense)"
      }
    },
    {
      "id": 414,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 414,
        "alternate_allele": "G",
        "cdna_change": "p.34G>C",
        "chromosome": "1",
        "end_position": "115258748",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12R",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258748",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12R (Missense)"
      }
    },
    {
      "id": 415,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 415,
        "alternate_allele": "T",
        "cdna_change": "p.34G>A",
        "chromosome": "1",
        "end_position": "115258748",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12S",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258748",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12S (Missense)"
      }
    },
    {
      "id": 416,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 416,
        "alternate_allele": "A",
        "cdna_change": "p.35G>T",
        "chromosome": "1",
        "end_position": "115258747",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12V",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258747",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12V (Missense)"
      }
    },
    {
      "id": 417,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 417,
        "alternate_allele": "G",
        "cdna_change": "c.38G>C",
        "chromosome": "1",
        "end_position": "115258744",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13A",
        "reference_allele": "C",
        "rsid": "rs121434596",
        "start_position": "115258744",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13A (Missense)"
      }
    },
    {
      "id": 418,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 418,
        "alternate_allele": "T",
        "cdna_change": "c.38G>A",
        "chromosome": "1",
        "end_position": "115258744",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13D",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258744",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13D (Missense)"
      }
    },
    {
      "id": 419,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 419,
        "alternate_allele": "G",
        "cdna_change": "c.37G>C",
        "chromosome": "1",
        "end_position": "115258745",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13R",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258745",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13R (Missense)"
      }
    },
    {
      "id": 420,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 420,
        "alternate_allele": "A",
        "cdna_change": "c.38G>T",
        "chromosome": "1",
        "end_position": "115258744",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13V",
        "reference_allele": "C",
        "rsid": "rs121434596",
        "start_position": "115258744",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13V (Missense)"
      }
    },
    {
      "id": 421,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 421,
        "alternate_allele": "C",
        "cdna_change": "c.181C>G",
        "chromosome": "1",
        "end_position": "115256530",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61E",
        "reference_allele": "G",
        "rsid": "rs121913254",
        "start_position": "115256530",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61E (Missense)"
      }
    },
    {
      "id": 422,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 422,
        "alternate_allele": "A",
        "cdna_change": "c.183A>T",
        "chromosome": "1",
        "end_position": "115256528",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61H",
        "reference_allele": "T",
        "rsid": "rs121913255",
        "start_position": "115256528",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61H (Missense)"
      }
    },
    {
      "id": 423,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 423,
        "alternate_allele": "A",
        "cdna_change": "c.182A>T",
        "chromosome": "1",
        "end_position": "115256529",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61L",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "115256529",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61L (Missense)"
      }
    },
    {
      "id": 424,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NRAS G12, G13, and Q61 variants as being associated with poor prognosis in patients with myelodysplastic syndromes, particularly in patients predicted to have lower-risk MDS.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 424,
        "alternate_allele": "G",
        "cdna_change": "c.182A>C",
        "chromosome": "1",
        "end_position": "115256529",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61P",
        "reference_allele": "T",
        "rsid": "rs11554290",
        "start_position": "115256529",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61P (Missense)"
      }
    },
    {
      "id": 425,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 425,
        "alternate_allele": "C",
        "cdna_change": "c.182A>G",
        "chromosome": "1",
        "end_position": "115256529",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61R",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "115256529",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61R (Missense)"
      }
    },
    {
      "id": 426,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 412,
        "alternate_allele": "A",
        "cdna_change": "c.34G>T",
        "chromosome": "1",
        "end_position": "115258748",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12C",
        "reference_allele": "C",
        "rsid": "rs121913250",
        "start_position": "115258748",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12C (Missense)"
      }
    },
    {
      "id": 427,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 413,
        "alternate_allele": "T",
        "cdna_change": "c.35G>A",
        "chromosome": "1",
        "end_position": "115258747",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12D",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258747",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12D (Missense)"
      }
    },
    {
      "id": 428,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 414,
        "alternate_allele": "G",
        "cdna_change": "p.34G>C",
        "chromosome": "1",
        "end_position": "115258748",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12R",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258748",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12R (Missense)"
      }
    },
    {
      "id": 429,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 415,
        "alternate_allele": "T",
        "cdna_change": "p.34G>A",
        "chromosome": "1",
        "end_position": "115258748",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12S",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258748",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12S (Missense)"
      }
    },
    {
      "id": 430,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 416,
        "alternate_allele": "A",
        "cdna_change": "p.35G>T",
        "chromosome": "1",
        "end_position": "115258747",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G12V",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258747",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G12V (Missense)"
      }
    },
    {
      "id": 431,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 417,
        "alternate_allele": "G",
        "cdna_change": "c.38G>C",
        "chromosome": "1",
        "end_position": "115258744",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13A",
        "reference_allele": "C",
        "rsid": "rs121434596",
        "start_position": "115258744",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13A (Missense)"
      }
    },
    {
      "id": 432,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 418,
        "alternate_allele": "T",
        "cdna_change": "c.38G>A",
        "chromosome": "1",
        "end_position": "115258744",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13D",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258744",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13D (Missense)"
      }
    },
    {
      "id": 433,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 419,
        "alternate_allele": "G",
        "cdna_change": "c.37G>C",
        "chromosome": "1",
        "end_position": "115258745",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13R",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "115258745",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13R (Missense)"
      }
    },
    {
      "id": 434,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 420,
        "alternate_allele": "A",
        "cdna_change": "c.38G>T",
        "chromosome": "1",
        "end_position": "115258744",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.G13V",
        "reference_allele": "C",
        "rsid": "rs121434596",
        "start_position": "115258744",
        "variant_annotation": "Missense",
        "feature": "NRAS p.G13V (Missense)"
      }
    },
    {
      "id": 435,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 421,
        "alternate_allele": "C",
        "cdna_change": "c.181C>G",
        "chromosome": "1",
        "end_position": "115256530",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61E",
        "reference_allele": "G",
        "rsid": "rs121913254",
        "start_position": "115256530",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61E (Missense)"
      }
    },
    {
      "id": 436,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 422,
        "alternate_allele": "A",
        "cdna_change": "c.183A>T",
        "chromosome": "1",
        "end_position": "115256528",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61H",
        "reference_allele": "T",
        "rsid": "rs121913255",
        "start_position": "115256528",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61H (Missense)"
      }
    },
    {
      "id": 437,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 423,
        "alternate_allele": "A",
        "cdna_change": "c.182A>T",
        "chromosome": "1",
        "end_position": "115256529",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61L",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "115256529",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61L (Missense)"
      }
    },
    {
      "id": 438,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 424,
        "alternate_allele": "G",
        "cdna_change": "c.182A>C",
        "chromosome": "1",
        "end_position": "115256529",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61P",
        "reference_allele": "T",
        "rsid": "rs11554290",
        "start_position": "115256529",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61P (Missense)"
      }
    },
    {
      "id": 439,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of this variant may suggest sensitivity to Selumetinib.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 151,
      "variant": {
        "id": 425,
        "alternate_allele": "C",
        "cdna_change": "c.182A>G",
        "chromosome": "1",
        "end_position": "115256529",
        "exon": "3",
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": "p.Q61R",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "115256529",
        "variant_annotation": "Missense",
        "feature": "NRAS p.Q61R (Missense)"
      }
    },
    {
      "id": 440,
      "context": "Metastatic",
      "deprecated": false,
      "description": "A retrospective study of 677 metastatic melanoma patients found that patients with BRAF and NRAS mutations had a higher risk of CNS involvement at diagnosis of stage IV disease (24% of BRAF and 23% of NRAS compared to 12% WT). Non-uveal melanoma patients tested for mutations within a median 6 months of diagnosis (n=313) showed an association between BRAF and NRAS mutation and a shorter survival (median 8.2 months vs. 15.1 months).",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 152,
      "variant": {
        "id": 409,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "1",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "NRAS",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "NRAS"
      }
    },
    {
      "id": 441,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 442,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 443,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 444,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 445,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 446,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 447,
      "context": "",
      "deprecated": false,
      "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 448,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 449,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "CCRCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Nivolumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 153,
      "variant": {
        "id": 449,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PBRM1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "PBRM1 (Nonsense)"
      }
    },
    {
      "id": 450,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with gastrointestinal stromal tumors and mutations in PDGFRA. Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 127,
      "variant": {
        "id": 450,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PDGFRA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PDGFRA"
      }
    },
    {
      "id": 451,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with gastrointestinal stromal tumors and mutations in PDGFRA. Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "PDGF-R inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 127,
      "variant": {
        "id": 451,
        "alternate_allele": "T",
        "cdna_change": "c.2525A>T",
        "chromosome": "4",
        "end_position": "55152093",
        "exon": "18",
        "feature_type": "somatic_variant",
        "gene": "PDGFRA",
        "protein_change": "p.D842V",
        "reference_allele": "A",
        "rsid": "rs121908585",
        "start_position": "55152093",
        "variant_annotation": "Missense",
        "feature": "PDGFRA p.D842V (Missense)"
      }
    },
    {
      "id": 452,
      "context": "",
      "deprecated": false,
      "description": "Avapritnib inhibited the autophosphorylation of PDGFRA p.D842V in cellular assays.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 451,
        "alternate_allele": "T",
        "cdna_change": "c.2525A>T",
        "chromosome": "4",
        "end_position": "55152093",
        "exon": "18",
        "feature_type": "somatic_variant",
        "gene": "PDGFRA",
        "protein_change": "p.D842V",
        "reference_allele": "A",
        "rsid": "rs121908585",
        "start_position": "55152093",
        "variant_annotation": "Missense",
        "feature": "PDGFRA p.D842V (Missense)"
      }
    },
    {
      "id": 453,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 453,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "4",
        "end_position": null,
        "exon": "18",
        "feature_type": "somatic_variant",
        "gene": "PDGFRA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PDGFRA"
      }
    },
    {
      "id": 454,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V.",
      "disease": {
        "name": "Gastrointestinal Stromal Tumor",
        "oncotree_code": "GIST",
        "oncotree_term": "Gastrointestinal Stromal Tumor"
      },
      "therapy": {
        "name": "Avapritinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 129,
      "variant": {
        "id": 451,
        "alternate_allele": "T",
        "cdna_change": "c.2525A>T",
        "chromosome": "4",
        "end_position": "55152093",
        "exon": "18",
        "feature_type": "somatic_variant",
        "gene": "PDGFRA",
        "protein_change": "p.D842V",
        "reference_allele": "A",
        "rsid": "rs121908585",
        "start_position": "55152093",
        "variant_annotation": "Missense",
        "feature": "PDGFRA p.D842V (Missense)"
      }
    },
    {
      "id": 455,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "CCRCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Nivolumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 153,
      "variant": {
        "id": 455,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PBRM1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "PBRM1 (Frameshift)"
      }
    },
    {
      "id": 456,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Alpelisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 154,
      "variant": {
        "id": 456,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PIK3CA"
      }
    },
    {
      "id": 457,
      "context": "",
      "deprecated": false,
      "description": "PIK3CA, but not AKT1 mutation, increased sensitivity to the PI3K inhibitor GDC-0941 and the allosteric AKT inhibitor MK-2206",
      "disease": {
        "name": "Breast Invasive Ductal Carcinoma",
        "oncotree_code": "IDC",
        "oncotree_term": "Breast Invasive Ductal Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 155,
      "variant": {
        "id": 457,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PIK3CA"
      }
    },
    {
      "id": 458,
      "context": "",
      "deprecated": false,
      "description": "Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 44,
      "variant": {
        "id": 457,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PIK3CA"
      }
    },
    {
      "id": 459,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 459,
        "alternate_allele": "C",
        "cdna_change": "c.1633G>C",
        "chromosome": "3",
        "end_position": "178936091",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E545Q",
        "reference_allele": "G",
        "rsid": "rs104886003",
        "start_position": "178936091",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E545Q (Missense)"
      }
    },
    {
      "id": 460,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 460,
        "alternate_allele": "C",
        "cdna_change": "c.1258T>C",
        "chromosome": "3",
        "end_position": "178927980",
        "exon": "8",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.C420R",
        "reference_allele": "T",
        "rsid": "rs121913272",
        "start_position": "178927980",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.C420R (Missense)"
      }
    },
    {
      "id": 461,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 461,
        "alternate_allele": "A",
        "cdna_change": "c.1624G>A",
        "chromosome": "3",
        "end_position": "178936082",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E542K",
        "reference_allele": "G",
        "rsid": "rs121913273",
        "start_position": "178936082",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E542K (Missense)"
      }
    },
    {
      "id": 462,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 462,
        "alternate_allele": "C",
        "cdna_change": "c.1624G>C",
        "chromosome": "3",
        "end_position": "178936082",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E542Q",
        "reference_allele": "G",
        "rsid": "rs121913273",
        "start_position": "178936082",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E542Q (Missense)"
      }
    },
    {
      "id": 463,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 463,
        "alternate_allele": "C",
        "cdna_change": "c.1634A>C",
        "chromosome": "3",
        "end_position": "178936092",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E545A",
        "reference_allele": "A",
        "rsid": "rs121913274",
        "start_position": "178936092",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E545A (Missense)"
      }
    },
    {
      "id": 464,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 464,
        "alternate_allele": "T",
        "cdna_change": "c.1635G>T",
        "chromosome": "3",
        "end_position": "178936093",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E545D",
        "reference_allele": "G",
        "rsid": "rs121913275",
        "start_position": "178936093",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E545D (Missense)"
      }
    },
    {
      "id": 465,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 464,
        "alternate_allele": "T",
        "cdna_change": "c.1635G>T",
        "chromosome": "3",
        "end_position": "178936093",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E545D",
        "reference_allele": "G",
        "rsid": "rs121913275",
        "start_position": "178936093",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E545D (Missense)"
      }
    },
    {
      "id": 466,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 466,
        "alternate_allele": "G",
        "cdna_change": "c.1634A>G",
        "chromosome": "3",
        "end_position": "178936092",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E545G",
        "reference_allele": "A",
        "rsid": "rs121913274",
        "start_position": "178936092",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E545G (Missense)"
      }
    },
    {
      "id": 467,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 467,
        "alternate_allele": "A",
        "cdna_change": "c.1633G>A",
        "chromosome": "3",
        "end_position": "178936091",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.E545K",
        "reference_allele": "G",
        "rsid": "rs104886003",
        "start_position": "178936091",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.E545K (Missense)"
      }
    },
    {
      "id": 468,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 468,
        "alternate_allele": "C",
        "cdna_change": "c.3145G>C",
        "chromosome": "3",
        "end_position": "178952090",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.G1049R",
        "reference_allele": "G",
        "rsid": "rs121913277",
        "start_position": "178952090",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.G1049R (Missense)"
      }
    },
    {
      "id": 469,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 469,
        "alternate_allele": "A",
        "cdna_change": "c.3145G>A",
        "chromosome": "3",
        "end_position": "178952090",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.G1049S",
        "reference_allele": "G",
        "rsid": "rs121913277",
        "start_position": "178952090",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.G1049S (Missense)"
      }
    },
    {
      "id": 470,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 470,
        "alternate_allele": "T",
        "cdna_change": "c.3140A>T",
        "chromosome": "3",
        "end_position": "178952085",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.H1047L",
        "reference_allele": "A",
        "rsid": "rs121913279",
        "start_position": "178952085",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.H1047L (Missense)"
      }
    },
    {
      "id": 471,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 471,
        "alternate_allele": "G",
        "cdna_change": "c.3140A>G",
        "chromosome": "3",
        "end_position": "178952085",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.H1047R",
        "reference_allele": "A",
        "rsid": "rs121913279",
        "start_position": "178952085",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.H1047R (Missense)"
      }
    },
    {
      "id": 472,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 472,
        "alternate_allele": "T",
        "cdna_change": "c.3139C>T",
        "chromosome": "3",
        "end_position": "178952084",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.H1047Y",
        "reference_allele": "C",
        "rsid": "rs121913281",
        "start_position": "178952084",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.H1047Y (Missense)"
      }
    },
    {
      "id": 473,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 473,
        "alternate_allele": "C",
        "cdna_change": "c.2102A>C",
        "chromosome": "3",
        "end_position": "178938860",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.H701P",
        "reference_allele": "A",
        "rsid": "rs121913282",
        "start_position": "178938860",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.H701P (Missense)"
      }
    },
    {
      "id": 474,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 474,
        "alternate_allele": "A",
        "cdna_change": "c.3129G>A",
        "chromosome": "3",
        "end_position": "178952074",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.M1043I",
        "reference_allele": "G",
        "rsid": "rs121913283",
        "start_position": "178952074",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.M1043I (Missense)"
      }
    },
    {
      "id": 475,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 474,
        "alternate_allele": "A",
        "cdna_change": "c.3129G>A",
        "chromosome": "3",
        "end_position": "178952074",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.M1043I",
        "reference_allele": "G",
        "rsid": "rs121913283",
        "start_position": "178952074",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.M1043I (Missense)"
      }
    },
    {
      "id": 476,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 476,
        "alternate_allele": "G",
        "cdna_change": "c.1616C>G",
        "chromosome": "3",
        "end_position": "178936074",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.P539R",
        "reference_allele": "C",
        "rsid": "rs121913285",
        "start_position": "178936074",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.P539R (Missense)"
      }
    },
    {
      "id": 477,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 477,
        "alternate_allele": "A",
        "cdna_change": "c.1636C>A",
        "chromosome": "3",
        "end_position": "178936094",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.Q546K",
        "reference_allele": "C",
        "rsid": "rs121913286",
        "start_position": "178936094",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.Q546K (Missense)"
      }
    },
    {
      "id": 478,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 60,
      "variant": {
        "id": 478,
        "alternate_allele": "G",
        "cdna_change": "c.3062A>G",
        "chromosome": "3",
        "end_position": "178952007",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": "p.Y1021C",
        "reference_allele": "A",
        "rsid": "rs121913288",
        "start_position": "178952007",
        "variant_annotation": "Missense",
        "feature": "PIK3CA p.Y1021C (Missense)"
      }
    },
    {
      "id": 479,
      "context": "",
      "deprecated": false,
      "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 156,
      "variant": {
        "id": 479,
        "alternate_allele": "C",
        "cdna_change": "c.946G>C",
        "chromosome": "19",
        "end_position": "50905974",
        "exon": "8",
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": "p.D316H",
        "reference_allele": "G",
        "rsid": "rs746087148",
        "start_position": "50905974",
        "variant_annotation": "Missense",
        "feature": "POLD1 p.D316H (Missense)"
      }
    },
    {
      "id": 480,
      "context": "",
      "deprecated": false,
      "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 156,
      "variant": {
        "id": 480,
        "alternate_allele": "G",
        "cdna_change": "c.947A>G",
        "chromosome": "19",
        "end_position": "50905975",
        "exon": "8",
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": "p.D316G",
        "reference_allele": "A",
        "rsid": "rs746087148",
        "start_position": "50905975",
        "variant_annotation": "Missense",
        "feature": "POLD1 p.D316G (Missense)"
      }
    },
    {
      "id": 481,
      "context": "",
      "deprecated": false,
      "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 156,
      "variant": {
        "id": 481,
        "alternate_allele": "T",
        "cdna_change": "c.1225C>T",
        "chromosome": "19",
        "end_position": "50906837",
        "exon": "10",
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": "p.R409W",
        "reference_allele": "C",
        "rsid": "rs778135510",
        "start_position": "50906837",
        "variant_annotation": "Missense",
        "feature": "POLD1 p.R409W (Missense)"
      }
    },
    {
      "id": 482,
      "context": "",
      "deprecated": false,
      "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 156,
      "variant": {
        "id": 482,
        "alternate_allele": "C",
        "cdna_change": "c.1421T>C",
        "chromosome": "19",
        "end_position": "50909701",
        "exon": "12",
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": "p.L474P",
        "reference_allele": "T",
        "rsid": "rs587777627",
        "start_position": "50909701",
        "variant_annotation": "Missense",
        "feature": "POLD1 p.L474P (Missense)"
      }
    },
    {
      "id": 483,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 483,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "19",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "POLD1"
      }
    },
    {
      "id": 484,
      "context": "",
      "deprecated": false,
      "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 483,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "19",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "POLD1"
      }
    },
    {
      "id": 485,
      "context": "",
      "deprecated": false,
      "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 483,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "19",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "POLD1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "POLD1"
      }
    },
    {
      "id": 486,
      "context": "",
      "deprecated": false,
      "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 156,
      "variant": {
        "id": 486,
        "alternate_allele": "C",
        "cdna_change": "c.1270C>G",
        "chromosome": "12",
        "end_position": "133250250",
        "exon": "13",
        "feature_type": "somatic_variant",
        "gene": "POLE",
        "protein_change": "p.L424V",
        "reference_allele": "G",
        "rsid": "rs483352909",
        "start_position": "133250250",
        "variant_annotation": "Missense",
        "feature": "POLE p.L424V (Missense)"
      }
    },
    {
      "id": 487,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 487,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "POLE",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "POLE"
      }
    },
    {
      "id": 488,
      "context": "",
      "deprecated": false,
      "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 487,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "POLE",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "POLE"
      }
    },
    {
      "id": 489,
      "context": "",
      "deprecated": false,
      "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 487,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "12",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "POLE",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "POLE"
      }
    },
    {
      "id": 490,
      "context": "",
      "deprecated": false,
      "description": "AZ8186 showed pharmacodynamic modulation of p-Akt in PC3 PTEN-deficient prostate tumor bearing mice and showed complete inhibition of tumor growth in mouse PTEN-deficient PC3 prostate tumor xenograft models. The publication states that AZ8186 entered into phase 1 study.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "PI3Kbeta Inhibitor AZD8186",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 158,
      "variant": {
        "id": 490,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "PTEN (Nonsense)"
      }
    },
    {
      "id": 491,
      "context": "",
      "deprecated": false,
      "description": "AZ8186 showed pharmacodynamic modulation of p-Akt in PC3 PTEN-deficient prostate tumor bearing mice and showed complete inhibition of tumor growth in mouse PTEN-deficient PC3 prostate tumor xenograft models. The publication states that AZ8186 entered into phase 1 study.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "PI3Kbeta Inhibitor AZD8186",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 158,
      "variant": {
        "id": 491,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "PTEN (Frameshift)"
      }
    },
    {
      "id": 492,
      "context": "",
      "deprecated": false,
      "description": "AZ8186 showed pharmacodynamic modulation of p-Akt in PC3 PTEN-deficient prostate tumor bearing mice and showed complete inhibition of tumor growth in mouse PTEN-deficient PC3 prostate tumor xenograft models. The publication states that AZ8186 entered into phase 1 study.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "PI3Kbeta Inhibitor AZD8186",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 158,
      "variant": {
        "id": 492,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "PTEN (Splice Site)"
      }
    },
    {
      "id": 493,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 159,
      "variant": {
        "id": 490,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "PTEN (Nonsense)"
      }
    },
    {
      "id": 494,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 159,
      "variant": {
        "id": 491,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "PTEN (Frameshift)"
      }
    },
    {
      "id": 495,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 159,
      "variant": {
        "id": 492,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "PTEN (Splice Site)"
      }
    },
    {
      "id": 496,
      "context": "",
      "deprecated": false,
      "description": "Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 44,
      "variant": {
        "id": 496,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PTEN"
      }
    },
    {
      "id": 497,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 160,
      "variant": {
        "id": 490,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "PTEN (Nonsense)"
      }
    },
    {
      "id": 498,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 160,
      "variant": {
        "id": 491,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "PTEN (Frameshift)"
      }
    },
    {
      "id": 499,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 160,
      "variant": {
        "id": 492,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "PTEN (Splice Site)"
      }
    },
    {
      "id": 500,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 160,
      "variant": {
        "id": 490,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "PTEN (Nonsense)"
      }
    },
    {
      "id": 501,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights variants in PTPN11 as being associated with shorter overall survival in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 501,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTPN11",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PTPN11"
      }
    },
    {
      "id": 502,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 502,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51B",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51B"
      }
    },
    {
      "id": 503,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 504,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 505,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 506,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 507,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 508,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 509,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 510,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 511,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 512,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 513,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 514,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 515,
      "context": "Primary",
      "deprecated": false,
      "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 516,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 510,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51D",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 517,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 517,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD54L",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD54L"
      }
    },
    {
      "id": 518,
      "context": "",
      "deprecated": false,
      "description": "RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 518,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RBM10",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RBM10"
      }
    },
    {
      "id": 519,
      "context": "",
      "deprecated": false,
      "description": "Certain missesnse mutations may predict resistance to RET inhibitors",
      "disease": {
        "name": "Medullary Thyroid Cancer",
        "oncotree_code": "THME",
        "oncotree_term": "Medullary Thyroid Cancer"
      },
      "therapy": {
        "name": "Selpercatinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 161,
      "variant": {
        "id": 519,
        "alternate_allele": "A",
        "cdna_change": "c.2410G>A",
        "chromosome": "10",
        "end_position": "43614996",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "RET",
        "protein_change": "p.V804M",
        "reference_allele": "G",
        "rsid": "rs79658334",
        "start_position": "43614996",
        "variant_annotation": "Missense",
        "feature": "RET p.V804M (Missense)"
      }
    },
    {
      "id": 520,
      "context": "",
      "deprecated": false,
      "description": "Certain missesnse mutations may predict sensitivity to RET inhibitors",
      "disease": {
        "name": "Medullary Thyroid Cancer",
        "oncotree_code": "THME",
        "oncotree_term": "Medullary Thyroid Cancer"
      },
      "therapy": {
        "name": "Selpercatinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 161,
      "variant": {
        "id": 520,
        "alternate_allele": "C",
        "cdna_change": "c.2753T>C",
        "chromosome": "10",
        "end_position": "43617416",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "RET",
        "protein_change": "p.M918T",
        "reference_allele": "T",
        "rsid": "rs74799832",
        "start_position": "43617416",
        "variant_annotation": "Missense",
        "feature": "RET p.M918T (Missense)"
      }
    },
    {
      "id": 521,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.",
      "disease": {
        "name": "Medullary Thyroid Cancer",
        "oncotree_code": "THME",
        "oncotree_term": "Medullary Thyroid Cancer"
      },
      "therapy": {
        "name": "Selpercatinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 162,
      "variant": {
        "id": 521,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RET"
      }
    },
    {
      "id": 522,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights RUNX1 nonsense and frameshift variants as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 522,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RUNX1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "RUNX1 (Nonsense)"
      }
    },
    {
      "id": 523,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights RUNX1 nonsense and frameshift variants as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 523,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RUNX1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "RUNX1 (Frameshift)"
      }
    },
    {
      "id": 524,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 524,
        "alternate_allele": "A",
        "cdna_change": "c.2572G>A",
        "chromosome": "18",
        "end_position": "42531877",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.E858K",
        "reference_allele": "G",
        "rsid": null,
        "start_position": "42531877",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.E858K (Missense)"
      }
    },
    {
      "id": 525,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 525,
        "alternate_allele": "T",
        "cdna_change": "c.2591C>T",
        "chromosome": "18",
        "end_position": "42531896",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.T864M",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "42531896",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.T864M (Missense)"
      }
    },
    {
      "id": 526,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 526,
        "alternate_allele": "A",
        "cdna_change": "c.2594T>A",
        "chromosome": "18",
        "end_position": "42531899",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.I865N",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "42531899",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.I865N (Missense)"
      }
    },
    {
      "id": 527,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 527,
        "alternate_allele": "A",
        "cdna_change": "c.2602G>A",
        "chromosome": "18",
        "end_position": "42531907",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.D868N",
        "reference_allele": "G",
        "rsid": "rs267607042",
        "start_position": "42531907",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.D868N (Missense)"
      }
    },
    {
      "id": 528,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 528,
        "alternate_allele": "T",
        "cdna_change": "c.2602G>T",
        "chromosome": "18",
        "end_position": "42531907",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.D868Y",
        "reference_allele": "G",
        "rsid": "rs267607042",
        "start_position": "42531907",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.D868Y (Missense)"
      }
    },
    {
      "id": 529,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 529,
        "alternate_allele": "T",
        "cdna_change": "c.2605A>T",
        "chromosome": "18",
        "end_position": "42531910",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.S869C",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "42531910",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.S869C (Missense)"
      }
    },
    {
      "id": 530,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SETBP1 E858, T864, I865, D868, S869, and G870 missense variants as being associated with disease progression in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 530,
        "alternate_allele": "A",
        "cdna_change": "c.2608G>A",
        "chromosome": "18",
        "end_position": "42531913",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "SETBP1",
        "protein_change": "p.G870S",
        "reference_allele": "G",
        "rsid": "rs267607040",
        "start_position": "42531913",
        "variant_annotation": "Missense",
        "feature": "SETBP1 p.G870S (Missense)"
      }
    },
    {
      "id": 531,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 531,
        "alternate_allele": "G",
        "cdna_change": "c.1864G>C",
        "chromosome": "2",
        "end_position": "198267493",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.E622Q",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "198267493",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.E622Q (Missense)"
      }
    },
    {
      "id": 532,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 532,
        "alternate_allele": "G",
        "cdna_change": "c.1866G>C",
        "chromosome": "2",
        "end_position": "198267491",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.E622D",
        "reference_allele": "C",
        "rsid": "rs763149798",
        "start_position": "198267491",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.E622D (Missense)"
      }
    },
    {
      "id": 533,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 533,
        "alternate_allele": "C",
        "cdna_change": "c.1868A>G",
        "chromosome": "2",
        "end_position": "198267489",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.Y623C",
        "reference_allele": "T",
        "rsid": "rs1039242157",
        "start_position": "198267489",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.Y623C (Missense)"
      }
    },
    {
      "id": 534,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 534,
        "alternate_allele": "A",
        "cdna_change": "c.1873C>T",
        "chromosome": "2",
        "end_position": "198267484",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.R625C",
        "reference_allele": "G",
        "rsid": "rs775623976",
        "start_position": "198267484",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.R625C (Missense)"
      }
    },
    {
      "id": 535,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 535,
        "alternate_allele": "T",
        "cdna_change": "c.1874G>A",
        "chromosome": "2",
        "end_position": "198267483",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.R625H",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "198267483",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.R625H (Missense)"
      }
    },
    {
      "id": 536,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 536,
        "alternate_allele": "G",
        "cdna_change": "c.1876A>C",
        "chromosome": "2",
        "end_position": "198267481",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.N626H",
        "reference_allele": "T",
        "rsid": "rs769888451",
        "start_position": "198267481",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.N626H (Missense)"
      }
    },
    {
      "id": 537,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 537,
        "alternate_allele": "A",
        "cdna_change": "c.1876A>T",
        "chromosome": "2",
        "end_position": "198267481",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.N626Y",
        "reference_allele": "T",
        "rsid": "rs769888451",
        "start_position": "198267481",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.N626Y (Missense)"
      }
    },
    {
      "id": 538,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 538,
        "alternate_allele": "C",
        "cdna_change": "c.1876A>G",
        "chromosome": "2",
        "end_position": "198267481",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.N626D",
        "reference_allele": "T",
        "rsid": "rs769888451",
        "start_position": "198267481",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.N626D (Missense)"
      }
    },
    {
      "id": 539,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 539,
        "alternate_allele": "C",
        "cdna_change": "c.1985A>G",
        "chromosome": "2",
        "end_position": "198267372",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.H662R",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "198267372",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.H662R (Missense)"
      }
    },
    {
      "id": 540,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 540,
        "alternate_allele": "G",
        "cdna_change": "c.1987A>C",
        "chromosome": "2",
        "end_position": "198267370",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.T663P",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "198267370",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.T663P (Missense)"
      }
    },
    {
      "id": 541,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 541,
        "alternate_allele": "G",
        "cdna_change": "c.1998G>C",
        "chromosome": "2",
        "end_position": "198267359",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.K666N",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "198267359",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.K666N (Missense)"
      }
    },
    {
      "id": 542,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 542,
        "alternate_allele": "G",
        "cdna_change": "c.1997A>C",
        "chromosome": "2",
        "end_position": "198267360",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.K666T",
        "reference_allele": "T",
        "rsid": null,
        "start_position": "198267360",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.K666T (Missense)"
      }
    },
    {
      "id": 543,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 543,
        "alternate_allele": "C",
        "cdna_change": "c.1996A>G",
        "chromosome": "2",
        "end_position": "198267361",
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.K666E",
        "reference_allele": "T",
        "rsid": "rs754688962",
        "start_position": "198267361",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.K666E (Missense)"
      }
    },
    {
      "id": 544,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 544,
        "alternate_allele": "C",
        "cdna_change": "c.2098A>G",
        "chromosome": "2",
        "end_position": "198266834",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.K700E",
        "reference_allele": "T",
        "rsid": "rs559063155",
        "start_position": "198266834",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.K700E (Missense)"
      }
    },
    {
      "id": 545,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 545,
        "alternate_allele": "C",
        "cdna_change": "c.2111T>G",
        "chromosome": "2",
        "end_position": "198266821",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.I704S",
        "reference_allele": "A",
        "rsid": "rs1574528840",
        "start_position": "198266821",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.I704S (Missense)"
      }
    },
    {
      "id": 546,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 546,
        "alternate_allele": "T",
        "cdna_change": "c.2219G>A",
        "chromosome": "2",
        "end_position": "198266713",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.G740E",
        "reference_allele": "C",
        "rsid": "rs776846119",
        "start_position": "198266713",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.G740E (Missense)"
      }
    },
    {
      "id": 547,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 547,
        "alternate_allele": "A",
        "cdna_change": "c.2219G>T",
        "chromosome": "2",
        "end_position": "198266713",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.G740V",
        "reference_allele": "C",
        "rsid": "rs776846119",
        "start_position": "198266713",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.G740V (Missense)"
      }
    },
    {
      "id": 548,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 548,
        "alternate_allele": "T",
        "cdna_change": "c.2225G>A",
        "chromosome": "2",
        "end_position": "198266611",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.G742D",
        "reference_allele": "C",
        "rsid": "rs755415626",
        "start_position": "198266611",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.G742D (Missense)"
      }
    },
    {
      "id": 549,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SF3B1 E622, Y623, R625, N626, H662, T663, K666, K700E, I704, G740, G742, and D781 missense variants as being associated with a favorable prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 549,
        "alternate_allele": "T",
        "cdna_change": "c.2343T>A",
        "chromosome": "2",
        "end_position": "198266493",
        "exon": "16",
        "feature_type": "somatic_variant",
        "gene": "SF3B1",
        "protein_change": "p.D781E",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "198266493",
        "variant_annotation": "Missense",
        "feature": "SF3B1 p.D781E (Missense)"
      }
    },
    {
      "id": 550,
      "context": "",
      "deprecated": false,
      "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Tozasertib Lactate",
        "type": "Targeted therapy",
        "strategy": "Aurora kinase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 163,
      "variant": {
        "id": 550,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "SMARCA4",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "SMARCA4 (Nonsense)"
      }
    },
    {
      "id": 551,
      "context": "",
      "deprecated": false,
      "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Tozasertib Lactate",
        "type": "Targeted therapy",
        "strategy": "Aurora kinase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 163,
      "variant": {
        "id": 551,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "SMARCA4",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "SMARCA4 (Frameshift)"
      }
    },
    {
      "id": 552,
      "context": "",
      "deprecated": false,
      "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Tozasertib Lactate",
        "type": "Targeted therapy",
        "strategy": "Aurora kinase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 163,
      "variant": {
        "id": 552,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "SMARCA4",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "SMARCA4 (Splice Site)"
      }
    },
    {
      "id": 553,
      "context": "de-novo metastatic castration sensitive",
      "deprecated": false,
      "description": "The presence of SPOP missense somatic variants was associated with improved survival outcomes in men with de novo metastatic castration-sensitive prostate cancer receiving standard androgen deprivation therapy.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-10-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 164,
      "variant": {
        "id": 553,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "17",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "SPOP",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "SPOP (Missense)"
      }
    },
    {
      "id": 554,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The presence of SPOP missense somatic variants was associated with improved response to abiraterone when considering 50% PSA falls, are less likely to progress, and are associated with longer median duration of abiraterone treatment.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 165,
      "variant": {
        "id": 553,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "17",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "SPOP",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "SPOP (Missense)"
      }
    },
    {
      "id": 555,
      "context": "High-risk localized",
      "deprecated": false,
      "description": "The presence of SPOP missense somatic variants was associated with improved response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 166,
      "variant": {
        "id": 553,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "17",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "SPOP",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "SPOP (Missense)"
      }
    },
    {
      "id": 556,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights STAG2 nonsense, frameshift, and splice site variants as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 556,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "STAG2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "STAG2 (Nonsense)"
      }
    },
    {
      "id": 557,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights STAG2 nonsense, frameshift, and splice site variants as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 557,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "STAG2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "STAG2 (Frameshift)"
      }
    },
    {
      "id": 558,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights STAG2 nonsense, frameshift, and splice site variants as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 558,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "STAG2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "STAG2 (Splice Site)"
      }
    },
    {
      "id": 559,
      "context": "",
      "deprecated": false,
      "description": "TET2 mutations are associated with an increased sensitivity to hypomethylating agents, such as AzaC. This study of 86 patients with MDS and AML observed a response rate of 86% in patients with mutated TET2 versus 45% in patients that were wild type, with a reported p-value of 0.007.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Azacitidine",
        "type": "Chemotherapy",
        "strategy": "Hypomethylating agent chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 167,
      "variant": {
        "id": 559,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TET2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TET2"
      }
    },
    {
      "id": 560,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights TP53 nonsense, frameshift, splice site, and missense variants except for P47S and P72R as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 560,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "TP53 (Missense)"
      }
    },
    {
      "id": 561,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights TP53 nonsense, frameshift, splice site, and missense variants except for P47S and P72R as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 561,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "TP53 (Nonsense)"
      }
    },
    {
      "id": 562,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights TP53 nonsense, frameshift, splice site, and missense variants except for P47S and P72R as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 562,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "TP53 (Frameshift)"
      }
    },
    {
      "id": 563,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights TP53 nonsense, frameshift, splice site, and missense variants except for P47S and P72R as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 563,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "TP53 (Splice Site)"
      }
    },
    {
      "id": 564,
      "context": "",
      "deprecated": false,
      "description": "Lenalidomide (Revlimid) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with myelodysplastic syndromes and nonsense, frameshift, splice site, or missense variants in TP53 except for P47S and P72R. These mutations may predict resistance or relapse to lenalidomide.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Lenalidomide",
        "type": "Targeted therapy",
        "strategy": "Immunomodulation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 561,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "TP53 (Nonsense)"
      }
    },
    {
      "id": 565,
      "context": "",
      "deprecated": false,
      "description": "Lenalidomide (Revlimid) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with myelodysplastic syndromes and nonsense, frameshift, splice site, or missense variants in TP53 except for P47S and P72R. These mutations may predict resistance or relapse to lenalidomide.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Lenalidomide",
        "type": "Targeted therapy",
        "strategy": "Immunomodulation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 562,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "TP53 (Frameshift)"
      }
    },
    {
      "id": 566,
      "context": "",
      "deprecated": false,
      "description": "Lenalidomide (Revlimid) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with myelodysplastic syndromes and nonsense, frameshift, splice site, or missense variants in TP53 except for P47S and P72R. These mutations may predict resistance or relapse to lenalidomide.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Lenalidomide",
        "type": "Targeted therapy",
        "strategy": "Immunomodulation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 563,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "TP53 (Splice Site)"
      }
    },
    {
      "id": 567,
      "context": "",
      "deprecated": false,
      "description": "Lenalidomide (Revlimid) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with myelodysplastic syndromes and nonsense, frameshift, splice site, or missense variants in TP53 except for P47S and P72R. These mutations may predict resistance or relapse to lenalidomide.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "Lenalidomide",
        "type": "Targeted therapy",
        "strategy": "Immunomodulation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 560,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "TP53 (Missense)"
      }
    },
    {
      "id": 568,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of mutant TP53 may suggest resistance to nutlin-3.",
      "disease": {
        "name": "Gastric Remnant Adenocarcinoma",
        "oncotree_code": "GRC",
        "oncotree_term": "Gastric Remnant Adenocarcinoma"
      },
      "therapy": {
        "name": "nutlin-3",
        "type": "Targeted therapy",
        "strategy": "MDM2-p53 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 168,
      "variant": {
        "id": 568,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TP53"
      }
    },
    {
      "id": 569,
      "context": "",
      "deprecated": false,
      "description": "Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 44,
      "variant": {
        "id": 568,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TP53"
      }
    },
    {
      "id": 570,
      "context": "",
      "deprecated": false,
      "description": "In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.",
      "disease": {
        "name": "Rectal Adenocarcinoma",
        "oncotree_code": "READ",
        "oncotree_term": "Rectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Chemoradiotherapy",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 138,
      "variant": {
        "id": 568,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TP53"
      }
    },
    {
      "id": 571,
      "context": "",
      "deprecated": false,
      "description": "Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 169,
      "variant": {
        "id": 571,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TSC1"
      }
    },
    {
      "id": 572,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 110,
      "variant": {
        "id": 572,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "TSC1 (Nonsense)"
      }
    },
    {
      "id": 573,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 110,
      "variant": {
        "id": 573,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "TSC1 (Frameshift)"
      }
    },
    {
      "id": 574,
      "context": "",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 572,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "TSC1 (Nonsense)"
      }
    },
    {
      "id": 575,
      "context": "",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 573,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "TSC1 (Frameshift)"
      }
    },
    {
      "id": 576,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a study of 184 everolimus-treated patients with RCC from a phase 2 randomized trial,  PFS neither differed on univariate analysis nor on multivariate testing based on variant status in TSC1, TSC2, or MTOR.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "RCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 149,
      "variant": {
        "id": 571,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TSC1"
      }
    },
    {
      "id": 577,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a study of 184 everolimus-treated patients with RCC from a phase 2 randomized trial,  PFS neither differed on univariate analysis nor on multivariate testing based on variant status in TSC1, TSC2, or MTOR.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "RCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 149,
      "variant": {
        "id": 577,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TSC2"
      }
    },
    {
      "id": 578,
      "context": "",
      "deprecated": false,
      "description": "Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 169,
      "variant": {
        "id": 577,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TSC2"
      }
    },
    {
      "id": 579,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 110,
      "variant": {
        "id": 579,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "TSC2 (Nonsense)"
      }
    },
    {
      "id": 580,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 110,
      "variant": {
        "id": 580,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "TSC2 (Frameshift)"
      }
    },
    {
      "id": 581,
      "context": "",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 579,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "TSC2 (Nonsense)"
      }
    },
    {
      "id": 582,
      "context": "",
      "deprecated": false,
      "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition",
      "disease": {
        "name": "Anaplastic Thyroid Cancer",
        "oncotree_code": "THAP",
        "oncotree_term": "Anaplastic Thyroid Cancer"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-19",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 111,
      "variant": {
        "id": 580,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TSC2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "TSC2 (Frameshift)"
      }
    },
    {
      "id": 583,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights ZRSR2 nonsense and frameshift variants as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 583,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ZRSR2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "ZRSR2 (Nonsense)"
      }
    },
    {
      "id": 584,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights ZRSR2 nonsense and frameshift variants as being associated with a poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 584,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ZRSR2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "ZRSR2 (Frameshift)"
      }
    },
    {
      "id": 585,
      "context": "",
      "deprecated": false,
      "description": "Germline variants in ATM and other DNA repair genes have been described in patients experiencing extreme normal tissue toxicity from radiation.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 170,
      "variant": {
        "id": 585,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "ATM",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ATM"
      }
    },
    {
      "id": 586,
      "context": "",
      "deprecated": false,
      "description": "Pathogenic germline variants in ATM may increase risk of acquiring CRC. Germline pathogenic variants in ATM were enriched in several large cohorts of CRC patients when the frequency of multiple DNA-repair genes was compared to that of ancestry-matched healthy patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 171,
      "variant": {
        "id": 586,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "ATM",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ATM"
      }
    },
    {
      "id": 587,
      "context": "",
      "deprecated": false,
      "description": "SK-CO-1 cells are homozygous for ATM c.2251-10>T, lack ATM protein expression, and are sensitive to the PARP inhibitor olaparib.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 57,
      "variant": {
        "id": 587,
        "alternate_allele": "G",
        "cdna_change": "c.2251-10T>G",
        "chromosome": "11",
        "end_position": "108128198",
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "ATM",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": "T",
        "rsid": "rs730881346",
        "start_position": "108128198",
        "variant_annotation": null,
        "feature": "ATM"
      }
    },
    {
      "id": 588,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 588,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BARD1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 589,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 588,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BARD1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 590,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 588,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BARD1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 591,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 588,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BARD1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 592,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 588,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BARD1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 593,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 588,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BARD1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BARD1"
      }
    },
    {
      "id": 594,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 595,
      "context": "Treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 596,
      "context": "Primary, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 597,
      "context": "HER2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endorcrine therapy.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 598,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 599,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 600,
      "context": "Primary",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 81,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 601,
      "context": "",
      "deprecated": false,
      "description": "Olaparib (Lynparza) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with chemotherapy-refractory ovarian cancer. These patients have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 173,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 602,
      "context": "",
      "deprecated": false,
      "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 602,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 603,
      "context": "HER2-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Olaparib (Lynparza) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease with HER2-negative tumors with germline BRCA1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 604,
      "context": "HER2-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Olaparib (Lynparza) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease with HER2-negative tumors with germline BRCA1/2 variants",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 605,
      "context": "Triple-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Carboplatin is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Carboplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 606,
      "context": "Triple-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Cisplatin is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Cisplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 607,
      "context": "HER2-negative locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 175,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 608,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 609,
      "context": "Treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 610,
      "context": "Primary, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 611,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 612,
      "context": "HER2-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Olaparib (Lynparza) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease that are also HER2-negative tumors with germline BRCA1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 613,
      "context": "HER2-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Talazoparib (Talzenna) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease that are also HER2-negative tumors with germline BRCA1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 614,
      "context": "Triple-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Carboplatin is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Carboplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 615,
      "context": "Triple-negative, recurrent or metastatic",
      "deprecated": false,
      "description": "Cisplatin is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Cisplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 174,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 616,
      "context": "HER2-negative locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 176,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 617,
      "context": "HER2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 618,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 619,
      "context": "Treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 620,
      "context": "Primary, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Niraparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-15",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 86,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 621,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 177,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 622,
      "context": "Advanced, treated with three or more prior lines of chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 177,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 623,
      "context": "Primary",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 177,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 624,
      "context": "",
      "deprecated": false,
      "description": "Olaparib (Lynparza) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with chemotherapy-refractory ovarian cancer. These patients have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 173,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 625,
      "context": "",
      "deprecated": false,
      "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 88,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 626,
      "context": "",
      "deprecated": false,
      "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 627,
      "context": "Metastatic castration resistant prostate cancer",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-10-22",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 58,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 628,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 628,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 629,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 628,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 630,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 628,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 631,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 628,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 632,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 628,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 633,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 628,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK1"
      }
    },
    {
      "id": 634,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 634,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 635,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 634,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 636,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 634,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 637,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 634,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 638,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 634,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 639,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 634,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 640,
      "context": "",
      "deprecated": false,
      "description": "CHEK2 variants may increase risk of acquiring testicular germ cells tumors. Germline pathogenic mutations in CHEK2 were enriched in both discovery and validation cohorts of European men with TGCTs, compared to the ExAC Non-Finnish Europeans cohort of healthy patients.",
      "disease": {
        "name": "Testicular Germ Cell Tumors",
        "oncotree_code": "TGCT",
        "oncotree_term": "Testicular Germ Cell Tumors"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 178,
      "variant": {
        "id": 640,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "CHEK2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 641,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 641,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "EPCAM",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "EPCAM"
      }
    },
    {
      "id": 642,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 642,
        "alternate_allele": "A",
        "cdna_change": "c.94C>T",
        "chromosome": "19",
        "end_position": "18194272",
        "exon": "2",
        "feature_type": "germline_variant",
        "gene": "IL12RB1",
        "pathogenic": null,
        "protein_change": "p.Q32*",
        "reference_allele": "G",
        "rsid": "rs121434492",
        "start_position": "18194272",
        "variant_annotation": "Nonsense",
        "feature": "IL12RB1"
      }
    },
    {
      "id": 643,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 643,
        "alternate_allele": "A",
        "cdna_change": "c.1624C>T",
        "chromosome": "19",
        "end_position": "18173082",
        "exon": "15",
        "feature_type": "germline_variant",
        "gene": "IL12RB1",
        "pathogenic": null,
        "protein_change": "p.Q542*",
        "reference_allele": "G",
        "rsid": "rs372833507",
        "start_position": "18173082",
        "variant_annotation": "Nonsense",
        "feature": "IL12RB1"
      }
    },
    {
      "id": 644,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 644,
        "alternate_allele": "C",
        "cdna_change": "c.1719dup",
        "chromosome": "22",
        "end_position": "31672776",
        "exon": "15",
        "feature_type": "germline_variant",
        "gene": "LIMK2",
        "pathogenic": null,
        "protein_change": "p.G574Rfs*12",
        "reference_allele": "-",
        "rsid": "rs540206607",
        "start_position": "31672776",
        "variant_annotation": "Frameshift",
        "feature": "LIMK2"
      }
    },
    {
      "id": 645,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 645,
        "alternate_allele": "G",
        "cdna_change": "c.1742dup",
        "chromosome": "22",
        "end_position": "31672807",
        "exon": "15",
        "feature_type": "germline_variant",
        "gene": "LIMK2",
        "pathogenic": null,
        "protein_change": "p.C582Lfs*4",
        "reference_allele": "-",
        "rsid": null,
        "start_position": "31672807",
        "variant_annotation": "Frameshift",
        "feature": "LIMK2"
      }
    },
    {
      "id": 646,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 646,
        "alternate_allele": "A",
        "cdna_change": "c.2049_2050insA",
        "chromosome": "22",
        "end_position": "31673114",
        "exon": "15",
        "feature_type": "germline_variant",
        "gene": "LIMK2",
        "pathogenic": null,
        "protein_change": "p.G684Tfs*16",
        "reference_allele": "-",
        "rsid": null,
        "start_position": "31673114",
        "variant_annotation": "Frameshift",
        "feature": "LIMK2"
      }
    },
    {
      "id": 647,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 647,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "MLH1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MLH1"
      }
    },
    {
      "id": 648,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 648,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "MLH3",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MLH3"
      }
    },
    {
      "id": 649,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 649,
        "alternate_allele": "A",
        "cdna_change": "c.1726C>T",
        "chromosome": "11",
        "end_position": "94180442",
        "exon": "15",
        "feature_type": "germline_variant",
        "gene": "MRE11",
        "pathogenic": null,
        "protein_change": "p.R576*",
        "reference_allele": "G",
        "rsid": "rs774277300",
        "start_position": "94180442",
        "variant_annotation": "Nonsense",
        "feature": "MRE11"
      }
    },
    {
      "id": 650,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 650,
        "alternate_allele": "-",
        "cdna_change": "c.1066del",
        "chromosome": "11",
        "end_position": "94201011",
        "exon": "10",
        "feature_type": "germline_variant",
        "gene": "MRE11",
        "pathogenic": null,
        "protein_change": "p.H356Tfs*34",
        "reference_allele": "C",
        "rsid": null,
        "start_position": "94201010",
        "variant_annotation": "Frameshift",
        "feature": "MRE11"
      }
    },
    {
      "id": 651,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 651,
        "alternate_allele": null,
        "cdna_change": "c.21-6_26del",
        "chromosome": "11",
        "end_position": "94224137",
        "exon": "3",
        "feature_type": "germline_variant",
        "gene": "MRE11",
        "pathogenic": null,
        "protein_change": "p.L7fs*18",
        "reference_allele": null,
        "rsid": "rs587780138",
        "start_position": "94224125",
        "variant_annotation": "Frameshift",
        "feature": "MRE11"
      }
    },
    {
      "id": 652,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 652,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "MSH2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MSH2"
      }
    },
    {
      "id": 653,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 652,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "MSH2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MSH2"
      }
    },
    {
      "id": 654,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 654,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "MSH6",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MSH6"
      }
    },
    {
      "id": 655,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 654,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "MSH6",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MSH6"
      }
    },
    {
      "id": 656,
      "context": "",
      "deprecated": false,
      "description": "Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 180,
      "variant": {
        "id": 656,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "NF1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "NF1"
      }
    },
    {
      "id": 657,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 658,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 659,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 660,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 661,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 662,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 663,
      "context": "",
      "deprecated": false,
      "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 657,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 664,
      "context": "",
      "deprecated": false,
      "description": "Pathogenic germline variants in PALB2 may increase risk of acquiring CRC. Germline pathogenic variants in PALB2 were enriched in several large cohorts of CRC patients when the frequency of multiple DNA-repair genes was compared to that of ancestry-matched healthy patients.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 171,
      "variant": {
        "id": 664,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PALB2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 665,
      "context": "",
      "deprecated": false,
      "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 665,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "PMS2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PMS2"
      }
    },
    {
      "id": 666,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 666,
        "alternate_allele": "A",
        "cdna_change": "c.1406dup",
        "chromosome": "14",
        "end_position": "50117073",
        "exon": "17",
        "feature_type": "germline_variant",
        "gene": "POLE2",
        "pathogenic": null,
        "protein_change": "p.L469Ffs*17",
        "reference_allele": "-",
        "rsid": "rs776517397",
        "start_position": "50117073",
        "variant_annotation": "Frameshift",
        "feature": "POLE2"
      }
    },
    {
      "id": 667,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 667,
        "alternate_allele": "T",
        "cdna_change": "c.1851_1852del",
        "chromosome": "7",
        "end_position": "124464070",
        "exon": "19",
        "feature_type": "germline_variant",
        "gene": "POT1",
        "pathogenic": null,
        "protein_change": "p.D617Efs*9",
        "reference_allele": "TTA",
        "rsid": "rs758673417",
        "start_position": "124464068",
        "variant_annotation": "Frameshift",
        "feature": "POT1"
      }
    },
    {
      "id": 668,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 668,
        "alternate_allele": "A",
        "cdna_change": "c.1087C>T",
        "chromosome": "7",
        "end_position": "124482937",
        "exon": "13",
        "feature_type": "germline_variant",
        "gene": "POT1",
        "pathogenic": null,
        "protein_change": "p.R363*",
        "reference_allele": "G",
        "rsid": "rs756198077",
        "start_position": "124482937",
        "variant_annotation": "Nonsense",
        "feature": "POT1"
      }
    },
    {
      "id": 669,
      "context": "",
      "deprecated": false,
      "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 179,
      "variant": {
        "id": 669,
        "alternate_allele": "A",
        "cdna_change": "c.224dup",
        "chromosome": "7",
        "end_position": "124511000",
        "exon": "7",
        "feature_type": "germline_variant",
        "gene": "POT1",
        "pathogenic": null,
        "protein_change": "p.N75Kfs*16",
        "reference_allele": "-",
        "rsid": null,
        "start_position": "124511000",
        "variant_annotation": "Frameshift",
        "feature": "POT1"
      }
    },
    {
      "id": 670,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 670,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51C",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 671,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 670,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51C",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 672,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 670,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51C",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 673,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 670,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51C",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 674,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 670,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51C",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 675,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 670,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51C",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 676,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 676,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51D",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 677,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 676,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51D",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 678,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 676,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51D",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 679,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Peritoneal Mesothelioma",
        "oncotree_code": "PEMESO",
        "oncotree_term": "Peritoneal Mesothelioma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 676,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51D",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 680,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 676,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51D",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 681,
      "context": "Primary",
      "deprecated": false,
      "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.",
      "disease": {
        "name": "Serous Ovarian Cancer",
        "oncotree_code": "SOC",
        "oncotree_term": "Serous Ovarian Cancer"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 59,
      "variant": {
        "id": 676,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RAD51D",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51D"
      }
    },
    {
      "id": 682,
      "context": "",
      "deprecated": false,
      "description": "Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 180,
      "variant": {
        "id": 682,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "RB1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RB1"
      }
    },
    {
      "id": 683,
      "context": "",
      "deprecated": false,
      "description": "Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 180,
      "variant": {
        "id": 683,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "TP53",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TP53"
      }
    },
    {
      "id": 684,
      "context": "Castration Resistant Prostate Cancer",
      "deprecated": false,
      "description": "Abiraterone (Zytiga) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with castration-resistant prostate cancer. Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 181,
      "variant": {
        "id": 684,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AR",
        "feature": "AR Amplification"
      }
    },
    {
      "id": 685,
      "context": "Castration Resistant Prostate Cancer",
      "deprecated": false,
      "description": "Abiraterone (Zytiga) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with prostate cancer. Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 181,
      "variant": {
        "id": 684,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AR",
        "feature": "AR Amplification"
      }
    },
    {
      "id": 686,
      "context": "Castration Resistant Prostate Cancer",
      "deprecated": false,
      "description": "Enzalutamide (Xtandi) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with prostate cancer. Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide",
        "type": "Hormone therapy",
        "strategy": "Antiandrogen",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 181,
      "variant": {
        "id": 684,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AR",
        "feature": "AR Amplification"
      }
    },
    {
      "id": 687,
      "context": "Triple-negative",
      "deprecated": false,
      "description": "In analysis of triple-negative breast cancer samples and cell lines, increased expression of androgen receptor was associated with increased risk of locoregional recurrence after RT. Radiation resistance in androgen receptor-postive, TNBC cell lines was reversed with enzalutamide.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 182,
      "variant": {
        "id": 684,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AR",
        "feature": "AR Amplification"
      }
    },
    {
      "id": 688,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-02-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 53,
      "variant": {
        "id": 688,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "ARID1A",
        "feature": "ARID1A Deletion"
      }
    },
    {
      "id": 689,
      "context": "Castration Resistant Prostate Cancer",
      "deprecated": false,
      "description": "Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).",
      "disease": {
        "name": "Prostate Neuroendocrine Cancer",
        "oncotree_code": "PRNE",
        "oncotree_term": "Prostate Neuroendocrine Cancer"
      },
      "therapy": {
        "name": "Danusertib",
        "type": "Targeted therapy",
        "strategy": "Aurora kinase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 183,
      "variant": {
        "id": 689,
        "cytoband": "20q13.2",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AURKA",
        "feature": "AURKA Amplification"
      }
    },
    {
      "id": 690,
      "context": "",
      "deprecated": false,
      "description": "Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 184,
      "variant": {
        "id": 689,
        "cytoband": "20q13.2",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AURKA",
        "feature": "AURKA Amplification"
      }
    },
    {
      "id": 691,
      "context": "Advanced",
      "deprecated": false,
      "description": "MYC amplified small cell lung cancer",
      "disease": {
        "name": "Small Cell Lung Cancer",
        "oncotree_code": "SCLC",
        "oncotree_term": "Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Barasertib",
        "type": "Targeted therapy",
        "strategy": "Aurora-B kinase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 185,
      "variant": {
        "id": 691,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "AURKB",
        "feature": "AURKB Amplification"
      }
    },
    {
      "id": 692,
      "context": "",
      "deprecated": false,
      "description": "BRAF V600E mutant colorectal cancer cell lines were cultured in increasing concentrations of the MEK inhibitor AZD6244 (Selumetinib). FISH analysis marked increase in BRAF gene copies in resistant cells.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Selumetinib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 186,
      "variant": {
        "id": 692,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "BRAF",
        "feature": "BRAF Amplification"
      }
    },
    {
      "id": 693,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Amplification of BRAF may predict resistance to RAF inhibition.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-06-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 78,
      "variant": {
        "id": 692,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "BRAF",
        "feature": "BRAF Amplification"
      }
    },
    {
      "id": 694,
      "context": "",
      "deprecated": false,
      "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 88,
      "variant": {
        "id": 694,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "BRCA2",
        "feature": "BRCA2 Deletion"
      }
    },
    {
      "id": 695,
      "context": "",
      "deprecated": false,
      "description": "CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 187,
      "variant": {
        "id": 695,
        "cytoband": "11p13",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CCND1",
        "feature": "CCND1 Amplification"
      }
    },
    {
      "id": 696,
      "context": "",
      "deprecated": false,
      "description": "CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 696,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CCND1",
        "feature": "CCND1 Amplification"
      }
    },
    {
      "id": 697,
      "context": "",
      "deprecated": false,
      "description": "Sensitivity to Bortezomib was observed in ovarian cancer cell lines.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Bortezomib",
        "type": "Targeted therapy",
        "strategy": "Proteasome inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 188,
      "variant": {
        "id": 697,
        "cytoband": "19q12",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CCNE1",
        "feature": "CCNE1 Amplification"
      }
    },
    {
      "id": 698,
      "context": "",
      "deprecated": false,
      "description": "PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-11-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 189,
      "variant": {
        "id": 698,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CD274",
        "feature": "CD274 Amplification"
      }
    },
    {
      "id": 699,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining >= 50% of tumor cells) or PD-L1 stained tumor-infiltrating immune cells covering >= 10% of the tumor area, with no EGFR or ALK genomic tumor aberrations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Atezolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 190,
      "variant": {
        "id": 698,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CD274",
        "feature": "CD274 Amplification"
      }
    },
    {
      "id": 700,
      "context": "Locally recurrent or metastatic triple-negative",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS>=10) as determined by an FDA approved test.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Chemotherapy + Pembrolizumab",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 191,
      "variant": {
        "id": 698,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CD274",
        "feature": "CD274 Amplification"
      }
    },
    {
      "id": 701,
      "context": "Recurrent locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab as a single agent for the treatment of patients with recurrent locally advanced or metastatic gastric adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test.",
      "disease": {
        "name": "Stomach Adenocarcinoma",
        "oncotree_code": "STAD",
        "oncotree_term": "Stomach Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-05-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 192,
      "variant": {
        "id": 698,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CD274",
        "feature": "CD274 Amplification"
      }
    },
    {
      "id": 702,
      "context": "Recurrent locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration granted approval to pembrolizumab as a single agent for the treatment of patients with recurrent locally advanced or metastatic gastric adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test.",
      "disease": {
        "name": "Adenocarcinoma of the Gastroesophageal Junction",
        "oncotree_code": "GEJ",
        "oncotree_term": "Adenocarcinoma of the Gastroesophageal Junction"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-05-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 192,
      "variant": {
        "id": 698,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CD274",
        "feature": "CD274 Amplification"
      }
    },
    {
      "id": 703,
      "context": "Stage II to Stage IIIa",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to atezolizumab as adjuvant treatment for patients following resection and platinum-based chemotherapy for adult patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Atezolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 193,
      "variant": {
        "id": 698,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CD274",
        "feature": "CD274 Amplification"
      }
    },
    {
      "id": 704,
      "context": "",
      "deprecated": false,
      "description": "Palbociclib (Ibrance) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with well-differentiated liposarcoma and CDK4 amplification. CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas, and palbociclib shows activity in this context.",
      "disease": {
        "name": "Well-Differentiated Liposarcoma",
        "oncotree_code": "WDLS",
        "oncotree_term": "Well-Differentiated Liposarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 194,
      "variant": {
        "id": 704,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CDK4",
        "feature": "CDK4 Amplification"
      }
    },
    {
      "id": 705,
      "context": "",
      "deprecated": false,
      "description": "Palbociclib (Ibrance) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with dedifferentiated liposarcoma and CDK4 amplification. CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas, and palbociclib shows activity in this context.",
      "disease": {
        "name": "Dedifferentiated Lipsarcoma",
        "oncotree_code": "DDLS",
        "oncotree_term": "Dedifferentiated Lipsarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 194,
      "variant": {
        "id": 704,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CDK4",
        "feature": "CDK4 Amplification"
      }
    },
    {
      "id": 706,
      "context": "",
      "deprecated": false,
      "description": "Treatment with CDK4 inhibitor PD033299 showed favorable progression free survival for patients with CDK4 amplification.",
      "disease": {
        "name": "Liposarcoma",
        "oncotree_code": "LIPO",
        "oncotree_term": "Liposarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 195,
      "variant": {
        "id": 704,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CDK4",
        "feature": "CDK4 Amplification"
      }
    },
    {
      "id": 707,
      "context": "",
      "deprecated": false,
      "description": "CDK4 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-09-14",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 704,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CDK4",
        "feature": "CDK4 Amplification"
      }
    },
    {
      "id": 708,
      "context": "",
      "deprecated": false,
      "description": "These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "EPZ015666",
        "type": "Targeted therapy",
        "strategy": "PRMT5 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 196,
      "variant": {
        "id": 708,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CDKN2A",
        "feature": "CDKN2A Deletion"
      }
    },
    {
      "id": 709,
      "context": "",
      "deprecated": false,
      "description": "CDKN2A loss was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 708,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CDKN2A",
        "feature": "CDKN2A Deletion"
      }
    },
    {
      "id": 710,
      "context": "",
      "deprecated": false,
      "description": "Either hemizygous or homozygous CDKN2C loss, identified by FISH, resulted in worse overall survival relative to wild type in a study of 515 multiple myeloma patients.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 197,
      "variant": {
        "id": 710,
        "cytoband": "1p32.3",
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CDKN2C",
        "feature": "CDKN2C Deletion"
      }
    },
    {
      "id": 711,
      "context": "",
      "deprecated": false,
      "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with del(1p) resulting in loss of CDKN2C.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 16,
      "variant": {
        "id": 711,
        "cytoband": "1p",
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CDKN2C",
        "feature": "CDKN2C Deletion"
      }
    },
    {
      "id": 712,
      "context": "",
      "deprecated": false,
      "description": "CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 198,
      "variant": {
        "id": 712,
        "cytoband": "22q11.21",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CRKL",
        "feature": "CRKL Amplification"
      }
    },
    {
      "id": 713,
      "context": "",
      "deprecated": false,
      "description": "Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 96,
      "variant": {
        "id": 713,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "EGFR",
        "feature": "EGFR Amplification"
      }
    },
    {
      "id": 714,
      "context": "",
      "deprecated": false,
      "description": "The combination of lapatinib with trastuzumab provided a statistically significant improvement in PFS compared with single-agent lapatinib when tested for erbb2 positive breast cancer patients, both primary and metastatic.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Lapatinib + Trastuzumab",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition + EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 199,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 715,
      "context": "",
      "deprecated": false,
      "description": "HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Trastuzumab Emtansine",
        "type": "Hormone therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 200,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 716,
      "context": "",
      "deprecated": false,
      "description": "Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Lapatinib",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition + EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 201,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 717,
      "context": "",
      "deprecated": false,
      "description": "Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Lapatinib + Trastuzumab",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition + EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 201,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 718,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Neratinib",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 202,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 719,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Pertuzumab + Trastuzumab",
        "type": "Combination therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 203,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 720,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Trastuzumab",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-05-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 204,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 721,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma.",
      "disease": {
        "name": "Stomach Adenocarcinoma",
        "oncotree_code": "STAD",
        "oncotree_term": "Stomach Adenocarcinoma"
      },
      "therapy": {
        "name": "Trastuzumab",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-05-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 204,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 722,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma.",
      "disease": {
        "name": "Adenocarcinoma of the Gastroesophageal Junction",
        "oncotree_code": "GEJ",
        "oncotree_term": "Adenocarcinoma of the Gastroesophageal Junction"
      },
      "therapy": {
        "name": "Trastuzumab",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-05-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 204,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 723,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Trastuzumab (Herceptin) in combination with chemotherapy is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic gastric cancer and HER2 overexpression or amplification. These patients showed significant improvement in median overall survival with the addition of trastuzumab to chemotherapy compared to chemotherapy alone. This benefit is limited to patients with a tumor score of IHC 3 + or IHC 2 + and FISH positive.",
      "disease": {
        "name": "Stomach Adenocarcinoma",
        "oncotree_code": "STAD",
        "oncotree_term": "Stomach Adenocarcinoma"
      },
      "therapy": {
        "name": "Chemotherapy + Trastuzumab",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 205,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 724,
      "context": "Advanced unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capecitabine + Trastuzumab + Tucatinib",
        "type": "Combination therapy",
        "strategy": "Thymidylate synthase inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 206,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 725,
      "context": "",
      "deprecated": false,
      "description": "Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 207,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 726,
      "context": "",
      "deprecated": false,
      "description": "Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 208,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 727,
      "context": "Locally advanced, inflammatory, or early stage",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 209,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 728,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab",
        "type": "Combination therapy",
        "strategy": "Taxane-based chemotherapy + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 209,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 729,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Chemotherapy + Margetuximab",
        "type": "Combination therapy",
        "strategy": "ER signaling inhibition + Chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 210,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 730,
      "context": "Locally advanced unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS >= 1), as determined by an FDA-approved test.",
      "disease": {
        "name": "Stomach Adenocarcinoma",
        "oncotree_code": "STAD",
        "oncotree_term": "Stomach Adenocarcinoma"
      },
      "therapy": {
        "name": "Fluoropyrimidine + Pembrolizumab + Platinum Compound + Trastuzumab",
        "type": "Combination therapy",
        "strategy": "Antimetabolite + ER signaling inhibition + PD-1/PD-L1 inhibition + Chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-04-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 211,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 731,
      "context": "Locally advanced unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS >= 1), as determined by an FDA-approved test.",
      "disease": {
        "name": "Adenocarcinoma of the Gastroesophageal Junction",
        "oncotree_code": "GEJ",
        "oncotree_term": "Adenocarcinoma of the Gastroesophageal Junction"
      },
      "therapy": {
        "name": "Fluoropyrimidine + Pembrolizumab + Platinum Compound + Trastuzumab",
        "type": "Combination therapy",
        "strategy": "Antimetabolite + ER signaling inhibition + PD-1/PD-L1 inhibition + Chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-04-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 211,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 732,
      "context": "",
      "deprecated": false,
      "description": "Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 212,
      "variant": {
        "id": 732,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ESR1",
        "feature": "ESR1 Amplification"
      }
    },
    {
      "id": 733,
      "context": "",
      "deprecated": false,
      "description": "Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.",
      "disease": {
        "name": "Breast Invasive Ductal Carcinoma",
        "oncotree_code": "IDC",
        "oncotree_term": "Breast Invasive Ductal Carcinoma"
      },
      "therapy": {
        "name": "Sirolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 109,
      "variant": {
        "id": 733,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "FBXW7",
        "feature": "FBXW7 Deletion"
      }
    },
    {
      "id": 734,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 734,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR1",
        "feature": "FGFR1 Amplification"
      }
    },
    {
      "id": 735,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 734,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR1",
        "feature": "FGFR1 Amplification"
      }
    },
    {
      "id": 736,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 734,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR1",
        "feature": "FGFR1 Amplification"
      }
    },
    {
      "id": 737,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 734,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR1",
        "feature": "FGFR1 Amplification"
      }
    },
    {
      "id": 738,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 738,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR2",
        "feature": "FGFR2 Amplification"
      }
    },
    {
      "id": 739,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 738,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR2",
        "feature": "FGFR2 Amplification"
      }
    },
    {
      "id": 740,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 738,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR2",
        "feature": "FGFR2 Amplification"
      }
    },
    {
      "id": 741,
      "context": "",
      "deprecated": false,
      "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Infigratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 213,
      "variant": {
        "id": 738,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR2",
        "feature": "FGFR2 Amplification"
      }
    },
    {
      "id": 742,
      "context": "Muscle-Invasive",
      "deprecated": false,
      "description": "In a retrospective study of 137 patients with high-grade invasive bladder cancer, patients with high HIF-1a expression had improved local relapse-free survival when receiving RT+CON compared with RT alone.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Carbogen + Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 214,
      "variant": {
        "id": 742,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "HIF1a",
        "feature": "HIF1a Amplification"
      }
    },
    {
      "id": 743,
      "context": "",
      "deprecated": false,
      "description": "In a mouse model of lung scamous cell carcinoma, deletion of KEAP1 promoted tumor aggressiveness, metastasis, and resistance to oxidative stress and radiotherapy (RT). KEAP1 / NRF2 mutation status predicted risk of local recurrence after RT in patients with non-small lung cancer (NSCLC).",
      "disease": {
        "name": "Lung Squamous Cell Carcinoma",
        "oncotree_code": "LUSC",
        "oncotree_term": "Lung Squamous Cell Carcinoma"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 215,
      "variant": {
        "id": 743,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "KEAP1",
        "feature": "KEAP1 Deletion"
      }
    },
    {
      "id": 744,
      "context": "",
      "deprecated": false,
      "description": "Imatinib (Gleevec) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and amplification of KIT; KIT amplifications appear to have minimal or no sensitivity to KIT inhibitors.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Imatinib",
        "type": "Targeted therapy",
        "strategy": "KIT inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 126,
      "variant": {
        "id": 744,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "KIT",
        "feature": "KIT Amplification"
      }
    },
    {
      "id": 745,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.",
      "disease": {
        "name": "Gastric Remnant Adenocarcinoma",
        "oncotree_code": "GRC",
        "oncotree_term": "Gastric Remnant Adenocarcinoma"
      },
      "therapy": {
        "name": "nutlin-3",
        "type": "Targeted therapy",
        "strategy": "MDM2-p53 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 168,
      "variant": {
        "id": 745,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MDM2",
        "feature": "MDM2 Amplification"
      }
    },
    {
      "id": 746,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Crizotinib (Xalkori) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic non-small cell lung cancer whose tumors harbor an amplification of MET.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 746,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MET",
        "feature": "MET Amplification"
      }
    },
    {
      "id": 747,
      "context": "",
      "deprecated": false,
      "description": "Gefitinib (Iressa) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with non-small cell lung cancer whose tumors harbor an amplification of MET, as amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 20,
      "variant": {
        "id": 746,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MET",
        "feature": "MET Amplification"
      }
    },
    {
      "id": 748,
      "context": "",
      "deprecated": false,
      "description": "Results from the METEOR trial (n=658) suggest that the MET expression level might not affect treatment outcomes with cabozantinib in this patient population.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "RCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Cabozantinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 216,
      "variant": {
        "id": 746,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MET",
        "feature": "MET Amplification"
      }
    },
    {
      "id": 749,
      "context": "",
      "deprecated": false,
      "description": "",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 217,
      "variant": {
        "id": 746,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MET",
        "feature": "MET Amplification"
      }
    },
    {
      "id": 750,
      "context": "",
      "deprecated": false,
      "description": "Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.",
      "disease": {
        "name": "Rectal Adenocarcinoma",
        "oncotree_code": "READ",
        "oncotree_term": "Rectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Chemotherapy + Surgery",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + Surgical removal",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 218,
      "variant": {
        "id": 750,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MIR17HG",
        "feature": "MIR17HG Amplification"
      }
    },
    {
      "id": 751,
      "context": "",
      "deprecated": false,
      "description": "Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.",
      "disease": {
        "name": "Rectal Adenocarcinoma",
        "oncotree_code": "READ",
        "oncotree_term": "Rectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Chemotherapy + Surgery",
        "type": "Combination therapy",
        "strategy": "Chemotherapy + Surgical removal",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 218,
      "variant": {
        "id": 751,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "MIR17HG",
        "feature": "MIR17HG Deletion"
      }
    },
    {
      "id": 752,
      "context": "Muscle-Invasive",
      "deprecated": false,
      "description": "In a cohort of 86 patients with muscle-invasive bladder cancer, high MRE11 expression as assessed by IHC was associated with improved cancer-specific survival when treated with radical radiotherapy compared to low MRE11 expression as well as high-expression MRE11 treated with cystectomy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Radiation Therapy",
        "type": "Radiation therapy",
        "strategy": "Radiation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 219,
      "variant": {
        "id": 752,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MRE11",
        "feature": "MRE11 Amplification"
      }
    },
    {
      "id": 753,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.",
      "disease": {
        "name": "Medulloblastoma",
        "oncotree_code": "MBL",
        "oncotree_term": "Medulloblastoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 220,
      "variant": {
        "id": 753,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MYC",
        "feature": "MYC Amplification"
      }
    },
    {
      "id": 754,
      "context": "",
      "deprecated": false,
      "description": "Amplification of 8q24 (which includes the MYC oncogene) was associated with poor outcomes in a study of 109 microdissected pancreatic adenocarcinoma tumors.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 54,
      "variant": {
        "id": 754,
        "cytoband": "8q24",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MYC",
        "feature": "MYC Amplification"
      }
    },
    {
      "id": 755,
      "context": "",
      "deprecated": false,
      "description": "PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 187,
      "variant": {
        "id": 755,
        "cytoband": "11p13",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "PAK1",
        "feature": "PAK1 Amplification"
      }
    },
    {
      "id": 756,
      "context": "",
      "deprecated": false,
      "description": "PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Tamoxifen",
        "type": "Hormone therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 187,
      "variant": {
        "id": 755,
        "cytoband": "11p13",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "PAK1",
        "feature": "PAK1 Amplification"
      }
    },
    {
      "id": 757,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "CCRCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Nivolumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2018-11-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 153,
      "variant": {
        "id": 757,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PBRM1",
        "feature": "PBRM1 Deletion"
      }
    },
    {
      "id": 758,
      "context": "",
      "deprecated": false,
      "description": "A heavily-pretreated, platinum-refractory ovarian cancer patient with PIK3CA amplification achieved radiologically stable disease for four months in a phase 1 clinical trial of pictisilib in solid tumors (RP2D of 330mg daily).",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Pictilisib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-01-29",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 221,
      "variant": {
        "id": 758,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "PIK3CA",
        "feature": "PIK3CA Amplification"
      }
    },
    {
      "id": 759,
      "context": "",
      "deprecated": false,
      "description": "AZ8186 showed pharmacodynamic modulation of p-Akt in PC3 PTEN-deficient prostate tumor bearing mice and showed complete inhibition of tumor growth in mouse PTEN-deficient PC3 prostate tumor xenograft models. The publication states that AZ8186 entered into phase 1 study.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "PI3Kbeta Inhibitor AZD8186",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 158,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 760,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 159,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 761,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss in the setting of KRAS G12D mutation was associated with an increased sensitivity to mTOR inhibition in a mouse model.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 222,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 762,
      "context": "",
      "deprecated": false,
      "description": "PTEN loss may predict resistance to immune checkpoint blockade",
      "disease": {
        "name": "Uterine Leiomyoma",
        "oncotree_code": "ULM",
        "oncotree_term": "Uterine Leiomyoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-03-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 160,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 763,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a study of everolimus-treated patients with RCC from a phase 2 randomized trial, everolimus treated patients with retained (n=50) versus lost (n=50) PTEN IHC expression had median PFS 5.3 months versus 10.5 months (HR, 2.5; P < 001). Such differences were not seen with sunitinib.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "RCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Everolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 149,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 764,
      "context": "Advanced",
      "deprecated": false,
      "description": "In a study of everolimus-treated patients with RCC from a phase 2 randomized trial, everolimus treated patients with retained (n=50) versus lost (n=50) PTEN IHC expression had median PFS 5.3 months versus 10.5 months (HR, 2.5; P < 001). Such differences were not seen with sunitinib.",
      "disease": {
        "name": "Renal Clear Cell Carcinoma",
        "oncotree_code": "RCC",
        "oncotree_term": "Renal Clear Cell Carcinoma"
      },
      "therapy": {
        "name": "Sunitinib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2019-08-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 149,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 765,
      "context": "",
      "deprecated": false,
      "description": "Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 28,
      "variant": {
        "id": 765,
        "cytoband": "13",
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "RB1",
        "feature": "RB1 Deletion"
      }
    },
    {
      "id": 766,
      "context": "",
      "deprecated": false,
      "description": "Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.",
      "disease": {
        "name": "Multiple Myeloma",
        "oncotree_code": "MM",
        "oncotree_term": "Multiple Myeloma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 28,
      "variant": {
        "id": 766,
        "cytoband": "17p13",
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "TP53",
        "feature": "TP53 Deletion"
      }
    },
    {
      "id": 767,
      "context": "",
      "deprecated": false,
      "description": "Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 184,
      "variant": {
        "id": 767,
        "cytoband": "20q11",
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "TPX2",
        "feature": "TPX2 Amplification"
      }
    },
    {
      "id": 768,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 223,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 769,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2020-11-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 223,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 770,
      "context": "",
      "deprecated": false,
      "description": "5-Fluorouracil is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with MSI-High colorectal cancer. These patients appear to not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Fluorouracil",
        "type": "Chemotherapy",
        "strategy": "Thymidylate synthase inhibition",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 771,
      "context": "",
      "deprecated": false,
      "description": "5-Fluorouracil is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with MSI-High colorectal cancer. These patients appear to not benefit from, and may be resistant to, 5-fluorouracil therapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Fluorouracil",
        "type": "Chemotherapy",
        "strategy": "Thymidylate synthase inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 772,
      "context": "",
      "deprecated": false,
      "description": "Patients with MSI-High colorectal cancer often have a favorable prognosis.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 80,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 773,
      "context": "Metastatic",
      "deprecated": false,
      "description": "A phase II study of 32 colorectal cancer patients (and 9 noncolorectal cancer patients) found an association between mismatch repair deficiency (measured by MSI status) and both immune-related objective response rate (40% of patients with MSI-High vs. 0% in MSI-Low) and immune-related progression-free survival rate (78% of MSI-High patients at 20 weeks vs. 11% in MSI-Low). Post-hoc cohort comparison showed hazard ratio for disease progression or death of 0.10 and for death of 0.22.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 774,
      "context": "",
      "deprecated": false,
      "description": "Signature 10 is related to mutant pole, which may suggest sensitivity to immunotherapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 774,
        "cosmic_signature": "SBS10a",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 775,
      "context": "",
      "deprecated": false,
      "description": "Signature 10 is related to mutant pole, which may suggest sensitivity to immunotherapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 775,
        "cosmic_signature": "SBS10b",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 776,
      "context": "",
      "deprecated": false,
      "description": "COSMIC Signature 10 is observed in some of the most hypermutant samples and recurrent POLE mutations. POLE mutant tumors are being included along with MMR-deficient tumors in several ongoing trials for sensitivity to immunotherapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 774,
        "cosmic_signature": "SBS10a",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 777,
      "context": "",
      "deprecated": false,
      "description": "COSMIC Signature 10 is observed in some of the most hypermutant samples and recurrent POLE mutations. POLE mutant tumors are being included along with MMR-deficient tumors in several ongoing trials for sensitivity to immunotherapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 775,
        "cosmic_signature": "SBS10b",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 778,
      "context": "",
      "deprecated": false,
      "description": "COSMIC Signature 10 is observed in some of the most hypermutant samples and recurrent POLE mutations. POLE mutant tumors are being included along with MMR-deficient tumors in several ongoing trials for sensitivity to immunotherapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 774,
        "cosmic_signature": "SBS10a",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 779,
      "context": "",
      "deprecated": false,
      "description": "COSMIC Signature 10 is observed in some of the most hypermutant samples and recurrent POLE mutations. POLE mutant tumors are being included along with MMR-deficient tumors in several ongoing trials for sensitivity to immunotherapy.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 157,
      "variant": {
        "id": 775,
        "cosmic_signature": "SBS10b",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 780,
      "context": "",
      "deprecated": false,
      "description": "APOBEC signature (COSMIC 2) suggests sensitivity to immunotherapy in bladder cancer.",
      "disease": {
        "name": "Urethral Urothelial Carcinoma",
        "oncotree_code": "UCU",
        "oncotree_term": "Urethral Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 224,
      "variant": {
        "id": 780,
        "cosmic_signature": "SBS2",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 781,
      "context": "",
      "deprecated": false,
      "description": "APOBEC signature (COSMIC 2) suggests sensitivity to immunotherapy in bladder cancer.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Durvalumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 224,
      "variant": {
        "id": 780,
        "cosmic_signature": "SBS2",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 782,
      "context": "",
      "deprecated": false,
      "description": "Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.",
      "disease": {
        "name": "Gastric Remnant Adenocarcinoma",
        "oncotree_code": "GRC",
        "oncotree_term": "Gastric Remnant Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 225,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 783,
      "context": "",
      "deprecated": false,
      "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.",
      "disease": {
        "name": "Gastric Remnant Adenocarcinoma",
        "oncotree_code": "GRC",
        "oncotree_term": "Gastric Remnant Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 225,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 784,
      "context": "",
      "deprecated": false,
      "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.",
      "disease": {
        "name": "Gastric Remnant Adenocarcinoma",
        "oncotree_code": "GRC",
        "oncotree_term": "Gastric Remnant Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 225,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 785,
      "context": "",
      "deprecated": false,
      "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 225,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 786,
      "context": "",
      "deprecated": false,
      "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 225,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 787,
      "context": "",
      "deprecated": false,
      "description": "Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Platinum Compound",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 85,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 788,
      "context": "",
      "deprecated": false,
      "description": "In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (transversion-high tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in transversion-low [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 136,
      "variant": {
        "id": 788,
        "cosmic_signature": "SBS4",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 789,
      "context": "",
      "deprecated": false,
      "description": "Smoking signature (COSMIC 4) suggests sensitivity to immunotherapy in lung cancer.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 136,
      "variant": {
        "id": 788,
        "cosmic_signature": "SBS4",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 790,
      "context": "",
      "deprecated": false,
      "description": "COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.",
      "disease": {
        "name": "Bladder Urothelial Carcinoma",
        "oncotree_code": "BLCA",
        "oncotree_term": "Bladder Urothelial Carcinoma"
      },
      "therapy": {
        "name": "Cisplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 226,
      "variant": {
        "id": 790,
        "cosmic_signature": "SBS5",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 791,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "Ovarian Epithelial Tumor",
        "oncotree_code": "OVT",
        "oncotree_term": "Ovarian Epithelial Tumor"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 792,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "High-Grade Serous Fallopian Tube Cancer",
        "oncotree_code": "HGSFT",
        "oncotree_term": "High-Grade Serous Fallopian Tube Cancer"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 793,
      "context": "HRD-positive advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.",
      "disease": {
        "name": "Peritoneal Serous Carcinoma",
        "oncotree_code": "PSEC",
        "oncotree_term": "Peritoneal Serous Carcinoma"
      },
      "therapy": {
        "name": "Bevacizumab + Olaparib",
        "type": "Targeted therapy",
        "strategy": "VEGF/VEGFR inhibition + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 87,
      "variant": {
        "id": 782,
        "cosmic_signature": "SBS3",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature"
      }
    },
    {
      "id": 794,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Nivolumab (Opdivo) in combination with ipilimumab (Yervoy) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option as an immunotherapy agent for patients with metastatic non-small cell lung cancer whose tumors have a high tumor mutational burden (TMB)",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ipilimumab + Nivolumab",
        "type": "Immunotherapy",
        "strategy": "CTLA-4 inhibition + PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 794,
        "classification": "High",
        "feature_type": "mutational_burden",
        "minimum_mutations": null,
        "mutations_per_mb": null,
        "feature": "High"
      }
    },
    {
      "id": 795,
      "context": "Metastatic",
      "deprecated": false,
      "description": "Nivolumab (Opdivo) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option as an immunotherapy agent for patients with metastatic non-small cell lung cancer whose tumors have a high tumor mutational burden (TMB)",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Nivolumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 11,
      "variant": {
        "id": 794,
        "classification": "High",
        "feature_type": "mutational_burden",
        "minimum_mutations": null,
        "mutations_per_mb": null,
        "feature": "High"
      }
    },
    {
      "id": 796,
      "context": "",
      "deprecated": false,
      "description": "In a validation set of 18 non-small cell lung cancer patients treated with pembrolizumab, a nonsynonymous mutational burden >= 178 was associated with durable clinical response in some patients (75% of patients with burden >= 178 showed a response, compared to 14% patients with burden < 178 that showed a response; sensitivity of 86%, specificity of 75%).",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-03-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 136,
      "variant": {
        "id": 796,
        "classification": "High",
        "feature_type": "mutational_burden",
        "minimum_mutations": "178",
        "mutations_per_mb": null,
        "feature": "High (>= 178 mutations)"
      }
    },
    {
      "id": 797,
      "context": "Metastatic",
      "deprecated": false,
      "description": "In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Ipilimumab",
        "type": "Immunotherapy",
        "strategy": "CTLA-4 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-03-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 227,
      "variant": {
        "id": 797,
        "classification": "High",
        "feature_type": "mutational_burden",
        "minimum_mutations": "100",
        "mutations_per_mb": null,
        "feature": "High (>= 100 mutations)"
      }
    },
    {
      "id": 798,
      "context": "Metastatic",
      "deprecated": false,
      "description": "A study of pretreatment biopsies of tumors from 110 patients showed that patients with a mutational load of >= 100 were significantly more likely to have a clinical benefit to ipilimumab.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "Ipilimumab",
        "type": "Immunotherapy",
        "strategy": "CTLA-4 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-03-12",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 228,
      "variant": {
        "id": 797,
        "classification": "High",
        "feature_type": "mutational_burden",
        "minimum_mutations": "100",
        "mutations_per_mb": null,
        "feature": "High (>= 100 mutations)"
      }
    },
    {
      "id": 799,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2021-09-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 223,
      "variant": {
        "id": 799,
        "classification": "High",
        "feature_type": "mutational_burden",
        "minimum_mutations": null,
        "mutations_per_mb": "10",
        "feature": "High (>= 10 mutations/Mb)"
      }
    },
    {
      "id": 800,
      "context": "",
      "deprecated": false,
      "description": "HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 57,
      "variant": {
        "id": 800,
        "feature_type": "knockdown",
        "gene": "ATM",
        "technique": "shRNA",
        "feature": "ATM (shRNA)"
      }
    },
    {
      "id": 801,
      "context": "",
      "deprecated": false,
      "description": "Loss of antigen presentation via B2M loss of function mutations results in increased survival of cancer cells in the presence of tumor infiltrating lymphocytes.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 229,
      "variant": {
        "id": 801,
        "feature_type": "knockdown",
        "gene": "B2M",
        "technique": "CRISPR-Cas9",
        "feature": "B2M (CRISPR-Cas9)"
      }
    },
    {
      "id": 802,
      "context": "",
      "deprecated": false,
      "description": "shRNA knockout in ovarian cancer suggests suggests sensitivity to PARP1/2 inhibition, specifically olaparib.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 230,
      "variant": {
        "id": 802,
        "feature_type": "knockdown",
        "gene": "CDK12",
        "technique": "shRNA",
        "feature": "CDK12 (shRNA)"
      }
    },
    {
      "id": 803,
      "context": "",
      "deprecated": false,
      "description": "siRNA knockout, gene depletion, of CDK12 shows sensitivity to PARP inhibitor veliparib in ovarian cancer cell lines.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Veliparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 231,
      "variant": {
        "id": 803,
        "feature_type": "knockdown",
        "gene": "CDK12",
        "technique": "siRNA",
        "feature": "CDK12 (siRNA)"
      }
    },
    {
      "id": 804,
      "context": "",
      "deprecated": false,
      "description": "CPT1A is involved in fatty acid oxidation, a key component of some tumor's metabolic processes. CPT1A knockdown in some melanoma BRAF V600E cell lines resulted in decreased proliferation and tumorigenesis.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": 1,
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 232,
      "variant": {
        "id": 804,
        "feature_type": "knockdown",
        "gene": "CPT1A",
        "technique": "shRNA",
        "feature": "CPT1A (shRNA)"
      }
    },
    {
      "id": 805,
      "context": "",
      "deprecated": false,
      "description": "RNAi knockdown of RAD17 in the HME-CC breast cancer cell line resulted in increased sensitivity to ABT-888, Veliparib (PARP inhibitor). If RAD50 is also knocked out, a further increase in sensitivity is observed.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Veliparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 233,
      "variant": {
        "id": 805,
        "feature_type": "knockdown",
        "gene": "RAD17",
        "technique": "shRNA",
        "feature": "RAD17 (shRNA)"
      }
    },
    {
      "id": 806,
      "context": "",
      "deprecated": false,
      "description": "RNAi knockdown of RAD17 in the HME-CC breast cancer cell line resulted in increased sensitivity to carboplatin. A further increase in sensitivity occurred when knocked down with RAD50.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Carboplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 233,
      "variant": {
        "id": 805,
        "feature_type": "knockdown",
        "gene": "RAD17",
        "technique": "shRNA",
        "feature": "RAD17 (shRNA)"
      }
    },
    {
      "id": 807,
      "context": "",
      "deprecated": false,
      "description": "RNAi knockdown of RAD50 in the HME-CC breast cancer cell line resulted in increased resistance to carboplatin.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Carboplatin",
        "type": "Chemotherapy",
        "strategy": "Platinum-based chemotherapy",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2017-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 233,
      "variant": {
        "id": 807,
        "feature_type": "knockdown",
        "gene": "RAD50",
        "technique": "shRNA",
        "feature": "RAD50 (shRNA)"
      }
    },
    {
      "id": 808,
      "context": "",
      "deprecated": false,
      "description": "Loss of antigen presentation via TAP2 loss of function mutations results in increased survival of cancer cells in the presence of tumor infiltrating lymphocytes.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-16",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 229,
      "variant": {
        "id": 808,
        "feature_type": "knockdown",
        "gene": "TAP2",
        "technique": "CRISPR-Cas9",
        "feature": "TAP2 (CRISPR-Cas9)"
      }
    },
    {
      "id": 809,
      "context": "",
      "deprecated": false,
      "description": "PPARGC1A silencing causes poorly metastatic melanoma cells to become invasive, while PPARGC1A rescue suppresses metastasis in human melanoma tumor samples.",
      "disease": {
        "name": "Melanoma",
        "oncotree_code": "MEL",
        "oncotree_term": "Melanoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2019-04-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 234,
      "variant": {
        "id": 809,
        "feature_type": "knockdown",
        "gene": "PPARGC1A",
        "technique": "CRSPR-Cas9",
        "feature": "PPARGC1A (CRSPR-Cas9)"
      }
    },
    {
      "id": 810,
      "context": "",
      "deprecated": false,
      "description": "WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.",
      "disease": {
        "name": "",
        "oncotree_code": "",
        "oncotree_term": ""
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2018-09-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 235,
      "variant": {
        "id": 810,
        "event": "Whole genome doubling",
        "feature_type": "aneuploidy",
        "feature": "Whole genome doubling"
      }
    },
    {
      "id": 811,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-07-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 236,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 812,
      "context": "newly diagnosed AML who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-07-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 237,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 813,
      "context": "newly diagnosed AML who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-07-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 237,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 814,
      "context": "newly diagnosed AML who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Azacitidine + Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-07-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 237,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 815,
      "context": "newly diagnosed AML who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Azacitidine + Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-07-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 237,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 816,
      "context": "Metastatic",
      "deprecated": false,
      "description": "A phase II study of 32 colorectal cancer patients (and 9 noncolorectal cancer patients) found an association between mismatch repair deficiency (measured by MSI status) and both immune-related objective response rate (40% of patients with MSI-High vs. 0% in MSI-Low) and immune-related progression-free survival rate (78% of MSI-High patients at 20 weeks vs. 11% in MSI-Low). Post-hoc cohort comparison showed hazard ratio for disease progression or death of 0.10 and for death of 0.22.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 147,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 817,
      "context": "Advanced",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca",
      "disease": {
        "name": "Endometrial Carcinoma",
        "oncotree_code": "UCEC",
        "oncotree_term": "Endometrial Carcinoma"
      },
      "therapy": {
        "name": "Pembrolizumab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-07-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 238,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 818,
      "context": "",
      "deprecated": false,
      "description": "A phase 1 trial observed antitumor activity in patients with ovarian cancer, prostate cancer, and breast cancer that were also carriers of BRCA1 or BRCA2 variants.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 239,
      "variant": {
        "id": 602,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 819,
      "context": "",
      "deprecated": false,
      "description": "A phase 1 trial observed antitumor activity in patients with ovarian cancer, prostate cancer, and breast cancer that were also carriers of BRCA1 or BRCA2 variants.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 239,
      "variant": {
        "id": 602,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 820,
      "context": "",
      "deprecated": false,
      "description": "A phase 1 trial observed antitumor activity in patients with ovarian cancer, prostate cancer, and breast cancer that were also carriers of BRCA1 or BRCA2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 239,
      "variant": {
        "id": 602,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 821,
      "context": "",
      "deprecated": false,
      "description": "A phase 1 trial observed antitumor activity in patients with ovarian cancer, prostate cancer, and breast cancer that were also carriers of BRCA1 or BRCA2 variants.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 239,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 822,
      "context": "",
      "deprecated": false,
      "description": "A phase 1 trial observed antitumor activity in patients with ovarian cancer, prostate cancer, and breast cancer that were also carriers of BRCA1 or BRCA2 variants.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 239,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 823,
      "context": "",
      "deprecated": false,
      "description": "A phase 1 trial observed antitumor activity in patients with ovarian cancer, prostate cancer, and breast cancer that were also carriers of BRCA1 or BRCA2 variants.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical trial",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 239,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 824,
      "context": "",
      "deprecated": false,
      "description": "Knockout of RB1 in a BRCA2 null LNCaP cells exhibited resistance to CDK4/6 inhibition with palbociclib.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 240,
      "variant": {
        "id": 824,
        "feature_type": "knockdown",
        "gene": "RB1",
        "technique": "shRNA",
        "feature": "RB1 (shRNA)"
      }
    },
    {
      "id": 825,
      "context": "",
      "deprecated": false,
      "description": "Silencing USP11 in human bone osteosarcoma epithelial cells (U2OS line) with siRNA led to spontaneous DDR activation and hypersensitivity to PARP inhibition, ionizing radiation, and other genotoxic stress agents.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 241,
      "variant": {
        "id": 825,
        "feature_type": "knockdown",
        "gene": "USP11",
        "technique": "siRNA",
        "feature": "USP11 (siRNA)"
      }
    },
    {
      "id": 826,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).",
      "disease": {
        "name": "Inflammatory Myofibroblastic Tumor",
        "oncotree_code": "IMT",
        "oncotree_term": "Inflammatory Myofibroblastic Tumor"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 242,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 827,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058684",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 827,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BRCA1 (Nonsense)"
      }
    },
    {
      "id": 828,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058684",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 828,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "BRCA1 (Frameshift)"
      }
    },
    {
      "id": 829,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058948",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 827,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BRCA1 (Nonsense)"
      }
    },
    {
      "id": 830,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058948",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 828,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "BRCA1 (Frameshift)"
      }
    },
    {
      "id": 831,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058948",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 214,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BRCA2 (Nonsense)"
      }
    },
    {
      "id": 832,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058948",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 832,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "BRCA2 (Frameshift)"
      }
    },
    {
      "id": 833,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058684",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 214,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BRCA2 (Nonsense)"
      }
    },
    {
      "id": 834,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058684",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 832,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "BRCA2 (Frameshift)"
      }
    },
    {
      "id": 835,
      "context": "",
      "deprecated": false,
      "description": "Four patients with uterine leiomyosarcoma and functional BRCA2 loss were evaluated for response to PARP inhibition with olaparib and all patients observed a durable response.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-10-31",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 244,
      "variant": {
        "id": 214,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "BRCA2 (Nonsense)"
      }
    },
    {
      "id": 836,
      "context": "",
      "deprecated": false,
      "description": "Four patients with uterine leiomyosarcoma and functional BRCA2 loss were evaluated for response to PARP inhibition with olaparib and all patients observed a durable response.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 244,
      "variant": {
        "id": 832,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "BRCA2 (Frameshift)"
      }
    },
    {
      "id": 837,
      "context": "",
      "deprecated": false,
      "description": "In a preclinical setting, treatment of PARP inhibition using olaparib and talazoparib caused more cell growth inhibition in LNCaP cells harboring both BRCA2 and RB1 variants than those only harboring BRCA2 variants.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib + Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 240,
      "variant": {
        "id": 837,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RB1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "RB1 (Nonsense)"
      }
    },
    {
      "id": 838,
      "context": "",
      "deprecated": false,
      "description": "In a preclinical setting, treatment of PARP inhibition using olaparib and talazoparib caused more cell growth inhibition in LNCaP cells harboring both BRCA2 and RB1 variants than those only harboring BRCA2 variants.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib + Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 240,
      "variant": {
        "id": 838,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RB1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "RB1 (Frameshift)"
      }
    },
    {
      "id": 839,
      "context": "",
      "deprecated": false,
      "description": "Loss of ARTX expression was associated with poor differentiation, which was associated with poor overall survival in univariate analysis in a study of 86 patients with leiomyosarcoma.",
      "disease": {
        "name": "Leiomyosarcoma",
        "oncotree_code": "LMS",
        "oncotree_term": "Leiomyosarcoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 245,
      "variant": {
        "id": 839,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "ATRX",
        "feature": "ATRX Deletion"
      }
    },
    {
      "id": 840,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058684",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 840,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "BRCA1",
        "feature": "BRCA1 Deletion"
      }
    },
    {
      "id": 841,
      "context": "",
      "deprecated": false,
      "description": "Loss-of-function of either BRCA1 or BRCA2 resulted in sensitization to PARP inhibition in both embryonic stem (ES) cells and nude mice lacking wild-type BRCA1 or BRCA2.",
      "disease": {
        "name": "Ovarian Cancer, Other",
        "oncotree_code": "OOVC",
        "oncotree_term": "Ovarian Cancer, Other"
      },
      "therapy": {
        "name": "KU0058948",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 243,
      "variant": {
        "id": 694,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "BRCA2",
        "feature": "BRCA2 Deletion"
      }
    },
    {
      "id": 842,
      "context": "",
      "deprecated": false,
      "description": "Four patients with uterine leiomyosarcoma and functional BRCA2 loss were evaluated for response to PARP inhibition with olaparib and all patients observed a durable response.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 244,
      "variant": {
        "id": 694,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "BRCA2",
        "feature": "BRCA2 Deletion"
      }
    },
    {
      "id": 843,
      "context": "",
      "deprecated": false,
      "description": "A patient with uterine leiomyosarcoma whose tumor harbored a CDKN2A mutant which inactivated p16INK4a experienced clinical benefit from treatment with palbociclib.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 246,
      "variant": {
        "id": 708,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CDKN2A",
        "feature": "CDKN2A Deletion"
      }
    },
    {
      "id": 844,
      "context": "",
      "deprecated": false,
      "description": "Deletion of CDKN2C may sensitize tumors of patients with uterine leiomyosarcoma to CDK4/6 inhibition.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 247,
      "variant": {
        "id": 844,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CDKN2C",
        "feature": "CDKN2C Deletion"
      }
    },
    {
      "id": 845,
      "context": "",
      "deprecated": false,
      "description": "Overexpression of MAPK7 and MAP2K4 were significantly associated with poor response to chemotherapy, tumor progression, and worse survival in a study of 30 patients.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Chemotherapy",
        "type": "Chemotherapy",
        "strategy": "Chemotherapy",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 248,
      "variant": {
        "id": 845,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MAP2K4",
        "feature": "MAP2K4 Amplification"
      }
    },
    {
      "id": 846,
      "context": "",
      "deprecated": false,
      "description": "Overexpression of MAPK7 and MAP2K4 were significantly associated with poor response to chemotherapy, tumor progression, and worse survival in a study of 30 patients.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 248,
      "variant": {
        "id": 845,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MAP2K4",
        "feature": "MAP2K4 Amplification"
      }
    },
    {
      "id": 847,
      "context": "",
      "deprecated": false,
      "description": "Overexpression of MAPK7 and MAP2K4 were significantly associated with poor response to chemotherapy, tumor progression, and worse survival in a study of 30 patients.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 248,
      "variant": {
        "id": 845,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MAP2K4",
        "feature": "MAP2K4 Amplification"
      }
    },
    {
      "id": 848,
      "context": "",
      "deprecated": false,
      "description": "Overexpression of MAPK7 and MAP2K4 were significantly associated with poor response to chemotherapy, tumor progression, and worse survival in a study of 30 patients.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Chemotherapy",
        "type": "Chemotherapy",
        "strategy": "Chemotherapy",
        "resistance": "",
        "sensitivity": 0
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 248,
      "variant": {
        "id": 848,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MAPK7",
        "feature": "MAPK7 Amplification"
      }
    },
    {
      "id": 849,
      "context": "",
      "deprecated": false,
      "description": "MYOCD was observed to be highly amplified and overexpressed in human retroperitoneal leiomyosarcomas (LMS) and, furthermore, that human retroperitoneal LMS differentiation is dependent on MYOCD amplification and overexpression.",
      "disease": {
        "name": "Leiomyosarcoma",
        "oncotree_code": "LMS",
        "oncotree_term": "Leiomyosarcoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Clinical evidence",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 249,
      "variant": {
        "id": 849,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MYOCD",
        "feature": "MYOCD Amplification"
      }
    },
    {
      "id": 850,
      "context": "",
      "deprecated": false,
      "description": "Overexpression of PDGFR alpha was observed to have an association with lymph node metastasis, suggesting an unfavorable phenotype, in a study of 181 tumor samples of invasive ductal breast carcinomas.",
      "disease": {
        "name": "Breast Invasive Ductal Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Breast Invasive Ductal Carcinoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 250,
      "variant": {
        "id": 850,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "PDGFRA",
        "feature": "PDGFRA Amplification"
      }
    },
    {
      "id": 851,
      "context": "",
      "deprecated": false,
      "description": "Loss of PTEN was correlated with shorter disease-specific survival but not overall survival in a study of 103 patients with uterine leiomyosarcoma.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 251,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 852,
      "context": "",
      "deprecated": false,
      "description": "Expression of Phospho-S6 Ribosomal Protein was suggestive of response to dual PI3K/mTOR inhibition in patient-derived xenograph leiomyosarcoma models.",
      "disease": {
        "name": "Uterine Leiomyosarcoma",
        "oncotree_code": "ULMS",
        "oncotree_term": "Uterine Leiomyosarcoma"
      },
      "therapy": {
        "name": "Alpelisib + Sapanisertib",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Inferential",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 251,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 853,
      "context": "",
      "deprecated": false,
      "description": "In a preclinical setting, treatment of PARP inhibition using olaparib and talazoparib caused more cell growth inhibition in LNCaP cells harboring both BRCA2 and RB1 variants than those only harboring BRCA2 variants.",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib + Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-08-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 240,
      "variant": {
        "id": 853,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "RB1",
        "feature": "RB1 Deletion"
      }
    },
    {
      "id": 854,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor 1 (FGFR1) rearrangements.",
      "disease": {
        "name": "Myeloid/Lymphoid Neoplasms",
        "oncotree_code": "MLN",
        "oncotree_term": "Myeloid/Lymphoid Neoplasms"
      },
      "therapy": {
        "name": "Pemigatinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-09-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 252,
      "variant": {
        "id": 854,
        "feature_type": "rearrangement",
        "gene1": "FGFR1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "FGFR1"
      }
    },
    {
      "id": 855,
      "context": "locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements.",
      "disease": {
        "name": "Intrahepatic Cholangiocarcinoma",
        "oncotree_code": "IHCH",
        "oncotree_term": "Intrahepatic Cholangiocarcinoma"
      },
      "therapy": {
        "name": "Futibatinib",
        "type": "Targeted therapy",
        "strategy": "FGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2022-10-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 253,
      "variant": {
        "id": 30,
        "feature_type": "rearrangement",
        "gene1": "FGFR2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "FGFR2"
      }
    },
    {
      "id": 856,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. This indication was approved for adult patients on 2022-09-21 and pediatric patients on 2024-05-29.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Selpercatinib",
        "type": "Targeted therapy",
        "strategy": "RET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 254,
      "variant": {
        "id": 52,
        "feature_type": "rearrangement",
        "gene1": "RET",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "RET Fusion"
      }
    },
    {
      "id": 857,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Olutasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-01-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 255,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 858,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Olutasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-01-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 255,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 859,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Olutasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-01-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 255,
      "variant": {
        "id": 859,
        "alternate_allele": "C",
        "cdna_change": "c.394C>G",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132G",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132G (Missense)"
      }
    },
    {
      "id": 860,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Olutasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-01-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 255,
      "variant": {
        "id": 860,
        "alternate_allele": "T",
        "cdna_change": "c.394C>A",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132S",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132S (Missense)"
      }
    },
    {
      "id": 861,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Olutasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-01-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 255,
      "variant": {
        "id": 861,
        "alternate_allele": "A",
        "cdna_change": "c.395G>T",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132L",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132L (Missense)"
      }
    },
    {
      "id": 862,
      "context": "Locally advanced or metastatic disease",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to adagrasib for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Adagrasib",
        "type": "Targeted therapy",
        "strategy": "RAS inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 256,
      "variant": {
        "id": 372,
        "alternate_allele": "A",
        "cdna_change": "c.34G>T",
        "chromosome": "12",
        "end_position": "25398285",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G12C",
        "reference_allele": "C",
        "rsid": "rs121913530",
        "start_position": "25398285",
        "variant_annotation": "Missense",
        "feature": "KRAS p.G12C (Missense)"
      }
    },
    {
      "id": 863,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Trastuzumab + Tucatinib",
        "type": "Targeted therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-02-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 257,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 864,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to elacestrant for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Elacestrant",
        "type": "Hormone therapy",
        "strategy": "ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-02-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 258,
      "variant": {
        "id": 864,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "6",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ESR1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ESR1"
      }
    },
    {
      "id": 865,
      "context": "Unresectable or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",
      "disease": {
        "name": "Low-Grade Glioma, NOS",
        "oncotree_code": "LGGNOS",
        "oncotree_term": "Low-Grade Glioma, NOS"
      },
      "therapy": {
        "name": "Dabrafenib + Trametinib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition + MEK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-04-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 259,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 866,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone + Olaparib + Prednisone",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + Corticosteroid + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 867,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone + Olaparib + Prednisone",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + Corticosteroid + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 868,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone + Olaparib + Prednisone",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + Corticosteroid + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 869,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone + Olaparib + Prednisone",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + Corticosteroid + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 870,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 871,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 872,
      "context": "HER2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 594,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 873,
      "context": "HER2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 172,
      "variant": {
        "id": 612,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": "1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 874,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 130,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATM",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ATM"
      }
    },
    {
      "id": 875,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 875,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "ATR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "ATR"
      }
    },
    {
      "id": 876,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 877,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 878,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 226,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CDK12",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CDK12"
      }
    },
    {
      "id": 879,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 234,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "CHEK2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "CHEK2"
      }
    },
    {
      "id": 880,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 880,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FANCA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "FANCA"
      }
    },
    {
      "id": 881,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 881,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MLH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MLH1"
      }
    },
    {
      "id": 883,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 883,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "NBN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "NBN"
      }
    },
    {
      "id": 884,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 441,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PALB2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PALB2"
      }
    },
    {
      "id": 885,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 503,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RAD51C",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RAD51C"
      }
    },
    {
      "id": 886,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone acetate + Niraparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-09-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 261,
      "variant": {
        "id": 602,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA1",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 887,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone acetate + Niraparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-09-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 261,
      "variant": {
        "id": 185,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA1"
      }
    },
    {
      "id": 888,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone acetate + Niraparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-09-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 261,
      "variant": {
        "id": 624,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "germline_variant",
        "gene": "BRCA2",
        "pathogenic": null,
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 889,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Abiraterone acetate + Niraparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-09-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 261,
      "variant": {
        "id": 201,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "BRCA2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "BRCA2"
      }
    },
    {
      "id": 890,
      "context": "Primary advanced or recurrent",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, for the treatment of adult patients primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite-instability-high.",
      "disease": {
        "name": "Endometrial Carcinoma",
        "oncotree_code": "UCEC",
        "oncotree_term": "Endometrial Carcinoma"
      },
      "therapy": {
        "name": "Dostarlimab",
        "type": "Immunotherapy",
        "strategy": "PD-1/PD-L1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 262,
      "variant": {
        "id": 768,
        "feature_type": "microsatellite_stability",
        "status": "MSI-High",
        "feature": "MSI-High"
      }
    },
    {
      "id": 891,
      "context": "",
      "deprecated": false,
      "description": "Two osteosarcoma cancer cell lines, KHOS and KHOSR2, were exposed to NSC59984 at concentrations ranging from 0.0001 - 100 micromolar for three days and cell viability significantly decreased after dosage of 10 and 20 micromolar for the two cell lines, respectively. NSC59984 restores TP53 pathway signaling via p73 activation and induces mutant TP53 degradation, mediated by the MDM2 proteasome pathway.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "NSC59984",
        "type": "Targeted therapy",
        "strategy": "Mutant p53 degradation",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-07-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 263,
      "variant": {
        "id": 568,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "TP53",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "TP53"
      }
    },
    {
      "id": 892,
      "context": "",
      "deprecated": false,
      "description": "Eighteen osteosarcoma cancer cell lines were subject to drug screens of 17 compounds, from which mutant RB1 status was observed to be associated with resistance to palbociclib.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": 1,
        "sensitivity": ""
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 264,
      "variant": {
        "id": 892,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RB1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RB1"
      }
    },
    {
      "id": 893,
      "context": "",
      "deprecated": false,
      "description": "Eighteen osteosarcoma cancer cell lines were subject to drug screens of 17 compounds. Three osteosarcoma cancer cell lines with FGFR1 amplified (G292, NOS1, and CAL72) and two with FGFR1 gains (HU09 and NY) were observed to be significantly more sensitive to AZ4547 and PD173074, both FGFR inhibitors, than cell lines without FGFR1 copy number alterations.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Fexagratinib",
        "type": "Targeted therapy",
        "strategy": "FGFR1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 264,
      "variant": {
        "id": 734,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR1",
        "feature": "FGFR1 Amplification"
      }
    },
    {
      "id": 894,
      "context": "",
      "deprecated": false,
      "description": "Eighteen osteosarcoma cancer cell lines were subject to drug screens of 17 compounds. Three osteosarcoma cancer cell lines with FGFR1 amplified (G292, NOS1, and CAL72) and two with FGFR1 gains (HU09 and NY) were observed to be significantly more sensitive to AZ4547 and PD173074, both FGFR inhibitors, than cell lines without FGFR1 copy number alterations.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "PD173074",
        "type": "Targeted therapy",
        "strategy": "FGFR1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 264,
      "variant": {
        "id": 734,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "FGFR1",
        "feature": "FGFR1 Amplification"
      }
    },
    {
      "id": 895,
      "context": "",
      "deprecated": false,
      "description": "Sensitivity to olaparib was observed across a broad osteosarcoma-focused cell panel in RB1-mutant or RB1 expression lacking cell lines relative to RB1-normal lines. Similar results in this study were observed with niraparib and talazoparib. The study also observed that the single-agent sensitivity to PARP inhibition with RB1-defective osteosarcoma cells extended to a xenograft of an RB1-defective osteosarcoma line (OHSN) in immunodeficient NRG mice.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Olaparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 265,
      "variant": {
        "id": 892,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "RB1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "RB1"
      }
    },
    {
      "id": 896,
      "context": "",
      "deprecated": false,
      "description": "Fifteen PDTX models were developed by directly grafting tumor samples from patients with osteosarcoma into immunocompromised mice. Treatment of both MYC-amplified PDTXs with CDK inhibitor AT7519 resulted in decreased tumor growth and levels of MYC protein and MYC target MCL1 were significantly reduced following treatment.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "CDK Inhibitor AT7519",
        "type": "Targeted therapy",
        "strategy": "CDK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 266,
      "variant": {
        "id": 753,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "MYC",
        "feature": "MYC Amplification"
      }
    },
    {
      "id": 897,
      "context": "",
      "deprecated": false,
      "description": "Fifteen PDTX models were developed by directly grafting tumor samples from patients with osteosarcoma into immunocompromised mice. Treatment of three CCNE1-amplified PDTX models resulted in significant inhibition of tumor growth. Furthermore, CC3 staining after short-term treatment confirmed a modest but statistically significant increase in apoptosis.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Dinaciclib",
        "type": "Targeted therapy",
        "strategy": "CDK1/2/5/9 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 266,
      "variant": {
        "id": 897,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CCNE1",
        "feature": "CCNE1 Amplification"
      }
    },
    {
      "id": 898,
      "context": "",
      "deprecated": false,
      "description": "Fifteen PDTX models were developed by directly grafting tumor samples from patients with osteosarcoma into immunocompromised mice. Two models were identified to harbor CDK4 amplifications, both of which demonstrated increased CDK4 gene and protein expression. Treatment of these two models with palbociclib resulted in significant growth arrest relative to control vehicle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Palbociclib",
        "type": "Targeted therapy",
        "strategy": "CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 266,
      "variant": {
        "id": 704,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "CDK4",
        "feature": "CDK4 Amplification"
      }
    },
    {
      "id": 899,
      "context": "",
      "deprecated": false,
      "description": "Fifteen PDTX models were developed by directly grafting tumor samples from patients with osteosarcoma into immunocompromised mice. Two models were identified to harbor alterations within the PI3K/AKT/mTOR pathway, one with biallelic PTEN loss and one with amplification of AKT1. High levels of phosphorylation of ribosomal protein S6 was observed in both models. Both models were treated with MK-2660, a pan-AKT inhibitor, and observed significant reduction of tumor growth relative to control vehicle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Akt Inhibitor MK2206",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 266,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 900,
      "context": "",
      "deprecated": false,
      "description": "Fifteen PDTX models were developed by directly grafting tumor samples from patients with osteosarcoma into immunocompromised mice. Two models were identified to harbor alterations within the PI3K/AKT/mTOR pathway, one with biallelic PTEN loss and one with amplification of AKT1. High levels of phosphorylation of ribosomal protein S6 was observed in both models. Both models were treated with MK-2660, a pan-AKT inhibitor, and observed significant reduction of tumor growth relative to control vehicle. The PTEN-deficient model was also treated with rapamycin to inhibit mTOR and significant tumor growth decrease was also observed.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Sirolimus",
        "type": "Targeted therapy",
        "strategy": "PI3K/AKT/mTOR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 266,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 901,
      "context": "",
      "deprecated": false,
      "description": "Response to talazoparib in osteosarcoma cell lines was associated with homologous recombination deficiency in a study of 5 cancer cell lines. Osteosarcoma cell lines MG63 and ZK-58 displayed the highest sensitivity to talazoparib, SaOS-2 and MNNG-HOS displayed intermediate sensitivity, and U2OS cells remained resistant. Cell lines MG63, ZK-58, and MNNG-HOS scored HRD-LOH positive according to a score (Abkevich et al. 2012). MG63 cells harbored copy losses in BAP1, FANCA, and FANCD2 while ZK-58 carried disruptive copy loss in BARD1 and copy gain in FANCD2. SaOS-2 cells harbored copy losses in CHEK2 and TP53 and MNNG-HOS cells have copy loss of ATM and disruptive copy gains in PTEN and FANCD2. The talazoparib-resistant cell line, U2OS, carried a heterozygous BRCA2 copy loss and one intact BRCA2 alelle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 267,
      "variant": {
        "id": 901,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "BAP1",
        "feature": "BAP1 Deletion"
      }
    },
    {
      "id": 902,
      "context": "",
      "deprecated": false,
      "description": "Response to talazoparib in osteosarcoma cell lines was associated with homologous recombination deficiency in a study of 5 cancer cell lines. Osteosarcoma cell lines MG63 and ZK-58 displayed the highest sensitivity to talazoparib, SaOS-2 and MNNG-HOS displayed intermediate sensitivity, and U2OS cells remained resistant. Cell lines MG63, ZK-58, and MNNG-HOS scored HRD-LOH positive according to a score (Abkevich et al. 2012). MG63 cells harbored copy losses in BAP1, FANCA, and FANCD2 while ZK-58 carried disruptive copy loss in BARD1 and copy gain in FANCD2. SaOS-2 cells harbored copy losses in CHEK2 and TP53 and MNNG-HOS cells have copy loss of ATM and disruptive copy gains in PTEN and FANCD2. The talazoparib-resistant cell line, U2OS, carried a heterozygous BRCA2 copy loss and one intact BRCA2 alelle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 267,
      "variant": {
        "id": 902,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "FANCA",
        "feature": "FANCA Deletion"
      }
    },
    {
      "id": 903,
      "context": "",
      "deprecated": false,
      "description": "Response to talazoparib in osteosarcoma cell lines was associated with homologous recombination deficiency in a study of 5 cancer cell lines. Osteosarcoma cell lines MG63 and ZK-58 displayed the highest sensitivity to talazoparib, SaOS-2 and MNNG-HOS displayed intermediate sensitivity, and U2OS cells remained resistant. Cell lines MG63, ZK-58, and MNNG-HOS scored HRD-LOH positive according to a score (Abkevich et al. 2012). MG63 cells harbored copy losses in BAP1, FANCA, and FANCD2 while ZK-58 carried disruptive copy loss in BARD1 and copy gain in FANCD2. SaOS-2 cells harbored copy losses in CHEK2 and TP53 and MNNG-HOS cells have copy loss of ATM and disruptive copy gains in PTEN and FANCD2. The talazoparib-resistant cell line, U2OS, carried a heterozygous BRCA2 copy loss and one intact BRCA2 alelle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 267,
      "variant": {
        "id": 903,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "BARD1",
        "feature": "BARD1 Deletion"
      }
    },
    {
      "id": 904,
      "context": "",
      "deprecated": false,
      "description": "Response to talazoparib in osteosarcoma cell lines was associated with homologous recombination deficiency in a study of 5 cancer cell lines. Osteosarcoma cell lines MG63 and ZK-58 displayed the highest sensitivity to talazoparib, SaOS-2 and MNNG-HOS displayed intermediate sensitivity, and U2OS cells remained resistant. Cell lines MG63, ZK-58, and MNNG-HOS scored HRD-LOH positive according to a score (Abkevich et al. 2012). MG63 cells harbored copy losses in BAP1, FANCA, and FANCD2 while ZK-58 carried disruptive copy loss in BARD1 and copy gain in FANCD2. SaOS-2 cells harbored copy losses in CHEK2 and TP53 and MNNG-HOS cells have copy loss of ATM and disruptive copy gains in PTEN and FANCD2. The talazoparib-resistant cell line, U2OS, carried a heterozygous BRCA2 copy loss and one intact BRCA2 alelle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 267,
      "variant": {
        "id": 904,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "CHEK2",
        "feature": "CHEK2 Deletion"
      }
    },
    {
      "id": 905,
      "context": "",
      "deprecated": false,
      "description": "Response to talazoparib in osteosarcoma cell lines was associated with homologous recombination deficiency in a study of 5 cancer cell lines. Osteosarcoma cell lines MG63 and ZK-58 displayed the highest sensitivity to talazoparib, SaOS-2 and MNNG-HOS displayed intermediate sensitivity, and U2OS cells remained resistant. Cell lines MG63, ZK-58, and MNNG-HOS scored HRD-LOH positive according to a score (Abkevich et al. 2012). MG63 cells harbored copy losses in BAP1, FANCA, and FANCD2 while ZK-58 carried disruptive copy loss in BARD1 and copy gain in FANCD2. SaOS-2 cells harbored copy losses in CHEK2 and TP53 and MNNG-HOS cells have copy loss of ATM and disruptive copy gains in PTEN and FANCD2. The talazoparib-resistant cell line, U2OS, carried a heterozygous BRCA2 copy loss and one intact BRCA2 alelle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 267,
      "variant": {
        "id": 905,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "TP53",
        "feature": "TP53 Deletion"
      }
    },
    {
      "id": 906,
      "context": "",
      "deprecated": false,
      "description": "Response to talazoparib in osteosarcoma cell lines was associated with homologous recombination deficiency in a study of 5 cancer cell lines. Osteosarcoma cell lines MG63 and ZK-58 displayed the highest sensitivity to talazoparib, SaOS-2 and MNNG-HOS displayed intermediate sensitivity, and U2OS cells remained resistant. Cell lines MG63, ZK-58, and MNNG-HOS scored HRD-LOH positive according to a score (Abkevich et al. 2012). MG63 cells harbored copy losses in BAP1, FANCA, and FANCD2 while ZK-58 carried disruptive copy loss in BARD1 and copy gain in FANCD2. SaOS-2 cells harbored copy losses in CHEK2 and TP53 and MNNG-HOS cells have copy loss of ATM and disruptive copy gains in PTEN and FANCD2. The talazoparib-resistant cell line, U2OS, carried a heterozygous BRCA2 copy loss and one intact BRCA2 alelle.",
      "disease": {
        "name": "Osteosarcoma",
        "oncotree_code": "OS",
        "oncotree_term": "Osteosarcoma"
      },
      "therapy": {
        "name": "Talazoparib",
        "type": "Targeted therapy",
        "strategy": "PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "Preclinical",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 267,
      "variant": {
        "id": 906,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "ATM",
        "feature": "ATM Deletion"
      }
    },
    {
      "id": 907,
      "context": "Pediatric",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Bosutinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 268,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 908,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Myelodysplastic Syndromes",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplastic Syndromes"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 269,
      "variant": {
        "id": 908,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "2",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 909,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Myelodysplastic Syndromes",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplastic Syndromes"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 269,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 910,
      "context": "Relapsed or refractory",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Myelodysplastic Syndromes",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplastic Syndromes"
      },
      "therapy": {
        "name": "Ivosidenib",
        "type": "Targeted therapy",
        "strategy": "IDH1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 269,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 911,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Binimetinib + Encorafenib",
        "type": "Targeted therapy",
        "strategy": "MEK inhibition + B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-11-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 270,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 912,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights FLT3 Internal Tandem Duplication and D835 missense codon changes as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 912,
        "alternate_allele": "G",
        "cdna_change": "c.2504A>C",
        "chromosome": "13",
        "end_position": "28592641",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": "p.D835A",
        "reference_allele": "T",
        "rsid": "rs121909646",
        "start_position": "28592641",
        "variant_annotation": "Missense",
        "feature": "FLT3 p.D835A (Missense)"
      }
    },
    {
      "id": 913,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights FLT3 Internal Tandem Duplication and D835 missense codon changes as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 913,
        "alternate_allele": "G",
        "cdna_change": "c.2505T>A",
        "chromosome": "13",
        "end_position": "28592640",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": "p.D835E",
        "reference_allele": "T",
        "rsid": "rs121913487",
        "start_position": "28592640",
        "variant_annotation": "Missense",
        "feature": "FLT3 p.D835E (Missense)"
      }
    },
    {
      "id": 914,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights FLT3 Internal Tandem Duplication and D835 missense codon changes as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 914,
        "alternate_allele": "G",
        "cdna_change": "c.2503G>C",
        "chromosome": "13",
        "end_position": "28592642",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": "p.D835H",
        "reference_allele": "C",
        "rsid": "rs121913488",
        "start_position": "28592642",
        "variant_annotation": "Missense",
        "feature": "FLT3 p.D835H (Missense)"
      }
    },
    {
      "id": 915,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights FLT3 Internal Tandem Duplication and D835 missense codon changes as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 915,
        "alternate_allele": "A",
        "cdna_change": "c.2503G>T",
        "chromosome": "13",
        "end_position": "28592642",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": "p.D835Y",
        "reference_allele": "C",
        "rsid": "rs121913488",
        "start_position": "28592642",
        "variant_annotation": "Missense",
        "feature": "FLT3 p.D835Y (Missense)"
      }
    },
    {
      "id": 916,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights GATA2 nonsense, frameshift, splice site, and missense codon changes in codons 349 - 398 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 916,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Missense",
        "feature": "FLT3 (Missense)"
      }
    },
    {
      "id": 917,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights GATA2 nonsense, frameshift, splice site, and missense codon changes in codons 349 - 398 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 917,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "FLT3 (Nonsense)"
      }
    },
    {
      "id": 918,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights GATA2 nonsense, frameshift, splice site, and missense codon changes in codons 349 - 398 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 918,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "FLT3 (Frameshift)"
      }
    },
    {
      "id": 919,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights GATA2 nonsense, frameshift, splice site, and missense codon changes in codons 349 - 398 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 919,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "FLT3",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "FLT3 (Splice Site)"
      }
    },
    {
      "id": 920,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights NPM1 p.W288Cfs*12 as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 920,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": "170837544",
        "exon": "11",
        "feature_type": "somatic_variant",
        "gene": "NPM1",
        "protein_change": "p.W288Cfs*12",
        "reference_allele": null,
        "rsid": null,
        "start_position": "170837543",
        "variant_annotation": "Frameshift",
        "feature": "NPM1 p.W288Cfs*12 (Frameshift)"
      }
    },
    {
      "id": 921,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SRSF2 missense and in-frame deletion variants involving P95 codon as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 921,
        "alternate_allele": "T",
        "cdna_change": "c.284C>A",
        "chromosome": "17",
        "end_position": "74732959",
        "exon": "1",
        "feature_type": "somatic_variant",
        "gene": "SRSF2",
        "protein_change": "p.P95H",
        "reference_allele": "G",
        "rsid": "rs751713049",
        "start_position": "74732959",
        "variant_annotation": "Missense",
        "feature": "SRSF2 p.P95H (Missense)"
      }
    },
    {
      "id": 922,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SRSF2 missense and in-frame deletion variants involving P95 codon as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 922,
        "alternate_allele": "A",
        "cdna_change": "c.284C>T",
        "chromosome": "17",
        "end_position": "74732959",
        "exon": "1",
        "feature_type": "somatic_variant",
        "gene": "SRSF2",
        "protein_change": "p.P95L",
        "reference_allele": "G",
        "rsid": "rs751713049",
        "start_position": "74732959",
        "variant_annotation": "Missense",
        "feature": "SRSF2 p.P95L (Missense)"
      }
    },
    {
      "id": 923,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SRSF2 missense and in-frame deletion variants involving P95 codon as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 923,
        "alternate_allele": "C",
        "cdna_change": "c.284C>G",
        "chromosome": "17",
        "end_position": "74732959",
        "exon": "1",
        "feature_type": "somatic_variant",
        "gene": "SRSF2",
        "protein_change": "p.P95R",
        "reference_allele": "G",
        "rsid": "rs751713049",
        "start_position": "74732959",
        "variant_annotation": "Missense",
        "feature": "SRSF2 p.P95R (Missense)"
      }
    },
    {
      "id": 924,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SRSF2 missense and in-frame deletion variants involving P95 codon as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 924,
        "alternate_allele": "C",
        "cdna_change": "c.283C>G",
        "chromosome": "17",
        "end_position": "74732960",
        "exon": "1",
        "feature_type": "somatic_variant",
        "gene": "SRSF2",
        "protein_change": "p.P95A",
        "reference_allele": "G",
        "rsid": "rs752405402",
        "start_position": "74732960",
        "variant_annotation": "Missense",
        "feature": "SRSF2 p.P95A (Missense)"
      }
    },
    {
      "id": 925,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights SRSF2 missense and in-frame deletion variants involving P95 codon as being associated with poor prognosis in patients with myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 925,
        "alternate_allele": "-",
        "cdna_change": "c.284_307del",
        "chromosome": "17",
        "end_position": "74732959",
        "exon": "1",
        "feature_type": "somatic_variant",
        "gene": "SRSF2",
        "protein_change": "p.P95_R102del",
        "reference_allele": "GGCGGCTGTGGTGTGAGTCCGGGG",
        "rsid": null,
        "start_position": "74732936",
        "variant_annotation": "Deletion",
        "feature": "SRSF2 p.P95_R102del (Deletion)"
      }
    },
    {
      "id": 926,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights WT1 frameshift, splice site, and nonsense variants as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 926,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "WT1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "WT1 (Nonsense)"
      }
    },
    {
      "id": 927,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights WT1 frameshift, splice site, and nonsense variants as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 927,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "WT1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "WT1 (Frameshift)"
      }
    },
    {
      "id": 928,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights WT1 frameshift, splice site, and nonsense variants as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 928,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "WT1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "WT1 (Splice Site)"
      }
    },
    {
      "id": 929,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 929,
        "alternate_allele": "C",
        "cdna_change": "c.100T>G",
        "chromosome": "21",
        "end_position": "44524457",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.S34A",
        "reference_allele": "A",
        "rsid": null,
        "start_position": "44524457",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.S34A (Missense)"
      }
    },
    {
      "id": 930,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 930,
        "alternate_allele": "A",
        "cdna_change": "c.101C>T",
        "chromosome": "21",
        "end_position": "44524456",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.S34F",
        "reference_allele": "G",
        "rsid": "rs371769427",
        "start_position": "44524456",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.S34F (Missense)"
      }
    },
    {
      "id": 931,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 931,
        "alternate_allele": "GA",
        "cdna_change": "c.101_102delinsTC",
        "chromosome": "21",
        "end_position": "44524456",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.S34F",
        "reference_allele": "AG",
        "rsid": null,
        "start_position": "44524455",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.S34F (Missense)"
      }
    },
    {
      "id": 932,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 932,
        "alternate_allele": "T",
        "cdna_change": "c.101C>A",
        "chromosome": "21",
        "end_position": "44524456",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.S34Y",
        "reference_allele": "G",
        "rsid": "rs371769427",
        "start_position": "44524456",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.S34Y (Missense)"
      }
    },
    {
      "id": 933,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 933,
        "alternate_allele": "AG",
        "cdna_change": "c.470_471inv",
        "chromosome": "21",
        "end_position": "44514777",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.Q157P",
        "reference_allele": "CT",
        "rsid": null,
        "start_position": "44514776",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.Q157P (Missense)"
      }
    },
    {
      "id": 934,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 934,
        "alternate_allele": "G",
        "cdna_change": "c.470A>C",
        "chromosome": "21",
        "end_position": "44514777",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.Q157P",
        "reference_allele": "T",
        "rsid": "rs371246226",
        "start_position": "44514777",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.Q157P (Missense)"
      }
    },
    {
      "id": 935,
      "context": "",
      "deprecated": false,
      "description": "The National Comprehensive Cancer Network\u00ae (NCCN\u00ae) highlights U2AF1 missense variants involving either S34 or Q157 codons as associated with poor prognosis in myelodysplastic syndromes.",
      "disease": {
        "name": "Myelodysplasia",
        "oncotree_code": "MDS",
        "oncotree_term": "Myelodysplasia"
      },
      "therapy": {
        "name": "",
        "type": "",
        "strategy": "",
        "resistance": "",
        "sensitivity": ""
      },
      "predictive_implication": "Guideline",
      "favorable_prognosis": 0,
      "created_on": "04/04/25",
      "last_updated": "2023-11-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 33,
      "variant": {
        "id": 935,
        "alternate_allele": "C",
        "cdna_change": "c.470A>G",
        "chromosome": "21",
        "end_position": "44514777",
        "exon": "6",
        "feature_type": "somatic_variant",
        "gene": "U2AF1",
        "protein_change": "p.Q157R",
        "reference_allele": "T",
        "rsid": "rs371246226",
        "start_position": "44514777",
        "variant_annotation": "Missense",
        "feature": "U2AF1 p.Q157R (Missense)"
      }
    },
    {
      "id": 937,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capivasertib + Fulvestrant",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-12-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 272,
      "variant": {
        "id": 457,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "3",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PIK3CA"
      }
    },
    {
      "id": 938,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capivasertib + Fulvestrant",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-12-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 272,
      "variant": {
        "id": 938,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "14",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "AKT1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "AKT1"
      }
    },
    {
      "id": 939,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capivasertib + Fulvestrant",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-12-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 272,
      "variant": {
        "id": 939,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "10",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Nonsense",
        "feature": "PTEN (Nonsense)"
      }
    },
    {
      "id": 940,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capivasertib + Fulvestrant",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-12-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 272,
      "variant": {
        "id": 940,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "10",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Frameshift",
        "feature": "PTEN (Frameshift)"
      }
    },
    {
      "id": 941,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capivasertib + Fulvestrant",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-12-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 272,
      "variant": {
        "id": 941,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "10",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PTEN",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "PTEN (Splice Site)"
      }
    },
    {
      "id": 942,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capivasertib + Fulvestrant",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2023-12-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 272,
      "variant": {
        "id": 759,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "PTEN",
        "feature": "PTEN Deletion"
      }
    },
    {
      "id": 943,
      "context": "Advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Capecitabine + Neratinib",
        "type": "Combination therapy",
        "strategy": "ER signaling inhibition + Thymidylate synthase inhibitor",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-01-08",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 202,
      "variant": {
        "id": 714,
        "cytoband": null,
        "direction": "Amplification",
        "feature_type": "copy_number",
        "gene": "ERBB2",
        "feature": "ERBB2 Amplification"
      }
    },
    {
      "id": 944,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation.",
      "disease": {
        "name": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease",
        "oncotree_code": "ECD",
        "oncotree_term": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 273,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 945,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation.",
      "disease": {
        "name": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease",
        "oncotree_code": "ECD",
        "oncotree_term": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease"
      },
      "therapy": {
        "name": "Vemurafenib",
        "type": "Targeted therapy",
        "strategy": "B-RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-01-30",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 273,
      "variant": {
        "id": 146,
        "alternate_allele": "TT",
        "cdna_change": "c.1798_1799GT>AA",
        "chromosome": "7",
        "end_position": "140453137",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600K",
        "reference_allele": "AC",
        "rsid": "rs121913227",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600K (Missense)"
      }
    },
    {
      "id": 946,
      "context": "Locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy.",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Amivantamab + Carboplatin + Pemetrexed",
        "type": "Combination therapy",
        "strategy": "EGFR inhibition + Platinum-based chemotherapy + Antifolate",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 274,
      "variant": {
        "id": 248,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Insertion",
        "feature": "EGFR (Insertion)"
      }
    },
    {
      "id": 947,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Cisplatin + Osimertinib + Pemetrexed",
        "type": "Combination therapy",
        "strategy": "Platinum-based chemotherapy + EGFR inhibition + Antifolate",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 275,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 948,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Cisplatin + Osimertinib + Pemetrexed",
        "type": "Combination therapy",
        "strategy": "Platinum-based chemotherapy + EGFR inhibition + Antifolate",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 275,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 949,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 276,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 950,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 276,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 951,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Tepotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 277,
      "variant": {
        "id": 398,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Splice Site",
        "feature": "MET (Splice Site)"
      }
    },
    {
      "id": 952,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Tepotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 277,
      "variant": {
        "id": 399,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "14",
        "feature_type": "somatic_variant",
        "gene": "MET",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "MET (Deletion)"
      }
    },
    {
      "id": 953,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL.",
      "disease": {
        "name": "Anaplastic Large Cell Lymphoma",
        "oncotree_code": "ALCL",
        "oncotree_term": "Anaplastic Large Cell Lymphoma"
      },
      "therapy": {
        "name": "Crizotinib",
        "type": "Targeted therapy",
        "strategy": "MET inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-03-04",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 278,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 954,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Entrectinib",
        "type": "Targeted therapy",
        "strategy": "ROS1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 40,
      "variant": {
        "id": 57,
        "feature_type": "rearrangement",
        "gene1": "ROS1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ROS1 Fusion"
      }
    },
    {
      "id": 955,
      "context": "Locally advanced or metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to repotrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Repotrectinib",
        "type": "Targeted therapy",
        "strategy": "ROS1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 271,
      "variant": {
        "id": 955,
        "feature_type": "rearrangement",
        "gene1": "ROS1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "ROS1"
      }
    },
    {
      "id": 956,
      "context": "Metastatic castration-resistant",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).",
      "disease": {
        "name": "Prostate Adenocarcinoma",
        "oncotree_code": "PRAD",
        "oncotree_term": "Prostate Adenocarcinoma"
      },
      "therapy": {
        "name": "Enzalutamide + Talazoparib",
        "type": "Combination therapy",
        "strategy": "Antiandrogen + PARP inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 260,
      "variant": {
        "id": 956,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "MRE11",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "MRE11"
      }
    },
    {
      "id": 957,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction.",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Chemotherapy + Ponatinib",
        "type": "Combination therapy",
        "strategy": "targets BCR-ABL + Chemotherapy",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 279,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 958,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) for whom no other kinase inhibitors are indicated.",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Ponatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 280,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 959,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Ponatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 280,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 960,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Ponatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 280,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 961,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in the chronic phase, accelerated phase, or blast phase.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Ponatinib",
        "type": "Targeted therapy",
        "strategy": "targets BCR-ABL",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-04-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 280,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 962,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to alectinib for the adjuvant treatment of adult patients following tumor resection of with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive) as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Alectinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-04-01",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 281,
      "variant": {
        "id": 9,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "ALK Fusion"
      }
    },
    {
      "id": 963,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",
      "disease": {
        "name": "Low-Grade Glioma, NOS",
        "oncotree_code": "LGGNOS",
        "oncotree_term": "Low-Grade Glioma, NOS"
      },
      "therapy": {
        "name": "Tovorafenib",
        "type": "Targeted therapy",
        "strategy": "RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 282,
      "variant": {
        "id": 146,
        "alternate_allele": "TT",
        "cdna_change": "c.1798_1799GT>AA",
        "chromosome": "7",
        "end_position": "140453137",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600K",
        "reference_allele": "AC",
        "rsid": "rs121913227",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600K (Missense)"
      }
    },
    {
      "id": 964,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",
      "disease": {
        "name": "Low-Grade Glioma, NOS",
        "oncotree_code": "LGGNOS",
        "oncotree_term": "Low-Grade Glioma, NOS"
      },
      "therapy": {
        "name": "Tovorafenib",
        "type": "Targeted therapy",
        "strategy": "RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 282,
      "variant": {
        "id": 964,
        "feature_type": "rearrangement",
        "gene1": "BRAF",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "BRAF"
      }
    },
    {
      "id": 965,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",
      "disease": {
        "name": "Low-Grade Glioma, NOS",
        "oncotree_code": "LGGNOS",
        "oncotree_term": "Low-Grade Glioma, NOS"
      },
      "therapy": {
        "name": "Tovorafenib",
        "type": "Targeted therapy",
        "strategy": "RAF inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 282,
      "variant": {
        "id": 965,
        "feature_type": "rearrangement",
        "gene1": "BRAF",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BRAF Fusion"
      }
    },
    {
      "id": 966,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (p.L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Erlotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 283,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 967,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (p.L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Erlotinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 283,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 968,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 284,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 969,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Gefitinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-06-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 284,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 970,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients of age 12 years and older with solid tumors that (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, (iii) have progressed following treatment or have no satisfactory alternative therapy. The FDA notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Repotrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-07-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 285,
      "variant": {
        "id": 36,
        "feature_type": "rearrangement",
        "gene1": "NTRK1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK1 Fusion"
      }
    },
    {
      "id": 971,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients of age 12 years and older with solid tumors that (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, (iii) have progressed following treatment or have no satisfactory alternative therapy. The FDA notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Repotrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-07-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 285,
      "variant": {
        "id": 39,
        "feature_type": "rearrangement",
        "gene1": "NTRK2",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK2 Fusion"
      }
    },
    {
      "id": 972,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients of age 12 years and older with solid tumors that (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, (iii) have progressed following treatment or have no satisfactory alternative therapy. The FDA notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
      "disease": {
        "name": "Any solid tumor",
        "oncotree_code": "",
        "oncotree_term": "Any solid tumor"
      },
      "therapy": {
        "name": "Repotrectinib",
        "type": "Targeted therapy",
        "strategy": "TRK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-07-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 285,
      "variant": {
        "id": 42,
        "feature_type": "rearrangement",
        "gene1": "NTRK3",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NTRK3 Fusion"
      }
    },
    {
      "id": 973,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The FDA notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval of this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Adagrasib + Cetuximab",
        "type": "Targeted therapy",
        "strategy": "RAS inhibition + EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-07-11",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 286,
      "variant": {
        "id": 372,
        "alternate_allele": "A",
        "cdna_change": "c.34G>T",
        "chromosome": "12",
        "end_position": "25398285",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G12C",
        "reference_allele": "C",
        "rsid": "rs121913530",
        "start_position": "25398285",
        "variant_annotation": "Missense",
        "feature": "KRAS p.G12C (Missense)"
      }
    },
    {
      "id": 974,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 908,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "2",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 975,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 976,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 859,
        "alternate_allele": "C",
        "cdna_change": "c.394C>G",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132G",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132G (Missense)"
      }
    },
    {
      "id": 977,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 978,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 861,
        "alternate_allele": "A",
        "cdna_change": "c.395G>T",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132L",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132L (Missense)"
      }
    },
    {
      "id": 979,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 860,
        "alternate_allele": "T",
        "cdna_change": "c.394C>A",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132S",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132S (Missense)"
      }
    },
    {
      "id": 980,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 319,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "15",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH2"
      }
    },
    {
      "id": 981,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 318,
        "alternate_allele": "T",
        "cdna_change": "c.515G>A",
        "chromosome": "15",
        "end_position": "90631837",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172K",
        "reference_allele": "C",
        "rsid": "rs121913503",
        "start_position": "90631837",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172K (Missense)"
      }
    },
    {
      "id": 982,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Astrocytoma",
        "oncotree_code": "ASTR",
        "oncotree_term": "Astrocytoma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 982,
        "alternate_allele": "C",
        "cdna_change": "c.514A>G",
        "chromosome": "15",
        "end_position": "90631839",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172G",
        "reference_allele": "T",
        "rsid": "rs1057519906",
        "start_position": "90631839",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172G (Missense)"
      }
    },
    {
      "id": 983,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 908,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "2",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH1"
      }
    },
    {
      "id": 984,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 311,
        "alternate_allele": "A",
        "cdna_change": "c.394C>T",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132C",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132C (Missense)"
      }
    },
    {
      "id": 985,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 859,
        "alternate_allele": "C",
        "cdna_change": "c.394C>G",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132G",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132G (Missense)"
      }
    },
    {
      "id": 986,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 310,
        "alternate_allele": "T",
        "cdna_change": "c.395G>A",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132H",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132H (Missense)"
      }
    },
    {
      "id": 987,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 861,
        "alternate_allele": "A",
        "cdna_change": "c.395G>T",
        "chromosome": "2",
        "end_position": "209113112",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132L",
        "reference_allele": "C",
        "rsid": "rs121913500",
        "start_position": "209113112",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132L (Missense)"
      }
    },
    {
      "id": 988,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 860,
        "alternate_allele": "T",
        "cdna_change": "c.394C>A",
        "chromosome": "2",
        "end_position": "209113113",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH1",
        "protein_change": "p.R132S",
        "reference_allele": "G",
        "rsid": "rs121913499",
        "start_position": "209113113",
        "variant_annotation": "Missense",
        "feature": "IDH1 p.R132S (Missense)"
      }
    },
    {
      "id": 989,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 319,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "15",
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "IDH2"
      }
    },
    {
      "id": 990,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. This approval is based on INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. IDH mutation status was determined using Oncomine Dx Target Test to confirm detection of IDH1 mutation variants (p.R132H, p.R132C, p.R132G, p.R132S, or p.R132L) and IDH2 mutation variants (p.R172K, p.R172M, p.R172W, p.R172S, or p.R172G). Within the vorasidenib arm of the trial, they observed 163 patients that were IDH1-positive and 5 that were IDH2-positive with the amino acid changes of: IDH1 p.R132C (8), p.R132G (5), p.R132H (146), p.R132L (2), p.R132S (2), and IDH2 p.R172K (5) and p.R172G (2).",
      "disease": {
        "name": "Oligodendroglioma",
        "oncotree_code": "ODG",
        "oncotree_term": "Oligodendroglioma"
      },
      "therapy": {
        "name": "Vorasidenib",
        "type": "Targeted therapy",
        "strategy": "IDH inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-09-03",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 287,
      "variant": {
        "id": 318,
        "alternate_allele": "T",
        "cdna_change": "c.515G>A",
        "chromosome": "15",
        "end_position": "90631837",
        "exon": "4",
        "feature_type": "somatic_variant",
        "gene": "IDH2",
        "protein_change": "p.R172K",
        "reference_allele": "C",
        "rsid": "rs121913503",
        "start_position": "90631837",
        "variant_annotation": "Missense",
        "feature": "IDH2 p.R172K (Missense)"
      }
    },
    {
      "id": 991,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Amivantamab + Lazertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 288,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 992,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Amivantamab + Lazertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 288,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 993,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 p.L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Amivantamab + Carboplatin + Pemetrexed",
        "type": "Combination therapy",
        "strategy": "EGFR inhibition + Platinum-based chemotherapy + Antifolate",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 289,
      "variant": {
        "id": 254,
        "alternate_allele": "G",
        "cdna_change": "c.2573T>G",
        "chromosome": "7",
        "end_position": "55259515",
        "exon": "21",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.L858R",
        "reference_allele": "T",
        "rsid": "rs121434568",
        "start_position": "55259515",
        "variant_annotation": "Missense",
        "feature": "EGFR p.L858R (Missense)"
      }
    },
    {
      "id": 994,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 p.L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Amivantamab + Carboplatin + Pemetrexed",
        "type": "Combination therapy",
        "strategy": "EGFR inhibition + Platinum-based chemotherapy + Antifolate",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 289,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 995,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to osimertinib for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 p.L858R mutations, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-10-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 290,
      "variant": {
        "id": 272,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": "7",
        "end_position": null,
        "exon": "19",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": "Deletion",
        "feature": "EGFR (Deletion)"
      }
    },
    {
      "id": 996,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to osimertinib for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 p.L858R mutations, as detected by an FDA-approved test.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Osimertinib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-10-02",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 290,
      "variant": {
        "id": 242,
        "alternate_allele": "T",
        "cdna_change": "c.2369C>T",
        "chromosome": "7",
        "end_position": "55249071",
        "exon": "20",
        "feature_type": "somatic_variant",
        "gene": "EGFR",
        "protein_change": "p.T790M",
        "reference_allele": "C",
        "rsid": "rs121434569",
        "start_position": "55249071",
        "variant_annotation": "Missense",
        "feature": "EGFR p.T790M (Missense)"
      }
    },
    {
      "id": 997,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Asciminib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 6,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 998,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and ABL1 p.T315I.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Asciminib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 6,
      "variant": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
      }
    },
    {
      "id": 999,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and ABL1 p.T315I.",
      "disease": {
        "name": "Chronic Myelogenous Leukemia",
        "oncotree_code": "CML",
        "oncotree_term": "Chronic Myelogenous Leukemia"
      },
      "therapy": {
        "name": "Asciminib",
        "type": "Targeted therapy",
        "strategy": "BCR-ABL inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-11-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 6,
      "variant": {
        "id": 66,
        "alternate_allele": "T",
        "cdna_change": "c.944C>T",
        "chromosome": "9",
        "end_position": "133748283",
        "exon": "5",
        "feature_type": "somatic_variant",
        "gene": "ABL1",
        "protein_change": "p.T315I",
        "reference_allele": "C",
        "rsid": "rs121913459",
        "start_position": "133748283",
        "variant_annotation": "Missense",
        "feature": "ABL1 p.T315I (Missense)"
      }
    },
    {
      "id": 1000,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with fulvestrant and palbociclib for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. Inavolisib's drug label further states that patients should be selected based on the presence of one or more PIK3CA mutations in plasma specimen. This approval is based on INAVO120 (NCT04191499), a phase 3 double-blind, randomized trial, where PIK3CA mutation status was prospectively determined in a central laboratory using the FoundationOne Liquid CDx assay on plasma-derived circulating tumor DNA (ctDNA) or in local laboratories using various validated polymerase chain reaction (PCR) or next-generation sequencing (NGS) assays on tumor tissue or plasma.",
      "disease": {
        "name": "Invasive Breast Carcinoma",
        "oncotree_code": "BRCA",
        "oncotree_term": "Invasive Breast Carcinoma"
      },
      "therapy": {
        "name": "Fulvestrant + Inavolisib + Palbociclib",
        "type": "Combination therapy",
        "strategy": "PI3K/AKT/mTOR inhibition + ER signaling inhibition + CDK4/6 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-11-07",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 291,
      "variant": {
        "id": 456,
        "alternate_allele": null,
        "cdna_change": null,
        "chromosome": null,
        "end_position": null,
        "exon": null,
        "feature_type": "somatic_variant",
        "gene": "PIK3CA",
        "protein_change": null,
        "reference_allele": null,
        "rsid": null,
        "start_position": null,
        "variant_annotation": null,
        "feature": "PIK3CA"
      }
    },
    {
      "id": 1001,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
      "disease": {
        "name": "Acute Myeloid Leukemia",
        "oncotree_code": "AML",
        "oncotree_term": "Acute Myeloid Leukemia"
      },
      "therapy": {
        "name": "Revumenib",
        "type": "Targeted therapy",
        "strategy": "Menin inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-12-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 292,
      "variant": {
        "id": 1001,
        "feature_type": "rearrangement",
        "gene1": "KMT2A",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Translocation",
        "feature": "KMT2A Translocation"
      }
    },
    {
      "id": 1002,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.",
      "disease": {
        "name": "Acute Lymphoid Leukemia",
        "oncotree_code": "ALL",
        "oncotree_term": "Acute Lymphoid Leukemia"
      },
      "therapy": {
        "name": "Revumenib",
        "type": "Targeted therapy",
        "strategy": "Menin inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2024-12-05",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 292,
      "variant": {
        "id": 1001,
        "feature_type": "rearrangement",
        "gene1": "KMT2A",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Translocation",
        "feature": "KMT2A Translocation"
      }
    },
    {
      "id": 1003,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Zenocutuzumab",
        "type": "Targeted therapy",
        "strategy": "NRG1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 293,
      "variant": {
        "id": 1003,
        "feature_type": "rearrangement",
        "gene1": "NRG1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NRG1 Fusion"
      }
    },
    {
      "id": 1004,
      "context": "",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.",
      "disease": {
        "name": "Pancreatic Adenocarcinoma",
        "oncotree_code": "PAAD",
        "oncotree_term": "Pancreatic Adenocarcinoma"
      },
      "therapy": {
        "name": "Zenocutuzumab",
        "type": "Targeted therapy",
        "strategy": "NRG1 inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 293,
      "variant": {
        "id": 1003,
        "feature_type": "rearrangement",
        "gene1": "NRG1",
        "gene2": null,
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "NRG1 Fusion"
      }
    },
    {
      "id": 1005,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted regular approval for ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. The product label instructs to select patients based on the presence of ALK rearrangement(s) in tumor specimens, and states that an FDA-approved test to detect ALK rearrangements for selecting patients for treatment with ensartinib is not yet available.",
      "disease": {
        "name": "Non-Small Cell Lung Cancer",
        "oncotree_code": "NSCLC",
        "oncotree_term": "Non-Small Cell Lung Cancer"
      },
      "therapy": {
        "name": "Ensartinib",
        "type": "Targeted therapy",
        "strategy": "ALK inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 294,
      "variant": {
        "id": 12,
        "feature_type": "rearrangement",
        "gene1": "ALK",
        "gene2": null,
        "locus": null,
        "rearrangement_type": null,
        "feature": "ALK"
      }
    },
    {
      "id": 1006,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF p.V600E variant, as detected by an FDA-approved test. mFOLFOX6 consists of oxaliplatin, folinic acid, and fluorouracil.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Cetuximab + Encorafenib + Fluorouracil + Oxaliplatin",
        "type": "Combination therapy",
        "strategy": "EGFR inhibition + B-RAF inhibition + Platinum-based chemotherapy + Thymidylate synthase inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-13",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 295,
      "variant": {
        "id": 144,
        "alternate_allele": "T",
        "cdna_change": "c.1799T>A",
        "chromosome": "7",
        "end_position": "140453136",
        "exon": "15",
        "feature_type": "somatic_variant",
        "gene": "BRAF",
        "protein_change": "p.V600E",
        "reference_allele": "A",
        "rsid": "rs113488022",
        "start_position": "140453136",
        "variant_annotation": "Missense",
        "feature": "BRAF p.V600E (Missense)"
      }
    },
    {
      "id": 1007,
      "context": "Metastatic",
      "deprecated": false,
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to panitumumab in combination with sotorasib for the treatment of adult patients with KRAS p.G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.",
      "disease": {
        "name": "Colorectal Adenocarcinoma",
        "oncotree_code": "COADREAD",
        "oncotree_term": "Colorectal Adenocarcinoma"
      },
      "therapy": {
        "name": "Panitumumab + Sotorasib",
        "type": "Targeted therapy",
        "strategy": "EGFR inhibition + RAS inhibition",
        "resistance": "",
        "sensitivity": 1
      },
      "predictive_implication": "FDA-Approved",
      "favorable_prognosis": "",
      "created_on": "04/04/25",
      "last_updated": "2025-02-06",
      "submitted_by": "breardon@broadinstitute.org",
      "validated": true,
      "source_id": 296,
      "variant": {
        "id": 372,
        "alternate_allele": "A",
        "cdna_change": "c.34G>T",
        "chromosome": "12",
        "end_position": "25398285",
        "exon": "2",
        "feature_type": "somatic_variant",
        "gene": "KRAS",
        "protein_change": "p.G12C",
        "reference_allele": "C",
        "rsid": "rs121913530",
        "start_position": "25398285",
        "variant_annotation": "Missense",
        "feature": "KRAS p.G12C (Missense)"
      }
    }
  ],
  "sources": [
    {
      "id": 1,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203341s020lbl.pdf",
      "citation": "Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203341s020lbl.pdf. Revised May 2021. Accessed September 16, 2021."
    },
    {
      "id": 2,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf",
      "citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020."
    },
    {
      "id": 3,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020."
    },
    {
      "id": 4,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016]. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 5,
      "type": "Journal",
      "doi": "10.1056/NEJMoa0912614",
      "nct": "NCT00471497",
      "pmid": 20525993,
      "url": "https://doi.org/10.1056/NEJMoa0912614",
      "citation": "Saglio G, Kim D, Issaragrisil S, et al. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia N Engl J Med. 2010; 362(24):2251-2259."
    },
    {
      "id": 6,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed November 6, 2024."
    },
    {
      "id": 7,
      "type": "FDA",
      "doi": "",
      "nct": "NCT02075840",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf",
      "citation": "Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020."
    },
    {
      "id": 8,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf",
      "citation": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf. Revised August 2011. Accessed March 4, 2024."
    },
    {
      "id": 9,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf",
      "citation": "Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020."
    },
    {
      "id": 10,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020."
    },
    {
      "id": 11,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Lung Cancer V.5.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 12,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1311107",
      "nct": "NCT01283516",
      "pmid": 24670165,
      "url": "https://doi.org/10.1056/NEJMoa1311107",
      "citation": "Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189-97."
    },
    {
      "id": 13,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Soft Tissue Sarcoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 10th, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 14,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1007056",
      "nct": "NCT00585195",
      "pmid": 20979472,
      "url": "https://doi.org/10.1056/NEJMoa1007056",
      "citation": "Butrynski JE, D'adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727-33."
    },
    {
      "id": 15,
      "type": "Journal",
      "doi": "10.1038/nature09504",
      "nct": "",
      "pmid": 20871596,
      "url": "https://doi.org/10.1038/nature09504",
      "citation": "Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73."
    },
    {
      "id": 16,
      "type": "Journal",
      "doi": "10.1038/nrclinonc.2016.122",
      "nct": "",
      "pmid": 27531699,
      "url": "https://doi.org/10.1038/nrclinonc.2016.122",
      "citation": "Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113."
    },
    {
      "id": 17,
      "type": "Journal",
      "doi": "10.1038/ng.2583",
      "nct": "",
      "pmid": 23502783,
      "url": "https://doi.org/10.1038/ng.2583",
      "citation": "Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-5."
    },
    {
      "id": 18,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Dermatofibrosarcoma V.1.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 19,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-13-0836",
      "nct": "",
      "pmid": 23897899,
      "url": "https://clincancerres.aacrjournals.org/content/19/19/5523.long",
      "citation": "Johung, Kimberly L. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer. Clin Cancer Res. 2013 Oct 1;19(19):5523-32."
    },
    {
      "id": 20,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Lung Cancer V.1.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 5, 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 21,
      "type": "Journal",
      "doi": "10.1038/nm.2166",
      "nct": "",
      "pmid": 20526349,
      "url": "https://doi.org/10.1038/nm.2166",
      "citation": "Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8."
    },
    {
      "id": 22,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bone Cancer V.1.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 6 2016]. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 23,
      "type": "Journal",
      "doi": "10.1371/journal.pgen.1004135",
      "nct": "",
      "pmid": 24550739,
      "url": "https://doi.org/10.1371/journal.pgen.1004135",
      "citation": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135."
    },
    {
      "id": 24,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf",
      "citation": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf. Revised April 2020. Accessed October 15th, 2020."
    },
    {
      "id": 25,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf",
      "citation": "QED Therapeutics, Inc. TRUSELTIQ (infigratinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021."
    },
    {
      "id": 26,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
      "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024."
    },
    {
      "id": 27,
      "type": "Journal",
      "doi": "10.1111/j.1365-2141.2007.06921.x",
      "nct": "",
      "pmid": 18302711,
      "url": "https://doi.org/10.1111/j.1365-2141.2007.06921.x",
      "citation": "Pineda-roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140(6):625-34."
    },
    {
      "id": 28,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 29,
      "type": "FDA",
      "doi": "",
      "nct": "NCT02122913",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf",
      "citation": "Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020."
    },
    {
      "id": 30,
      "type": "Journal",
      "doi": "10.1136/esmoopen-2015-000023",
      "nct": "",
      "pmid": 27843590,
      "url": "https://doi.org/10.1136/esmoopen-2015-000023",
      "citation": "Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2)."
    },
    {
      "id": 31,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf",
      "citation": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023."
    },
    {
      "id": 32,
      "type": "Journal",
      "doi": "10.1038/sj.onc.1206543",
      "nct": "",
      "pmid": 12944919,
      "url": "https://doi.org/10.1038/sj.onc.1206543",
      "citation": "Trempat P, Villalva C, Laurent G, et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor  alpha receptor: a new clinical target for STI571/Glivec Oncogene. 2003; 22(36):5702-5706."
    },
    {
      "id": 33,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myelodysplastic Syndromes V.2.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 2, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 34,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-13-0035",
      "nct": "NCT01639508",
      "pmid": 23533264,
      "url": "https://doi.org/10.1158/2159-8290.CD-13-0035",
      "citation": "Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630-5."
    },
    {
      "id": 35,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf",
      "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020."
    },
    {
      "id": 36,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s009lbl.pdf",
      "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s009lbl.pdf. Revised June 2024. Accessed July 11, 2024."
    },
    {
      "id": 37,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf",
      "citation": "Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023."
    },
    {
      "id": 38,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf",
      "citation": "Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf. Revised 12/2020. Accessed December 3, 2020."
    },
    {
      "id": 39,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s016lbl.pdf",
      "citation": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s016lbl.pdf. Revised March 2016. Accessed March 4, 2024."
    },
    {
      "id": 41,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": 15735013,
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myelodysplastic Syndromes V.2.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 2, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 42,
      "type": "Journal",
      "doi": "10.1371/journal.pone.0060408",
      "nct": "",
      "pmid": 23565244,
      "url": "https://doi.org/10.1371/journal.pone.0060408",
      "citation": "Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408."
    },
    {
      "id": 43,
      "type": "Journal",
      "doi": "10.1038/sj.onc.1210237",
      "nct": "",
      "pmid": 17237811,
      "url": "https://doi.org/10.1038/sj.onc.1210237",
      "citation": "Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9."
    },
    {
      "id": 44,
      "type": "Journal",
      "doi": "10.1200/JCO.2017.75.7310",
      "nct": "NCT01576172",
      "pmid": 29261439,
      "url": "https://doi.org/10.1200/JCO.2017.75.7310",
      "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."
    },
    {
      "id": 45,
      "type": "Journal",
      "doi": "10.1126/science.1062538",
      "nct": "",
      "pmid": 11423618,
      "url": "https://doi.org/10.1126/science.1062538",
      "citation": "Gorre, Mercedes E., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293.5531 (2001): 876-880."
    },
    {
      "id": 46,
      "type": "Journal",
      "doi": "10.1182/blood-2010-12-326405",
      "nct": "",
      "pmid": 27760149,
      "url": "https://doi.org/10.1182/blood-2010-12-326405",
      "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405"
    },
    {
      "id": 47,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 48,
      "type": "Journal",
      "doi": "10.1158/1535-7163.MCT-15-0230",
      "nct": "",
      "pmid": 26351323,
      "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230",
      "citation": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1 E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51."
    },
    {
      "id": 49,
      "type": "Journal",
      "doi": "10.1158/1535-7163.MCT-15-0230",
      "nct": "",
      "pmid": 26351323,
      "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230",
      "citation": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51."
    },
    {
      "id": 50,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-13-0846",
      "nct": "",
      "pmid": 24675041,
      "url": "https://doi.org/10.1158/2159-8290.CD-13-0846",
      "citation": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673."
    },
    {
      "id": 51,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-14-1220",
      "nct": "",
      "pmid": 25320358,
      "url": "https://doi.org/10.1158/1078-0432.CCR-14-1220",
      "citation": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80."
    },
    {
      "id": 52,
      "type": "Journal",
      "doi": "10.1172/JCI72763",
      "nct": "",
      "pmid": 24569458,
      "url": "https://doi.org/10.1172/JCI72763",
      "citation": "Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6."
    },
    {
      "id": 53,
      "type": "Journal",
      "doi": "10.1038/s41591-018-0012-z",
      "nct": "",
      "pmid": 29736026,
      "url": "https://doi.org/10.1038/s41591-018-0012-z",
      "citation": "Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562."
    },
    {
      "id": 54,
      "type": "Journal",
      "doi": "10.1038/ncomms7744",
      "nct": "",
      "pmid": 25855536,
      "url": "https://doi.org/10.1038/ncomms7744",
      "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."
    },
    {
      "id": 55,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-20-0868",
      "nct": "",
      "pmid": 32988960,
      "url": "https://doi.org/10.1158/2159-8290.CD-20-0868",
      "citation": "Yap TA, Tan DSP, Terbuch A, et al. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discovery. 2021;11(1):80-91."
    },
    {
      "id": 56,
      "type": "Journal",
      "doi": "10.18632/oncotarget.14400",
      "nct": "",
      "pmid": 28055970,
      "url": "https://doi.org/10.18632/oncotarget.14400",
      "citation": "Ma J, Setton J, Morris L, et al. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM Oncotarget. 2016; 8(6)."
    },
    {
      "id": 57,
      "type": "Journal",
      "doi": "10.1016/j.tranon.2017.01.007",
      "nct": "",
      "pmid": 28182994,
      "url": "https://doi.org/10.1016/j.tranon.2017.01.007",
      "citation": "Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196."
    },
    {
      "id": 58,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."
    },
    {
      "id": 59,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-13-2287",
      "nct": "",
      "pmid": 24240112,
      "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287",
      "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."
    },
    {
      "id": 60,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-09-2828",
      "nct": "",
      "pmid": 20453058,
      "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828",
      "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."
    },
    {
      "id": 61,
      "type": "Journal",
      "doi": "10.1038/srep14060",
      "nct": "",
      "pmid": 26358404,
      "url": "https://doi.org/10.1038/srep14060",
      "citation": "De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060."
    },
    {
      "id": 62,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020."
    },
    {
      "id": 63,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020."
    },
    {
      "id": 64,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf",
      "citation": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020."
    },
    {
      "id": 65,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf",
      "citation": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020."
    },
    {
      "id": 66,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.4.2018. \u00a9 National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed March 20 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 67,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed March 20 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 68,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 69,
      "type": "Journal",
      "doi": "10.1186/s40425-016-0148-7",
      "nct": "NCT01673854",
      "pmid": 27532019,
      "url": "https://doi.org/10.1186/s40425-016-0148-7",
      "citation": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44."
    },
    {
      "id": 70,
      "type": "Journal",
      "doi": "10.3892/ijo.2016.3594",
      "nct": "",
      "pmid": 27572607,
      "url": "https://doi.org/10.3892/ijo.2016.3594",
      "citation": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74."
    },
    {
      "id": 71,
      "type": "Journal",
      "doi": "10.1073/pnas.0905833106",
      "nct": "",
      "pmid": 19915144,
      "url": "https://doi.org/10.1073/pnas.0905833106",
      "citation": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6."
    },
    {
      "id": 72,
      "type": "Journal",
      "doi": "10.1016/j.biopha.2016.06.038",
      "nct": "",
      "pmid": 27399807,
      "url": "https://doi.org/10.1016/j.biopha.2016.06.038",
      "citation": "Fondello C, Agnetti L, Villaverde MS, Simian M, Glikin GC, Finocchiaro LM. The combination of bleomycin with suicide or interferon-beta gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomed Pharmacother. 2016;83:290-301."
    },
    {
      "id": 73,
      "type": "Journal",
      "doi": "10.1080/15384047.2016.1250987",
      "nct": "",
      "pmid": 27786591,
      "url": "https://doi.org/10.1080/15384047.2016.1250987",
      "citation": "Hong SK, Starenki D, Wu PK, Park JI. Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biol Ther. 2016;"
    },
    {
      "id": 74,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1502309",
      "nct": "NCT01524978",
      "pmid": 26287849,
      "url": "https://doi.org/10.1056/NEJMoa1502309",
      "citation": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36."
    },
    {
      "id": 75,
      "type": "Journal",
      "doi": "10.18632/oncotarget.12328",
      "nct": "",
      "pmid": 27690220,
      "url": "https://doi.org/10.18632/oncotarget.12328",
      "citation": "Kawaguchi K, Murakami T, Chmielowski B, et al. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2016;"
    },
    {
      "id": 76,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-15-1192",
      "nct": "",
      "pmid": 27048246,
      "url": "https://doi.org/10.1158/2159-8290.CD-15-1192",
      "citation": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600."
    },
    {
      "id": 77,
      "type": "Journal",
      "doi": "10.18632/oncotarget.12791",
      "nct": "",
      "pmid": 27783987,
      "url": "https://doi.org/10.18632/oncotarget.12791",
      "citation": "Suarez-kelly LP, Kemper GM, Duggan MC, et al. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;"
    },
    {
      "id": 78,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-13-0631",
      "nct": "",
      "pmid": 24265154,
      "url": "https://doi.org/10.1158/2159-8290.CD-13-0631",
      "citation": "Wagle, Nikhil, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer discovery 4.1 (2014): 61-68."
    },
    {
      "id": 79,
      "type": "Journal",
      "doi": "10.18632/oncotarget.4014",
      "nct": "",
      "pmid": 26023796,
      "url": "https://doi.org/10.18632/oncotarget.4014",
      "citation": "Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993-2005."
    },
    {
      "id": 80,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 81,
      "type": "FDA",
      "doi": "",
      "nct": "NCT01844986",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."
    },
    {
      "id": 82,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf",
      "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020."
    },
    {
      "id": 83,
      "type": "Journal",
      "doi": "10.1200/JCO.2009.26.9589",
      "nct": "",
      "pmid": 20406929,
      "url": "https://doi.org/10.1200/JCO.2009.26.9589",
      "citation": "Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-9."
    },
    {
      "id": 84,
      "type": "Journal",
      "doi": "10.1200/JCO.2016.71.3677",
      "nct": "",
      "pmid": 28221868,
      "url": "https://doi.org/10.1200/JCO.2016.71.3677",
      "citation": "Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."
    },
    {
      "id": 85,
      "type": "Journal",
      "doi": "10.1038/nature14169",
      "nct": "",
      "pmid": 25719666,
      "url": "https://doi.org/10.1038/nature14169",
      "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501."
    },
    {
      "id": 86,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf",
      "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."
    },
    {
      "id": 87,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020."
    },
    {
      "id": 88,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1506859",
      "nct": "NCT01682772",
      "pmid": 26510020,
      "url": "https://doi.org/10.1056/NEJMoa1506859",
      "citation": "Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708."
    },
    {
      "id": 89,
      "type": "Journal",
      "doi": "10.1016/j.cell.2016.02.065",
      "nct": "",
      "pmid": 26997480,
      "url": "https://doi.org/10.1016/j.cell.2016.02.065",
      "citation": "Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44."
    },
    {
      "id": 90,
      "type": "Journal",
      "doi": "10.1200/JCO.2009.27.4324",
      "nct": "",
      "pmid": 20823417,
      "url": "https://doi.org/10.1200/JCO.2009.27.4324",
      "citation": "Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."
    },
    {
      "id": 91,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf. Revised March 2017. Accessed March 4, 2024."
    },
    {
      "id": 92,
      "type": "Journal",
      "doi": "10.1016/S1556-0864(16)30246-5",
      "nct": "NCT02143466",
      "pmid": 27599705,
      "url": "https://doi.org/10.1016/S1556-0864(16)30246-5",
      "citation": "Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4 Suppl):S115."
    },
    {
      "id": 93,
      "type": "Journal",
      "doi": "10.1016/S1556-0864(16)30243-X",
      "nct": "NCT01588145",
      "pmid": "",
      "url": "https://doi.org/10.1016/S1556-0864(16)30243-X",
      "citation": "Park K, Lee J, Han J, et al. 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose Journal of Thoracic Oncology. 2016; 11(4):S113-."
    },
    {
      "id": 94,
      "type": "Journal",
      "doi": "10.1016/j.tips.2016.09.003",
      "nct": "NCT01708954",
      "pmid": 27717507,
      "url": "https://doi.org/ 10.1016/j.tips.2016.09.003",
      "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903."
    },
    {
      "id": 95,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1413654",
      "nct": "NCT01526928",
      "pmid": 25923550,
      "url": "https://doi.org/10.1056/NEJMoa1413654",
      "citation": "Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-9."
    },
    {
      "id": 96,
      "type": "Journal",
      "doi": "10.1200/JCO.2005.01.0793",
      "nct": "",
      "pmid": 15998907,
      "url": "https://doi.org/10.1200/JCO.2005.01.0793",
      "citation": "Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37."
    },
    {
      "id": 97,
      "type": "Journal",
      "doi": "10.1186/s13045-016-0268-z",
      "nct": "",
      "pmid": 27071706,
      "url": "https://doi.org/10.1186/s13045-016-0268-z",
      "citation": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34."
    },
    {
      "id": 98,
      "type": "Journal",
      "doi": "10.1093/annonc/mdt573",
      "nct": "",
      "pmid": 24478319,
      "url": "https://doi.org/10.1093/annonc/mdt573",
      "citation": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428."
    },
    {
      "id": 99,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf",
      "citation": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020."
    },
    {
      "id": 100,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1713137",
      "nct": "",
      "pmid": 29151359,
      "url": "https://doi.org/10.1056/NEJMoa1713137",
      "citation": "Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated -Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med. 2018; 378(2):113-125."
    },
    {
      "id": 101,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Revised December 2020. Accessed February 2nd, 2021."
    },
    {
      "id": 102,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf",
      "citation": "Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021."
    },
    {
      "id": 103,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf",
      "citation": "Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf. Revised September 2021. Accessed September 16th, 2021."
    },
    {
      "id": 104,
      "type": "Journal",
      "doi": "10.1038/nature25475",
      "nct": "",
      "pmid": 29420467,
      "url": "https://doi.org/10.1038/nature25475",
      "citation": "Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."
    },
    {
      "id": 105,
      "type": "Journal",
      "doi": "10.1001/jamaoncol.2016.1056",
      "nct": "",
      "pmid": 27310333,
      "url": "https://doi.org/10.1001/jamaoncol.2016.1056",
      "citation": "Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6."
    },
    {
      "id": 106,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-14-0623",
      "nct": "",
      "pmid": 25096233,
      "url": "https://doi.org/10.1158/2159-8290.CD-14-0623",
      "citation": "Van Allen, Eliezer M., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer discovery 4.10 (2014): 1140-1153."
    },
    {
      "id": 107,
      "type": "Journal",
      "doi": "10.1038/ng.2823",
      "nct": "",
      "pmid": 24185510,
      "url": "https://doi.org/10.1038/ng.2823",
      "citation": "Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51."
    },
    {
      "id": 108,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf",
      "citation": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020."
    },
    {
      "id": 109,
      "type": "Journal",
      "doi": "10.1126/science.1162981",
      "nct": "",
      "pmid": 18787170,
      "url": "https://doi.org/10.1126/science.1162981",
      "citation": "Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502."
    },
    {
      "id": 110,
      "type": "Journal",
      "doi": "10.1126/science.1226344",
      "nct": "",
      "pmid": 22923433,
      "url": "https://doi.org/10.1126/science.1226344",
      "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221."
    },
    {
      "id": 111,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1403352",
      "nct": "",
      "pmid": 25295501,
      "url": "https://doi.org/10.1056/NEJMoa1403352",
      "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33."
    },
    {
      "id": 112,
      "type": "Journal",
      "doi": "10.1038/leu.2013.14",
      "nct": "",
      "pmid": 23392356,
      "url": "https://doi.org/10.1038/leu.2013.14",
      "citation": "Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8."
    },
    {
      "id": 113,
      "type": "Journal",
      "doi": "10.1038/sj.leu.2404374",
      "nct": "",
      "pmid": 16990784,
      "url": "https://doi.org/10.1038/sj.leu.2404374",
      "citation": "Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14."
    },
    {
      "id": 114,
      "type": "Journal",
      "doi": "10.1038/nature11143",
      "nct": "",
      "pmid": 22722193,
      "url": "https://doi.org/10.1038/nature11143",
      "citation": "Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60."
    },
    {
      "id": 115,
      "type": "FDA",
      "doi": "",
      "nct": "NCT02074839",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf",
      "citation": "Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020."
    },
    {
      "id": 116,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Glioma V.1.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 117,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf",
      "citation": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021."
    },
    {
      "id": 118,
      "type": "FDA",
      "doi": "",
      "nct": "NCT01915498",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf",
      "citation": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020."
    },
    {
      "id": 119,
      "type": "Journal",
      "doi": "10.1186/s13045-017-0431-1",
      "nct": "",
      "pmid": 28245838,
      "url": "https://doi.org/10.1186/s13045-017-0431-1",
      "citation": "Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61."
    },
    {
      "id": 120,
      "type": "Journal",
      "doi": "10.1182/blood-2015-03-635821",
      "nct": "",
      "pmid": 26443624,
      "url": "https://doi.org/10.1182/blood-2015-03-635821",
      "citation": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83."
    },
    {
      "id": 121,
      "type": "Journal",
      "doi": "10.1056/NEJMoa051113",
      "nct": "",
      "pmid": 15858187,
      "url": "https://doi.org/10.1056/NEJMoa051113",
      "citation": "Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90."
    },
    {
      "id": 122,
      "type": "Journal",
      "doi": "10.1182/blood-2014-04-566687",
      "nct": "",
      "pmid": 25193870,
      "url": "https://doi.org/10.1182/blood-2014-04-566687",
      "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100."
    },
    {
      "id": 123,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf",
      "citation": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020."
    },
    {
      "id": 124,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf",
      "citation": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020."
    },
    {
      "id": 125,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": 20571149,
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Head and Neck Cancers V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 126,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 127,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/gist_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Gastrointestinal Stromal Tumors V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 10 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 128,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/thymic_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Thymomas and Thymic Carcinomas V.1.2021. \u00a9 National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed November 19 2020. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 129,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf",
      "citation": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021."
    },
    {
      "id": 130,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-15-0589",
      "nct": "NCT02154490",
      "pmid": 26728409,
      "url": "https://doi.org/10.1158/1078-0432.CCR-15-0589",
      "citation": "Tao Z, Le blanc JM, Wang C, et al. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. Clin Cancer Res. 2016;22(1):122-33."
    },
    {
      "id": 131,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-14-1814",
      "nct": "NCT01155453",
      "pmid": 25500057,
      "url": "https://doi.org/10.1158/1078-0432.CCR-14-1814",
      "citation": "Bedard PL, Tabernero J, Janku F, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730-8."
    },
    {
      "id": 132,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf",
      "citation": "Amgen Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021."
    },
    {
      "id": 133,
      "type": "Journal",
      "doi": "10.1038/ctg.2016.18",
      "nct": "",
      "pmid": 27010960,
      "url": "https://doi.org/10.1038/ctg.2016.18",
      "citation": "Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."
    },
    {
      "id": 134,
      "type": "Journal",
      "doi": "10.1093/jnci/djx031",
      "nct": "",
      "pmid": 28954285,
      "url": "https://doi.org/10.1093/jnci/djx031",
      "citation": "Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."
    },
    {
      "id": 135,
      "type": "Journal",
      "doi": "10.1038/nature18600",
      "nct": "",
      "pmid": 27338794,
      "url": "https://doi.org/10.1038/nature18600",
      "citation": "Manchado E, Weissmueller S, Morris JP, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534(7609):647-651."
    },
    {
      "id": 136,
      "type": "Journal",
      "doi": "10.1126/science.aaa1348",
      "nct": "",
      "pmid": 25765070,
      "url": "https://doi.org/10.1126/science.aaa1348",
      "citation": "Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8."
    },
    {
      "id": 137,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-13-0646",
      "nct": "",
      "pmid": 24444711,
      "url": "https://doi.org/10.1158/2159-8290.CD-13-0646",
      "citation": "Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452-65."
    },
    {
      "id": 138,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-19-0908",
      "nct": "",
      "pmid": 31253631,
      "url": "https://doi.org/10.1158/1078-0432.CCR-19-0908",
      "citation": "Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;"
    },
    {
      "id": 139,
      "type": "Journal",
      "doi": "10.1016/j.cllc.2014.09.005",
      "nct": "",
      "pmid": 25450872,
      "url": "https://doi.org/10.1016/j.cllc.2014.09.005",
      "citation": "Mak RH, Hermann G, Lewis JH, et al. Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer Clinical Lung Cancer. 2015; 16(1):24-32."
    },
    {
      "id": 140,
      "type": "Journal",
      "doi": "10.1158/0008-5472.CAN-08-0099",
      "nct": "",
      "pmid": 18632602,
      "url": "https://doi.org/10.1158/0008-5472.CAN-08-0099",
      "citation": "Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8."
    },
    {
      "id": 141,
      "type": "Journal",
      "doi": "10.1200/JCO.2012.44.7888",
      "nct": "",
      "pmid": 23569304,
      "url": "https://doi.org/10.1200/JCO.2012.44.7888",
      "citation": "Trunzer, Kerstin, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology 31.14 (2013): 1767-1774."
    },
    {
      "id": 142,
      "type": "Journal",
      "doi": "10.1200/JCO.2010.33.2312",
      "nct": "",
      "pmid": 21383288,
      "url": "https://doi.org/10.1200/JCO.2010.33.2312",
      "citation": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96."
    },
    {
      "id": 143,
      "type": "Journal",
      "doi": "10.1001/jamaoncol.2015.34",
      "nct": "",
      "pmid": 26181029,
      "url": "https://doi.org/10.1001/jamaoncol.2015.34",
      "citation": "Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2."
    },
    {
      "id": 144,
      "type": "Journal",
      "doi": "10.1111/pcmr.12516",
      "nct": "",
      "pmid": 27540956,
      "url": "https://doi.org/10.1111/pcmr.12516",
      "citation": "Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;"
    },
    {
      "id": 145,
      "type": "Journal",
      "doi": "10.1158/0008-5472.CAN-08-2881",
      "nct": "",
      "pmid": 19318576,
      "url": "https://doi.org/10.1158/0008-5472.CAN-08-2881",
      "citation": "Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31."
    },
    {
      "id": 146,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024."
    },
    {
      "id": 147,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1500596",
      "nct": "NCT01876511",
      "pmid": 26028255,
      "url": "https://doi.org/10.1056/NEJMoa1500596",
      "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."
    },
    {
      "id": 148,
      "type": "Journal",
      "doi": "10.1038/leu.2011.261",
      "nct": "",
      "pmid": 22005786,
      "url": "https://doi.org/10.1038/leu.2011.261",
      "citation": "Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7."
    },
    {
      "id": 149,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-18-1833",
      "nct": "NCT00903175",
      "pmid": 30327302,
      "url": "https://doi.org/10.1158/1078-0432.CCR-18-1833",
      "citation": "Voss MH, Chen D, Reising A, et al. PTEN Expression, Not Mutation Status in, or, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019;25(2):506-514."
    },
    {
      "id": 150,
      "type": "Journal",
      "doi": "10.1158/0008-5472.can-13-1616",
      "nct": "",
      "pmid": 23980093,
      "url": "https://doi.org/10.1158/0008-5472.can-13-1616",
      "citation": "Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298."
    },
    {
      "id": 151,
      "type": "Journal",
      "doi": "10.1200/JCO.2007.14.4956",
      "nct": "",
      "pmid": 18390968,
      "url": "https://doi.org/10.1200/JCO.2007.14.4956",
      "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46."
    },
    {
      "id": 152,
      "type": "Journal",
      "doi": "10.1002/cncr.26724",
      "nct": "",
      "pmid": 22180178,
      "url": "https://doi.org/10.1002/cncr.26724",
      "citation": "Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-23."
    },
    {
      "id": 153,
      "type": "Journal",
      "doi": "10.1126/science.aan5951",
      "nct": "",
      "pmid": 29301960,
      "url": "https://doi.org/10.1126/science.aan5951",
      "citation": "Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806."
    },
    {
      "id": 154,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020."
    },
    {
      "id": 155,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-13-0884",
      "nct": "",
      "pmid": 23888070,
      "url": "https://doi.org/10.1158/1078-0432.CCR-13-0884",
      "citation": "Beaver JA, Gustin JP, Yi KH, et al. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res. 2013;19(19):5413-22."
    },
    {
      "id": 156,
      "type": "Journal",
      "doi": "10.1038/gim.2015.75",
      "nct": "",
      "pmid": 4823640,
      "url": "https://doi.org/10.1038/gim.2015.75",
      "citation": "Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32."
    },
    {
      "id": 157,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-17-0226",
      "nct": "",
      "pmid": 28630051,
      "url": "https://doi.org/10.1158/2159-8290.CD-17-0226",
      "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693."
    },
    {
      "id": 158,
      "type": "Journal",
      "doi": "10.1021/jm501629p",
      "nct": "",
      "pmid": 25514658,
      "url": "https://doi.org/10.1021/jm501629p",
      "citation": "Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62."
    },
    {
      "id": 159,
      "type": "Journal",
      "doi": "10.1016/j.immuni.2017.02.001",
      "nct": "",
      "pmid": 28228279,
      "url": "https://doi.org/10.1016/j.immuni.2017.02.001",
      "citation": "George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204."
    },
    {
      "id": 160,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-15-0283",
      "nct": "",
      "pmid": 26645196,
      "url": "https://doi.org/10.1158/2159-8290.CD-15-0283",
      "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16."
    },
    {
      "id": 161,
      "type": "Journal",
      "doi": "10.1093/annonc/mdy137",
      "nct": "",
      "pmid": 29912274,
      "url": "https://doi.org/10.1093/annonc/mdy137",
      "citation": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876."
    },
    {
      "id": 162,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf",
      "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 2, 2024."
    },
    {
      "id": 163,
      "type": "Journal",
      "doi": "10.1038/ncomms14098",
      "nct": "",
      "pmid": 28102363,
      "url": "https://doi.org/10.1038/ncomms14098",
      "citation": "Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098."
    },
    {
      "id": 164,
      "type": "Journal",
      "doi": "10.1016/j.eururo.2020.06.033",
      "nct": "",
      "pmid": 32624276,
      "url": "https://doi.org/10.1016/j.eururo.2020.06.033",
      "citation": "Swami U, Isaacsson Velho P, Nussenzveig R, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol. 2020;78(5):652-656."
    },
    {
      "id": 165,
      "type": "Journal",
      "doi": "",
      "nct": "",
      "pmid": 30068710,
      "url": "https://doi.org/10.1158/1078-0432.CCR-18-0937",
      "citation": "Boysen G, Rodrigues DN, Rescigno P, et al. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clin Cancer Res. 2018;24(22):5585-5593."
    },
    {
      "id": 166,
      "type": "Journal",
      "doi": "10.1016/j.celrep.2021.109665",
      "nct": "",
      "pmid": 34496240,
      "url": "https://doi.org/10.1016/j.celrep.2021.109665",
      "citation": "Tewari AK, Cheung ATM, Crowdis J, et al. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. 2021;36(10)"
    },
    {
      "id": 167,
      "type": "Journal",
      "doi": "10.1038/leu.2011.71",
      "nct": "",
      "pmid": 21494260,
      "url": "https://doi.org/10.1038/leu.2011.71",
      "citation": "Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152"
    },
    {
      "id": 168,
      "type": "Journal",
      "doi": "10.1111/j.1349-7006.2010.01821.x",
      "nct": "",
      "pmid": 21205074,
      "url": "https://doi.org/10.1111/j.1349-7006.2010.01821.x",
      "citation": "Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."
    },
    {
      "id": 169,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020."
    },
    {
      "id": 170,
      "type": "Journal",
      "doi": "10.1016/j.ijrobp.2009.02.057",
      "nct": "",
      "pmid": 19616740,
      "url": "https://doi.org/10.1016/j.ijrobp.2009.02.057",
      "citation": "Pollard JM, Gatti RA. Clinical Radiation Sensitivity With DNA Repair Disorders: An Overview International Journal of Radiation Oncology*Biology*Physics. 2009; 74(5):1323-1331."
    },
    {
      "id": 171,
      "type": "Journal",
      "doi": "10.1016/j.ajhg.2018.01.018",
      "nct": "",
      "pmid": 29478780,
      "url": "https://doi.org/10.1016/j.ajhg.2018.01.018",
      "citation": "AlDubayan SH, Giannakis M, Moore ND, et al. Inherited DNA-Repair Defects in Colorectal Cancer The American Journal of Human Genetics. 2018; 102(3):401-414."
    },
    {
      "id": 172,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023."
    },
    {
      "id": 173,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Ovarian Cancer V.1.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 174,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Invasive Breast Cancer NCCN Evidence Blocks V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 10 2019]. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 175,
      "type": "FDA",
      "doi": "",
      "nct": "NCT01945775",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf",
      "citation": "Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf. Revised October 2020. Accessed September 16, 2021."
    },
    {
      "id": 176,
      "type": "FDA",
      "doi": "",
      "nct": "NCT01945775",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf",
      "citation": "Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf. Revised October 2020. Accessed November 12, 2020."
    },
    {
      "id": 177,
      "type": "FDA",
      "doi": "",
      "nct": "NCT01844986",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."
    },
    {
      "id": 178,
      "type": "Journal",
      "doi": "10.1001/jamaoncol.2018.6477",
      "nct": "",
      "pmid": 30676620,
      "url": "https://doi.org/10.1001/jamaoncol.2018.6477",
      "citation": "AlDubayan SH, Pyle LC, Gamulin M, et al. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( ) With Susceptibility to Testicular Germ Cell Tumors JAMA Oncol. 2019; 5(4):514-."
    },
    {
      "id": 179,
      "type": "Journal",
      "doi": "10.1038/ncomms11883",
      "nct": "",
      "pmid": 27329137,
      "url": "https://doi.org/10.1038/ncomms11883",
      "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."
    },
    {
      "id": 180,
      "type": "Journal",
      "doi": "10.1007/s00247-008-1015-6",
      "nct": "",
      "pmid": 19083227,
      "url": "https://doi.org/10.1007/s00247-008-1015-6",
      "citation": "Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31."
    },
    {
      "id": 181,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 182,
      "type": "Journal",
      "doi": "10.1038/s41523-017-0038-2",
      "nct": "",
      "pmid": 28840192,
      "url": "https://doi.org/10.1038/s41523-017-0038-2",
      "citation": "Speers C, Zhao SG, Chandler B, et al. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer npj Breast Cancer. 2017; 3(1)."
    },
    {
      "id": 183,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-11-0130",
      "nct": "",
      "pmid": 22389870,
      "url": "https://doi.org/10.1158/2159-8290.CD-11-0130",
      "citation": "Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95."
    },
    {
      "id": 184,
      "type": "Journal",
      "doi": "10.1136/gutjnl-2011-301153",
      "nct": "",
      "pmid": 22207630,
      "url": "https://doi.org/10.1136/gutjnl-2011-301153",
      "citation": "Sillars-Hardebol, Anke H., et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut 61.11 (2012): 1568-1575."
    },
    {
      "id": 185,
      "type": "Journal",
      "doi": "10.1158/1535-7163.MCT-16-0298",
      "nct": "",
      "pmid": 27496133,
      "url": "https://doi.org/10.1158/1535-7163.MCT-16-0298",
      "citation": "Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322."
    },
    {
      "id": 186,
      "type": "Journal",
      "doi": "10.1126/scisignal.2001148",
      "nct": "",
      "pmid": 21098728,
      "url": "https://doi.org/10.1126/scisignal.2001148",
      "citation": "Corcoran, Ryan B., et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science signaling 3.149 (2010): ra84."
    },
    {
      "id": 187,
      "type": "Journal",
      "doi": "10.1038/sj.onc.1210506",
      "nct": "",
      "pmid": 17486065,
      "url": "https://doi.org/10.1038/sj.onc.1210506",
      "citation": "Bostner, Josefine, et al. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26.49 (2007): 6997-7005."
    },
    {
      "id": 188,
      "type": "Journal",
      "doi": "10.1073/pnas.1314302110",
      "nct": "",
      "pmid": 24218601,
      "url": "https://doi.org/10.1073/pnas.1314302110",
      "citation": "Etemadmoghadam, Dariush, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."
    },
    {
      "id": 189,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1501824",
      "nct": "NCT01295827",
      "pmid": 25891174,
      "url": "https://doi.org/10.1056/NEJMoa1501824",
      "citation": "Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28."
    },
    {
      "id": 190,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s029lbl.pdf",
      "citation": "Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s029lbl.pdf. Revised September 2020. Accessed October 22, 2020."
    },
    {
      "id": 191,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf",
      "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf. Revised November 2020. Accessed November 4, 2020."
    },
    {
      "id": 192,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s097lbl.pdf",
      "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s097lbl.pdf. Revised May 2021. Accessed May 6, 2021."
    },
    {
      "id": 193,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034s042lbl.pdf",
      "citation": "Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034s042lbl.pdf. Revised October 2021. Accessed November 3, 2021."
    },
    {
      "id": 194,
      "type": "Guideline",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Soft Tissue Sarcoma V.1.2021. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed November 19th, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 195,
      "type": "Journal",
      "doi": "10.1200/JCO.2012.46.5476",
      "nct": "NCT01209598",
      "pmid": 23569312,
      "url": "https://doi.org/10.1200/JCO.2012.46.5476",
      "citation": "Dickson, Mark A., et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of clinical oncology 31.16 (2013): 2024-2028."
    },
    {
      "id": 196,
      "type": "Journal",
      "doi": "10.1126/science.aad5214",
      "nct": "",
      "pmid": 26912360,
      "url": "https://doi.org/10.1126/science.aad5214",
      "citation": "Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."
    },
    {
      "id": 197,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-08-0347",
      "nct": "",
      "pmid": 18829482,
      "url": "https://doi.org/10.1158/1078-0432.CCR-08-0347",
      "citation": "Leone, Paola E., et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clinical Cancer Research 14.19 (2008): 6033-6041."
    },
    {
      "id": 198,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-11-0046",
      "nct": "",
      "pmid": 22586683,
      "url": "https://doi.org/10.1158/2159-8290.CD-11-0046",
      "citation": "Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25."
    },
    {
      "id": 199,
      "type": "Journal",
      "doi": "10.1200/JCO.2008.21.4437",
      "nct": "NCT00320385",
      "pmid": 20124187,
      "url": "https://doi.org/10.1200/JCO.2008.21.4437",
      "citation": "Blackwell, Kimberly L., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology 28.7 (2010): 1124-1130."
    },
    {
      "id": 200,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf",
      "citation": "Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."
    },
    {
      "id": 201,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020."
    },
    {
      "id": 202,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf",
      "citation": "Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024."
    },
    {
      "id": 203,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf",
      "citation": "Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020."
    },
    {
      "id": 204,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf",
      "citation": "Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020."
    },
    {
      "id": 205,
      "type": "Guideline",
      "doi": "",
      "nct": "NCT01041404",
      "pmid": 20728210,
      "url": "https://www.nccn.org/professionals/physician_gls/pdf/gastric_blocks.pdf",
      "citation": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Gastric Cancer V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org."
    },
    {
      "id": 206,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf",
      "citation": "Seattle Genetics, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf. Revised April 2020. Accessed October 15, 2020."
    },
    {
      "id": 207,
      "type": "Journal",
      "doi": "10.1016/S0959-8049(97)10157-5",
      "nct": "",
      "pmid": 9797688,
      "url": "https://doi.org/10.1016/S0959-8049(97)10157-5",
      "citation": "F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"
    },
    {
      "id": 208,
      "type": "Journal",
      "doi": "",
      "nct": "",
      "pmid": 14617784,
      "url": "https://mct.aacrjournals.org/content/2/11/1113.long",
      "citation": "Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20."
    },
    {
      "id": 209,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
      "citation": "Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020."
    },
    {
      "id": 210,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf",
      "citation": "MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021."
    },
    {
      "id": 211,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s170lbl.pdf",
      "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s170lbl.pdf. Revised March 2025. Accessed April 1, 2025."
    },
    {
      "id": 212,
      "type": "Journal",
      "doi": "10.1007/s10549-010-0984-y",
      "nct": "",
      "pmid": 20556506,
      "url": "https://doi.org/10.1007/s10549-010-0984-y",
      "citation": "Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55."
    },
    {
      "id": 213,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-12-0210",
      "nct": "",
      "pmid": 23002168,
      "url": "https://doi.org/10.1158/2159-8290.CD-12-0210",
      "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."
    },
    {
      "id": 214,
      "type": "Journal",
      "doi": "10.1038/bjc.2014.315",
      "nct": "",
      "pmid": 24937673,
      "url": "https://doi.org/10.1038/bjc.2014.315",
      "citation": "Hunter BA, Eustace A, Irlam JJ, et al. Expression of hypoxia-inducible factor-1_ predicts benefit from hypoxia modification in invasive bladder cancer Br J Cancer. 2014; 111(3):437-443."
    },
    {
      "id": 215,
      "type": "Journal",
      "doi": "10.1158/2159-8290.cd-16-0127",
      "nct": "",
      "pmid": 27663899,
      "url": "https://doi.org/10.1158/2159-8290.cd-16-0127",
      "citation": "Jeong Y, Hoang NT, Lovejoy A, et al. Role of / and Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Cancer Discov. 2017; 7(1):86-101."
    },
    {
      "id": 216,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1510016",
      "nct": "NCT01865747",
      "pmid": 26406150,
      "url": "https://doi.org/10.1056/NEJMoa1510016",
      "citation": "Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-23."
    },
    {
      "id": 217,
      "type": "Journal",
      "doi": "10.1016/j.jtho.2021.02.010",
      "nct": "",
      "pmid": 33676017,
      "url": "https://doi.org/10.1016/j.jtho.2021.02.010",
      "citation": "A phase 1 trial of crizotinib (NCT00585195) in patients with MET amplified non-small cell lung cancer observed an objective response rate of 6 out of 15 patients with MET amplified gene copy number greater than or equal to 6. The study enrolled 38 patients with MET-to-CEP7 ratios greater than equal to 1.8 by local FISH testing."
    },
    {
      "id": 218,
      "type": "Journal",
      "doi": "10.2147/OTT.S105760",
      "nct": "",
      "pmid": 27226732,
      "url": "https://doi.org/10.2147/OTT.S105760",
      "citation": "Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42."
    },
    {
      "id": 219,
      "type": "Journal",
      "doi": "10.1158/0008-5472.CAN-10-1202",
      "nct": "",
      "pmid": 20843819,
      "url": "https://doi.org/10.1158/0008-5472.CAN-10-1202",
      "citation": "Choudhury A, Nelson LD, Teo MTW, et al. MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer Cancer Research. 2010; 70(18):7017-7026."
    },
    {
      "id": 220,
      "type": "Journal",
      "doi": "10.1007/s00401-011-0923-y",
      "nct": "",
      "pmid": 22139329,
      "url": "https://doi.org/10.1007/s00401-011-0923-y",
      "citation": "Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."
    },
    {
      "id": 221,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-14-0947",
      "nct": "NCT00876122",
      "pmid": 25370471,
      "url": "https://doi.org/10.1158/1078-0432.CCR-14-0947",
      "citation": "Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77-86."
    },
    {
      "id": 222,
      "type": "Journal",
      "doi": "10.1136/gutjnl-2013-306202",
      "nct": "",
      "pmid": 24717934,
      "url": "https://doi.org/10.1136/gutjnl-2013-306202",
      "citation": "Morran DC, Wu J, Jamieson NB, et al. Targeting mTOR dependency in pancreatic cancer. Gut. 2014;63(9):1481-9."
    },
    {
      "id": 223,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf",
      "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."
    },
    {
      "id": 224,
      "type": "Journal",
      "doi": "10.1038/srep27702",
      "nct": "",
      "pmid": 27283319,
      "url": "https://doi.org/10.1038/srep27702",
      "citation": "Mullane SA, Werner L, Rosenberg J, et al. Correlation of Apobec Mrna Expression with overall Survival and PD-L1 expression in urothelial carcinoma. Sci Rep. 2016; 6:27702."
    },
    {
      "id": 225,
      "type": "Journal",
      "doi": "10.1038/ncomms9683",
      "nct": "",
      "pmid": 26511885,
      "url": "https://doi.org/10.1038/ncomms9683",
      "citation": "Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683."
    },
    {
      "id": 226,
      "type": "Journal",
      "doi": "10.1038/ng.3557",
      "nct": "",
      "pmid": 27111033,
      "url": "https://doi.org/10.1038/ng.3557",
      "citation": "Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606."
    },
    {
      "id": 227,
      "type": "Journal",
      "doi": "10.1056/NEJMoa1406498",
      "nct": "",
      "pmid": 25409260,
      "url": "https://doi.org/10.1056/NEJMoa1406498",
      "citation": "Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99."
    },
    {
      "id": 228,
      "type": "Journal",
      "doi": "10.1126/science.aad0095",
      "nct": "",
      "pmid": 26359337,
      "url": "https://doi.org/10.1126/science.aad0095",
      "citation": "Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-11."
    },
    {
      "id": 229,
      "type": "Journal",
      "doi": "10.1038/nature23477",
      "nct": "",
      "pmid": 28783722,
      "url": "https://doi.org/10.1038/nature23477",
      "citation": "Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy Nature. 2017; 548(7669):537-542."
    },
    {
      "id": 230,
      "type": "Journal",
      "doi": "10.1158/0008-5472.CAN-13-2541",
      "nct": "",
      "pmid": 24240700,
      "url": "https://doi.org/10.1158/0008-5472.CAN-13-2541",
      "citation": "Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2014;74(1):287-97."
    },
    {
      "id": 231,
      "type": "Journal",
      "doi": "10.1074/jbc.M114.551143",
      "nct": "",
      "pmid": 24554720,
      "url": "https://doi.org/10.1074/jbc.M114.551143",
      "citation": "Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem. 2014;289(13):9247-53."
    },
    {
      "id": 232,
      "type": "Journal",
      "doi": "10.1016/j.biocel.2016.10.019",
      "nct": "",
      "pmid": 27793752,
      "url": "https://doi.org/10.1016/j.biocel.2016.10.019",
      "citation": "Sung GJ, Choi HK, Kwak S, et al. Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation. Int J Biochem Cell Biol. 2016;81(Pt A):76-81."
    },
    {
      "id": 233,
      "type": "Journal",
      "doi": "10.1007/s10549-011-1846-y",
      "nct": "",
      "pmid": 22048815,
      "url": "https://doi.org/10.1007/s10549-011-1846-y",
      "citation": "Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133(3):865-80."
    },
    {
      "id": 234,
      "type": "Journal",
      "doi": "10.1038/nature19347",
      "nct": "",
      "pmid": 27580028,
      "url": "https://doi.org/10.1038/nature19347",
      "citation": "Luo C, Lim JH, Lee Y, et al. A PGC1alpha-mediated transcriptional axis suppresses melanoma metastasis. Nature. 2016;537(7620):422-426."
    },
    {
      "id": 235,
      "type": "Journal",
      "doi": "10.1038/s41588-018-0165-1",
      "nct": "",
      "pmid": 30013179,
      "url": "https://doi.org/10.1038/s41588-018-0165-1",
      "citation": "Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195."
    },
    {
      "id": 236,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf. Revised March 2022. Accessed July 7, 2022."
    },
    {
      "id": 237,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf",
      "citation": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022."
    },
    {
      "id": 238,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf",
      "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf. Revised March 2022. Accessed July 7, 2022."
    },
    {
      "id": 239,
      "type": "Journal",
      "doi": "10.1056/NEJMoa0900212",
      "nct": "NCT00516373",
      "pmid": 19553641,
      "url": "https://doi.org/10.1056/NEJMoa0900212",
      "citation": "Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009)."
    },
    {
      "id": 240,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-19-1570",
      "nct": "",
      "pmid": 31796516,
      "url": "https://doi.org/10.1158/1078-0432.CCR-19-1570",
      "citation": "Chakraborty G, Armenia J, Mazzu YZ, et al. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clin Cancer Res. 2020;26(8):2047-2064."
    },
    {
      "id": 241,
      "type": "Journal",
      "doi": "10.1074/jbc.M110.104745",
      "nct": "",
      "pmid": 20233726,
      "url": "https://doi.org/10.1074/jbc.M110.104745",
      "citation": "Wiltshire TD, Lovejoy CA, Wang T, Xia F, O'Connor MJ, Cortez D. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem. 2010;285(19):14565-14571."
    },
    {
      "id": 242,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf",
      "citation": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022."
    },
    {
      "id": 243,
      "type": "Journal",
      "doi": "10.1038/nature03445",
      "nct": "",
      "pmid": 15829967,
      "url": "https://doi.org/10.1038/nature03445",
      "citation": "Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005)."
    },
    {
      "id": 244,
      "type": "Journal",
      "doi": "10.1634/theoncologist.2018-0448",
      "nct": "",
      "pmid": 30541756,
      "url": "https://doi.org/10.1634/theoncologist.2018-0448",
      "citation": "Seligson ND, Kautto EA, Passen EN, et al. BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma. Oncologist. 2019;24(7):973-979."
    },
    {
      "id": 245,
      "type": "Journal",
      "doi": "10.1097/PAS.0000000000000324",
      "nct": "",
      "pmid": 25229770,
      "url": "https://doi.org/10.1097/PAS.0000000000000324",
      "citation": "Liau, J.-Y. et al. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Am. J. Surg. Pathol. 39, 23644 (2015)."
    },
    {
      "id": 246,
      "type": "Journal",
      "doi": "10.1634/theoncologist.2016-0310",
      "nct": "",
      "pmid": 28283584,
      "url": "https://doi.org/10.1634/theoncologist.2016-0310",
      "citation": "Elvin JA, Gay LM, Ort R, et al. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. Oncologist. 2017;22(4):416-421."
    },
    {
      "id": 247,
      "type": "Journal",
      "doi": "10.1200/PO.20.00040",
      "nct": "",
      "pmid": 28283584,
      "url": "https://doi.org/10.1200/PO.20.00040",
      "citation": "Williams EA, Sharaf R, Decker B, et al. CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. JCO Precis Oncol. 2020;4."
    },
    {
      "id": 248,
      "type": "Journal",
      "doi": "10.1016/j.humpath.2011.08.003",
      "nct": "",
      "pmid": 22154052,
      "url": "https://doi.org/10.1016/j.humpath.2011.08.003",
      "citation": "Tesser-Gamba, F. et al. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. Hum. Pathol. 43, 994-1002 (2012)."
    },
    {
      "id": 249,
      "type": "Journal",
      "doi": "10.1158/0008-5472.CAN-08-1443",
      "nct": "",
      "pmid": 19276386,
      "url": "https://doi.org/10.1158/0008-5472.CAN-08-1443",
      "citation": "Perot, G. et al. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res. 69, 2269-2278 (2009)."
    },
    {
      "id": 250,
      "type": "Journal",
      "doi": "10.1186/bcr1304",
      "nct": "",
      "pmid": 16168125,
      "url": "https://doi.org/10.1186/bcr1304",
      "citation": "Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005;7(5):R788-R795."
    },
    {
      "id": 251,
      "type": "Journal",
      "doi": "10.1158/1078-0432.CCR-16-2149",
      "nct": "",
      "pmid": 28232476,
      "url": "https://doi.org/10.1158/1078-0432.CCR-16-2149",
      "citation": "Cuppens, T. et al. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative. Clin. Cancer Res. 23, 1274-1285 (2017)."
    },
    {
      "id": 252,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf",
      "citation": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022."
    },
    {
      "id": 253,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf",
      "citation": "Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022."
    },
    {
      "id": 254,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf",
      "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf. Revised May 2024. Accessed June 3, 2024."
    },
    {
      "id": 255,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf",
      "citation": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023."
    },
    {
      "id": 256,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf",
      "citation": "Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised Dec 2022. Accessed January 5th, 2023."
    },
    {
      "id": 257,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf",
      "citation": "Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023."
    },
    {
      "id": 258,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf",
      "citation": "Stemline Therapeutics, Inc. Orserdu (elacestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf. Revised January 2023. Accessed February 2, 2023."
    },
    {
      "id": 259,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf",
      "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023."
    },
    {
      "id": 260,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf",
      "citation": "Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023."
    },
    {
      "id": 261,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf",
      "citation": "Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023."
    },
    {
      "id": 262,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf",
      "citation": "GlaxoSmithKline LLC. Jemperli (dostarlimab-gxly) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf. Revised July 2023. Accessed September 6, 2023."
    },
    {
      "id": 263,
      "type": "Journal",
      "doi": "10.1002/jor.24227",
      "nct": "",
      "pmid": 30131505,
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/jor.24227",
      "citation": "Tang F, Min L, Seebacher NA, et al. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. J Orthop Res. 2019;37(3):789-798."
    },
    {
      "id": 264,
      "type": "Journal",
      "doi": "10.1038/s41598-018-29043-z",
      "nct": "",
      "pmid": 30006631,
      "url": "https://www.nature.com/articles/s41598-018-29043-z",
      "citation": "Holme H, Gulati A, Brough R, et al. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci Rep. 2018;8(1)."
    },
    {
      "id": 265,
      "type": "Journal",
      "doi": "10.1038/s41467-021-27291-8",
      "nct": "",
      "pmid": 34862364,
      "url": "https://www.nature.com/articles/s41467-021-27291-8",
      "citation": "Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, et al. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun. 2021;12(1)."
    },
    {
      "id": 266,
      "type": "Journal",
      "doi": "10.1158/2159-8290.CD-17-1152",
      "nct": "",
      "pmid": 30266815,
      "url": "https://aacrjournals.org/cancerdiscovery/article/9/1/46/10398/Genome-Informed-Targeted-Therapy-for",
      "citation": "Sayles LC, Breese MR, Koehne AL, et al. Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discovery. 2019;9(1):46-63."
    },
    {
      "id": 267,
      "type": "Journal",
      "doi": "10.18632/oncotarget.10720",
      "nct": "",
      "pmid": 27447864,
      "url": "https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1470204513700494",
      "citation": "Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget. 2016;8(30):48794-48806."
    },
    {
      "id": 268,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
      "citation": "Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023."
    },
    {
      "id": 269,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf",
      "citation": "Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023."
    },
    {
      "id": 270,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf",
      "citation": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023."
    },
    {
      "id": 272,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed December 5, 2023."
    },
    {
      "id": 273,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf",
      "citation": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed January 30, 2024."
    },
    {
      "id": 274,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf",
      "citation": "Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf. Revised March 2024. Accessed March 4, 2024."
    },
    {
      "id": 275,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024."
    },
    {
      "id": 276,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf. Revised April 2018. Accessed March 4, 2024."
    },
    {
      "id": 277,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf",
      "citation": "EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024."
    },
    {
      "id": 278,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf",
      "citation": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf. Revised January 2021. Accessed August 4th, 2022."
    },
    {
      "id": 40,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf",
      "citation": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf. Revised August 2019. Accessed November 12, 2020."
    },
    {
      "id": 271,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf",
      "citation": "Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf. Revised November 2023. Accessed December 5, 2023."
    },
    {
      "id": 279,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf",
      "citation": "Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024."
    },
    {
      "id": 280,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s008lbl.pdf",
      "citation": "Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s008lbl.pdf. Revised December 2013. Accessed April 11, 2024."
    },
    {
      "id": 281,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf",
      "citation": "Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf. Revised April 2024. Accessed June 3, 2024."
    },
    {
      "id": 282,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf",
      "citation": "Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed June 3, 2024."
    },
    {
      "id": 283,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf",
      "citation": "OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed June 3, 2024."
    },
    {
      "id": 284,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf",
      "citation": "Astrazeneca Pharmaceuticals LP. Iressa (gefitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf. Revised May 2021. Accessed June 3, 2024."
    },
    {
      "id": 285,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf",
      "citation": "Bristol-Myers Squibb Company. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed July 11, 2024."
    },
    {
      "id": 286,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf",
      "citation": "Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf. Revised June 2024. Accessed July 11, 2024."
    },
    {
      "id": 287,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
      "citation": "Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed September 3, 2024."
    },
    {
      "id": 288,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf",
      "citation": "Janssen Biotech, Inc. Lazcluze (lazertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf. Revised August 2024. Accessed September 3, 2024."
    },
    {
      "id": 289,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf",
      "citation": "Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 2, 2024."
    },
    {
      "id": 290,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf",
      "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 2, 2024."
    },
    {
      "id": 291,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf",
      "citation": "Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed November 6, 2024."
    },
    {
      "id": 292,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf",
      "citation": "Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed December 5, 2024."
    },
    {
      "id": 293,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
      "citation": "Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed December 5, 2024."
    },
    {
      "id": 294,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf",
      "citation": "Xcovery Holdings, Inc. Ensacove (ensartinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf. Revised December 2024. Accessed February 6, 2025."
    },
    {
      "id": 295,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf",
      "citation": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed February 6, 2025."
    },
    {
      "id": 296,
      "type": "FDA",
      "doi": "",
      "nct": "",
      "pmid": "",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125147s213lbl.pdf",
      "citation": "Amgen Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125147s213lbl.pdf. Revised January 2025. Accessed February 6, 2025."
    }
  ]
}